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Consumption of n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) is associated 
with higher n-3 LCPUFA status in the circulation, which has in turn has been 
associated with a number of health benefits in humans. n-3 LCPUFA cardiovascular 
health benefits are well known and there is emerging evidence for mental health 
benefits. Limited studies have indicated that there is a positive correlation between an 
improvement of Ultra-High-Risk (UHR) of developing psychosis symptoms and the 
intake of n-3 LCPUFA; however there is a need for further studies involving larger 
randomized-controlled studies since the previous work was conducted with low 
numbers. These studies have also shown that people classified as UHR of developing 
psychosis have reduced n-3 PUFA, n-6 PUFA and n-3 index. What is unknown is the 
molecular phospholipid data and how that data may relate to developing psychosis and 
also how this is affected by n-3 LCPUFA supplementation. 
 
The first aim of this thesis was to develop an automated high-throughput technique for 
the analysis of n-3 index, fatty acids and molecular phospholipid profile in human 
erythrocytes. To achieve this a robotic liquid handling workstation (Hamilton Star) was 
utilized for lipid extraction from erythrocytes that allows extraction of 186 samples per 
day. Advances in mass spectrometry instrumentation have enabled increased 
sensitivity in the detection, accurate characterization, identification, and quantitation of 
membrane lipid species from human erythrocytes samples. The high throughput 
method described here offers considerable advantages in terms of simplicity and 
throughput compared to gas chromatography flame ionization method and provides 
additional information on molecular phospholipid concentrations. 
 
The second aim of this thesis was to compare n-3 index, fatty acids and molecular 
phospholipid species from erythrocytes of people with UHR (n =285) with age-matched 
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healthy controls (n =120). It was hypothesized that the n-3 index, erythrocyte fatty acids 
and phospholipid molecular species differ between the UHR of developing psychosis 
and the healthy groups (The UHR of developing psychosis group having a lower n-3 
index than the healthy group). A significant decrease in levels of eicosapentaenoic acid 
(EPA, 29.3%), docosahexaenoic acid (DHA, 27.2%), arachidonic acid (AA, 15.8%) and 
n-3 index (26.9%) was found in the erythrocytes of the UHR group compared to healthy 
controls. Additionally, at a lipid class level, the UHR group had higher concentrations of 
sphingomyelin (16%) and lower concentrations phosphatidylethanolamine (46%) 
compared to healthy group; these differences may represent a promising prodromal 
risk biomarker in the UHR population to aid clinical diagnosis. 
 
The third aim of this thesis was to evaluate the effect of n-3 LCPUFA supplementation 
on erythrocyte membranes from individuals at UHR of developing psychosis. It was 
hypothesized that n-3 LCPUFA supplementation would alter n-3 status in these 
individuals. n-3 LCPUFA supplementation significantly increased the 20:5, 22:6 and 
most of 22:5 fatty acid containing lipid species, with a range of increased levels of 12%-
50%. Furthermore, n-3 LCPUFA supplementation significantly decreased 18:2, 20:3, 
20:4, 22:4 fatty acid containing lipid species, with a range of decreased levels of 7.4%-
43%. Additionally, the omega-3 index was significantly increased by 37% after 6 
months of receiving n-3 LCPUFA capsules. The response of n-3 index to n-3 LCPUFA 
supplementation was much lower than previous studies that administered EPA+DHA 
for up to 12 months; this is likely a consequence of low compliance (< 44%) in both 
groups. 
 
People at UHR of developing psychosis have a 30% chance of developing the illness 
within three years. The final aim of this thesis was to identify potential biomarkers, i.e., 
n-3 index, fatty acids and/or molecular phospholipid species that may be a predictor of 
transition to psychosis for people at UHR. Results showed that there were no 
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differences in the omega-3 index, fatty acids or molecular phospholipid species 
observed between those with UHR that did and did not transition to psychosis. This 
suggests that the n-3 index, fatty acids or molecular phospholipid species are not 
useful markers to predict transition to psychosis in people at UHR of developing 
psychosis. 
 
This thesis presents an optimized method that allows the identification and 
quantification of the n-3 index, fatty acids and molecular phospholipid species in 
erythrocytes; using automated extraction and ESI-MS analysis. The throughput ESI-MS 
method does however, have limitation, the double bond location cannot be determined, 
e.g., this method is unable to determine whether 22:5 DPA is 22:5n-3 or 22:5n-6 or if 
18:1 is 18:1n-9 or 18:1n-7. A significant outcome of this thesis was identifying that 
people at UHR of developing psychosis have lower n-3 index, fatty acids and 
phospholipid levels compared to healthy subjects. However, none of the assessed 
lipids i.e., n-3 index, fatty acids and molecular phospholipid species were able to 
predict the transition to psychosis in those at UHR of psychosis. Given the numerous 
differences in lipid levels between those at UHR of psychosis and healthy controls, it 
could be argued that the lipid pathology commences prior to the development of 
psychosis. The lack of lipid differences between those at UHR that transitioned to 
psychosis and those at UHR that did not suggests that another trigger is required for 
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 Literature Review 
1.1 Lipids 
The term “Lipids” was initially defined as organic compounds that are soluble in organic 
solvents but insoluble in water, and that are commonly present in or derived from the 
living organisms (Christie & Han 2012). This chemical class covers a broad range of 
molecules, such as fatty acids, triacylglycerols (TAG), phospholipids, sterols, 
sphingolipids and terpenes. However, this definition does not cover all lipids in 
biological systems, since several new classes (such as lipopolysaccharides) are now 
widely regarded as lipids, even though they are not soluble in organic solvents 
(Ivanova et al., 2007). The International Lipid Classification and Nomenclature 
Committee on the initiative of the LIPID MAPS Consortium broadly define lipids as 
“hydrophobic or amphipathic small molecules that may originate entirely or in part by 
carbanion based condensations of ketoacyl thioesters (fatty acyls, glycerolipids, 
glycerophospholipids, sphingolipids, saccharolipids, and polyketides) and/or by 
carbocation-based condensations of isoprene units (prenol lipids and sterol lipids)” 
(Fahy et al., 2011). 
1.1.1 General lipid structures, classification and nomenclature  
Lipids are characterized by structural diversity and complexity, with over 37,000 unique 
structures currently stored in LIPID MAPS, the most comprehensive lipid structure 
database, and up to 180,000 different structures of lipids in theory (Brugger, 2014). 
Simple lipids (usually neutral) are defined as those yielding at most two types of 
primary products per mole upon hydrolysis (such as acylglycerols, ether acylglycerols, 
sterols and their esters and waxes); Complex lipids (usually polar) yield three or more 
primary hydrolysis products per mole (such as phospholipids and glycolipids). In 2005, 
The International Lipid Classification and Nomenclature Committee and The LIPID 
MAPS Consortium established a comprehensive classification system for lipids that 
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covers both eukaryotic and prokaryotic sources. This commonly accepted system 
classified lipids into eight well-defined categories (Fatty Acyls, Glycerolipids, 
Glycerophospholipids, Sphingolipids, Sterol lipids, Prenol lipids, Saccharolipids, 
Polyketides) (Fahy et al., 2009, 2011). 
Considering the vast complexity of lipids (containing positional and conformational 
isomers of fatty acids and/or double bonds), use of a uniform nomenclature is 
essential. The “gold standard” for chemical nomenclature is provided by the 
International Union of Pure and Applied Chemistry (IUPAC) and also includes lipids 
(Anon 1967; Anon 1970; Moss 1978), although these recommendations are somewhat 
outdated nowadays. The LIPID Metabolites And Pathways Strategy (LIPID MAPS) 
consortium, founded in 2003, has provided a widely accepted lipid nomenclature for 
lipidomics (Fahy et al. 2005; Fahy et al. 2009), describing lipids on various levels. On 
the simplest level, a lipid is only identified with its class and monoisotopic molecular 
mass. In contrast, for the most precise and unambiguous identification, the positions of 
the fatty acyls need to be known, as do the positions and conformations of the double 
bonds. The entire complexity however cannot always be deduced from lipidomic 
analyses. For example, the identities of fatty acyl constituents of phospholipids can 
never be deduced from single stage mass spectrometry. Further elucidating the 
structure of fatty acyls, especially the location or the conformations of double bonds, is 
tremendously difficult and requires specialized techniques such as ozonolysis (Sun et 
al. 2013; Batarseh et al. 2018). 
It is essential that lipidomic results are reported at the correct identification level, and 
that as few assumptions as possible are made concerning the structure. In particular, 
automated tools used for data analysis of large-scale untargeted lipidomics or 
metabolomics studies often erroneously assume a deeper level than is actually 
reached and their matching algorithms may for example report results at the fatty acyl 
structure level, although the method is based only on full scan or tandem mass 
spectrometric measurement (Liebisch et al. 2015).  
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1.2 Membrane bilayer &  Phospholipids  
Biological membranes provide a barrier within and around the cells of all living 
organisms. These membranes primarily consist of a lipid bilayer and embedded 
proteins. The lipid bilayer includes both phospholipids and cholesterol, but the 
phospholipids are the most important structural component of the membrane (Figure 
1.1). The basic structure of lipid membranes was described in 1972 as the fluid mosaic 
model (Singer & Nicolson, 1972). The hydrophobic hydrocarbon tails of the 
phospholipids face each other to form an oily centre and the polar head groups face 
outwards towards the aqueous solutions on either side of the membrane. Only small 
hydrophobic solutes are able to pass through this barrier and there is low permeability 
for polar inorganic compounds and ionic molecules, giving the cell control over 
processes occurring across the cellular membrane (Singer & Nicolson, 1972). 
 
Figure 1.1: structure of a typical biological membrane_modified from 
http://fig.cox.miami.edu/faculty/dana/membrane.jpg; visited 12/04/2017 
 
The physical properties of the lipid bilayer are affected by its lipid composition, as well 
as the temperature and membrane pressure (Williams, 1998). Temperature affects a 
lipid membrane, the acyl moieties of membrane phospholipids change from a solid, 
hexagonal close packing to a fluid as the temperature is increased (Cronan & 




degree of unsaturation (i.e. number of double bonds) will affect the fluidity of the lipid 
bilayer (Leekumjorn et al., 2009). The presence of a double bond in the acyl chain 
creates more freedom of movement at the carbon next to the double bond, thus 
increased desaturation results in the hydrocarbon chain are more loosely packed than 
those of saturated fatty acids in the lipid bilayer (Lee, 2003). 
Phospholipids and specific fatty acids within phospholipids play important structural 
and functional roles in the membrane bilayer. One type of phospholipid class is the 
glycerophospholipid, consisting of a 3-carbon glycerol backbone with each of the three 
carbons denoted as sn-1, sn-2 or sn-3 in terms of position and a phosphate group is 
attached at the sn-3 position and two fatty acyl chains are attached at the sn-1 and sn-
2 positions. Another type of phospholipid is sphingomyelin, part of a class of lipids 
named sphingolipids; this lipid contains a sphingosine backbone instead of a glycerol 
backbone and has only one attached fatty acyl chain.  
The differences in the structure of the head group determine the classes of 
phospholipids. The following are the most abundant phospholipids in human red blood 
cell membranes: phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), sphingomyelin (SM) and phosphatidylinositol (PI) (Belhocine 
& Prato 2011; Hussein, 2013). PC and SM are primarily found in the outer monolayer, 
the amino phospholipids, PE, PS and PI are mainly to be found in the inner monolayer 
(Butikofer et al. 1990; Srinivasan et al., 1999). The type of head group is known to not 
only affect its position in the membrane bilayer (Tresset, 2009), but it also affects its 
distribution between tissues (Veloso et al., 2011) and its interaction with protein (Lee, 
2003). 
Membrane phospholipids typically consist of at least 50% unsaturated fatty acids, with 
the sn-1 position usually saturated fatty acids (SFA) or monounsaturated fatty acids 
(MUFA) and the sn-2 position commonly taken up by an unsaturated acyl chain usually 
polyunsaturated fatty acids (PUFA) (Lands, 2000). In some tissues, however there is a 
higher proportion of unsaturated fatty acids present in the phospholipid, which 
21 
 
increases the fluidity of the membrane; for example, in the eye and brain (Geiser, 
1990). 
1.3 Fatty Acids  
The basic composition of fatty acids involves a hydrocarbon chain with a carboxylic 
acid (-COOH) moiety. Two structural characteristics determine how specific fatty acids 
are named: the length of the hydrocarbon chain and the number / position of double 
bonds. 
 
The three types or families of fatty acids are those that are saturated (SFA), 
monounsaturated (MUFA) and poly unsaturated (PUFA) - depending on the number of 
double bonds occurring between carbon atoms. They also are classified by length 
within the carbon chain, with the short-chain fatty acids containing less than eight 
carbons, the medium-chain fatty acids having between 8 and 12 carbons (Huang et al., 
2011; Schmalz & Kerrigan, 2003) and the long-chain fatty acids, consisting of 16 or 
more carbons (Schonfeld & Wojtczak, 2016). From a nutritional perspective, however, 
the classification changes. In terms of essential fatty acids (described below), they are 
labeled as short-chain when having 18 carbons and are considered as long-chain when 
containing 20 or more carbons (Nichols et al., 2010). 
1.3.1 Saturated Fatty Acids  
SFA are those whose chain contains only carbon-carbon single bonds. These carbons 
are saturated completely with hydrogen atoms, thus the name SFA. SFA provide 
rigidity because their physical properties allow them to be stacked tightly. They become 
solid at room temperature when used to make a food fat such as butter.  
These fatty acids also have important structural properties which provide a useful 
energy source. Stearic acid, (containing 18 carbons) and palmitic acid (containing 16 
carbons) are the most common SFA found in animal product (Schmalz & Kerrigan, 
2003). Vegetable derivatives of SFA are also found, including palm oil, coconut oil, and 
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palm kernel oil, all produced from vegetables that are normally found in locations with 
tropical climates (Johnson & Sanders, 1994).  
 1.3.2 Unsaturated fatty acids 
 
In cases where one or more double bonds are present in the carbon chain, the fatty 
acid is referred to as unsaturated fatty acids. Examples of unsaturated fatty acids 
include MUFA and PUFA (Table 1.1). When one or more pairs of hydrogen atoms have 
been removed, this causes the formation of a double bond, which results in a kink or 
bend developing in the fatty acid molecule. Because the unsaturated fatty acids 
containing several double bonds usually occupy more space, thereby making a fat 
containing them liquid (an oil) and cell membranes more fluid (Schmalz & Kerrigan, 
2003).  
Table 1.1: Examples of unsaturated fatty acids 
Common Name Scientific Name 
Molecular 
Name Abbreviation 
Monounsaturated Fatty Acids 
Vaccenic Acid 11-octadecenoic acid 18:1 n-7 VA 
Oleic Acid 9-octadenoic acid 18:1 n-9 OA 
n-3 Polyunsaturated Fatty Acid 
alpha-linolenic acid 9,12,15-octadecatrienoic acid 18:3 n-3 ALA 
Stearidonic acid (SDA) 6,9,12,15-octadecatetraenoic acid 18:4 n-3 SDA 
Eicosapentaenoic acid 5,8,11,14,17-eicosapentaenoic acid 20:5 n-3 EPA 
Docosapentaenoic acid 7,10,13,16,19-docosapentaenoic acid 22:5 n-3 n-3 DPA 
Docosahexaenoic acid 4,7,10,13,16,19-docosahexaenoic 22:6 n-3 DHA 
n-6 Polyunsaturated Fatty Acid 
Linoleic acid 9,12-Octadecadienoic acid 18:2 n-6 LA 
Gamma-linolenic acid 6,9,12-Octadecatrienoic acid 18:3 n-6 GLA 
Arachidonic acid 5,8,11,14-eicosatetraenoic acid 20:4 n-6 AA 




Fatty acids that contain one double bond are MUFA. Typical examples of MUFA 
include palmitoleic acid (16:1 n−7), cis-vaccenic acid (18:1 n−7) and oleic acid (18:1 
n−9, OA). MUFA are found in vegetable oils such as olive oil and canola oil (Schmalz & 
Kerrigan, 2003). MUFA is also found in beef fat and lard fats. Additional sources of 
MUFA include avocado, grape seed oil, peanut oil, macadamia nut oil, tea oil and also 
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whole grain wheat, popcorn, cereal, oatmeal, and camellia (Schmalz & Kerrigan, 2003).   
 
The name given to fatty acids containing more than one double bond is PUFA. For 
example, n-3 and n-6 fatty acids indicate fatty acids in which the first double bond 
begins at 3 and 6 carbons from the methyl end, respectively. The fatty acid with the 
symbol 18:3 n-3 is identified by 18 carbon atoms and 3 double bonds with the first 
double bond at the third carbon atom from the methyl end (Gurr et al., 2002). 
Linoleic acid (LA) is classified as an essential fatty acid and is the primary PUFA found 
in western diets (Meyer et al., 2016). High proportion of LA found in vegetable oils, 
such as, corn, safflower, sunflower and soybean oils (Schmalz & Kerrigan, 2003). 
Other sources of high levels of LA include evening primrose and borage oil. Muscle 
and organ meats are animal products that provide a major source of n-6 PUFA in the 
form of arachidonic acid (ARA) (Sinclair, 1991). 
The n-3 polyunsaturated fatty acids (n-3 PUFA) can be found in both short and long-
chain varieties. Alpha-linolenic acid (ALA) contains 18 carbons and 3 double bonds. 
Classifying ALA as essential means that all vertebrates are incapable of 
biosynthesizing it denovo. n-3 LCPUFA are eicosapentaenoic acid (EPA), 
docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA). Comparing them to 
ALA, these fatty acids have an elongated and highly unsaturated content. To be 
specific, EPA contains 20 carbons and 5 double bonds, while DPA has 22 carbons with 
5 double bonds and DHA has 22 carbons 6 double bonds. 
The dietary source of n-3 LCPUFA mainly comes from fish and seafood (Oken, 2015; 
Gil & Gil, 2015). The initial production of n-3 LCPUFA occurs from small aquatic plants 
- marine micro-algae that is found and consumed within the bottom of the marine food 
chain, and then accumulated in the fish and other seafood thereby bioaccumulating in 
the seafood chain (Nichols et al., 2010). Marine fish, most particularly oily fish such as 
sardines, mackerel, tuna, salmon, herring, anchovies and oysters, provide the richest 
food sources of n-3 LCPUFA (Nichols et al., 2010). Lower amounts can be found in 
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meat (Howe et al., 2006) especially lean meat and eggs (Meyer et al., 2003). Foods 
that have been enriched with n-3 LCPUFA such as bread, eggs, margarine and other 
spreads, milk products, and any infant formula also provide a small amount of n-3 
LCPUFA (Whelan & Rust 2006). Likewise, meat products or meat may be enriched 
with n-3 LCPUFA by the animals’ diet (Kitessa et al., 2004; Wood et al., 1999). Another 
possible source of n-3 LCPUFA is obtained by genetic modification, which transfers the 
genes responsible for the production of n-3 LCPUFA to plants that are land-based 
(Wood et al., 1999; Truksa et al., 2006; Nichols et al., 2010). 
1.4 n-3 LCPUFA Metabolism 
The process of converting dietary ALA into EPA and DHA primarily takes place in the 
endoplasmic reticulum of the cells of the liver by a series of enzymatic processes (Scott 
& Bazan, 1989). The processes involve a range of elongation enzymes that will add 
carbon units, along with desaturation enzymes e.g. Δ-5 and Δ-6 desaturases which 
insert double bonds in the fatty acid molecules (Burdge, 2006) (Figure 1.2).  
The low n-3 fatty acid conversion rate in humans is brought about because only a small 
percentage of ingested fatty acids are subjected to elongation in the process of 
creating the long-chain PUFA (Barceló-Coblijn & Murphy, 2009) and the same 
enzymes are used by both ALA and LA fatty acids and this result in significant 
competition (Brenna et al., 2009). To explain it in more detail, in the human body 
(including the brain), large quantities of ALA and LA undergo degradation by way of 
processes of β- oxidation (Barceló-Coblijn & Murphy, 2009). The products that come as 
a result of this are used to produce adenosine triphosphate (ATP), a highly essential 
source of energy for cellular activities (Burdge & Calder, 2006; Russo, 2009). The 
percentage of fatty acids that remains is either stored in adipose tissues or is used to 
produce neutral and polar lipids such as phospholipids, sphingolipids and triglycerides 
in tissues and organs such as the brain and liver (Barceló-Coblijn & Murphy, 2009; 
Russo, 2009).  
n-3 DPA is an elongated metabolite of EPA. It plays an intermediary role in the 
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conversion process of EPA and DHA (Voss et al., 1991). The enzyme fatty acids 
elongase-2 (Elovl-2) and Elovl -5 (Wang et al., 2005) are responsible for mediating the 
conversion of EPA to DPA. During this process, an active interchange of EPA and DHA 
takes place in the endothelial cells, which then results in the accumulation of DPA n-3 
(Rosenthal & Hill, 1986). 
The conversion process shown in (Figure 1.2) is inefficient and highly variable 
(Breslow, 2006). Isotope-labelled ALA feeding trials indicate that roughly 0.2 to 21% of 
ALA that is consumed is then converted into EPA (Emken et al., 1994; Gerster, 1998; 
Burdge, 2006). Another influence on this conversion process is the fact that the gender 
also plays a role, since it has been established that there is a higher conversion rate in 
women (Burdge & Calder, 2006). In a study focusing on adult males, the conversion 
rate of ALA to EPA was indicated as roughly 8%; while in the case of DHA, the range 
was from 0 - 4% (Emken et al., 1994). This suggests that men rely more on pre-formed 
DHA while in the case of women, the conversion of ALA to DHA is shown to be 
considerably greater. In addition plasma conversion of EPA and DHA from ALA has 
been shown to be 21% and 9.2% higher in women than men (Burdge & Wootton, 
2002). It would seem that a possible explanation for the apparent synthesis of DHA in 
women is due to an up-regulation of the desaturation and elongation pathway due to 
































Figure 1.2: Metabolism of n-3 LCPUFA (Modified from SanGiovanni & Chew, 2005, 
Ratnayake & Galli, 2009). 
 
 
1.5 Biomarkers for n-3 LCPUFA status  
A biomarker is generally referred to a measurable indicator of some biological state or 
condition. There are several tissues that are potential suitable biomarkers of n-3 
LCPUFA status. These include cheek cells, adipose tissue biopsies, plasma, whole 
blood and erythrocyte membranes (Hirsch et al., 1960; McMurchie et al., 1984a; Arab, 










































 In table 1.2, the typical n-3 fatty acid composition of adult human body tissues are 
shown. 
Table 1.2: proportions of n-3 fatty acid composition in blood, cell and tissue lipid 
fractions from adult human tissues. Table adapted from (Burdge & Calder, 2006). 
Lipid fraction 
% of Total fatty acids 
ALA EPA DHA 
Plasma phosphatidylcholine 0.1 0.8 2.9 
Plasma cholesteryl ester 0.4 0.8 0.5 
Plasma TAG 0.3 0.2 1.1 
Platelet phosphatidylcholine 0.3 0.2 1.1 
Platelet phosphatidylethanolamine 0.2 0.6 6.3 
Mononuclear cell phospholipid 0.1 0.3 2.3 
Neutrophil phospholipid - 0.6 1.3 
Erythrocytes phospholipid - 0.8 3.5 
Liver phosphatidylethanolamine 0.2 1.6 7.7 
Brain grey matter phosphatidylethanolamine 0.1 - 24.3 
Brain grey matter phosphatidylserine - - 36.3 
Brain grey matter phosphatidylcholine - - 3.1 
Brain white matter phosphatidylethanolamine - - 3.4 
Retina phosphatidylcholine - - 22.2 
Retina phosphatidylethanolamine - - 18.5 
Retina phosphatidylserine - - 4.6 
Testis total lipids - - 8.5 
Sperm phospholipid - - 35.2 
White adipose tissue     0.7   0.1 
ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; TAG, triglycerides 
1.5.1 Cheek cells  
An analysis of fatty acids in cheek (buccal epithelial) cells by McMurchie et al., (1984a) 
showed that this type of analysis delivered an appropriate measure of dietary lipids in 
human body. The examination consists of an initial collection of cheek cells by 
vigorously rinsing the mouth using 40ml of distilled water this following by centrifugation 
for 10min and the pellet of cells resuspended in 1 ml distilled water. In the presence of an 
antioxidant, the total lipids are then extracted from the cheek cell and the phospholipids 
methylated in 1% (v/v) H2SO4 in methanol, and separated by thin-layer 
chromatography (TLC) from the other lipid classes. Fatty acid methyl esters (FAME) are 
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then assessed by gas-liquid chromatography (McMurchie et al., 1984a). 
The composition of cheek cell fatty acid gave a sensitive marker of human fatty acids 
and reflect the dietary LCPUFA consumption in preterm infants (McMurchie et al., 
1984a; Koletzko et al., 1999). Moreover, the DHA content in newborn infants cheek cell 
phospholipids was highly correlated with that of both plasma phospholipids r=0.53 and 
0.83 at 36 weeks and at 57 weeks respectively and erythrocytes lipids r=0.46 and 0.72 
at 36 weeks and at 57 weeks respectively (Hoffman et al., 1999). Nevertheless, in 12 
week period diet intervention study showed interesting results, the level of LA in the 
cheek cell phospholipids responded to an alteration from a low to a high PUFA/ SFA 
diet but not to the opposite manipulation (McMurchie et al., 1984b). This demonstrated 
that cheek cell phospholipids’ response to the alterations in dietary intake of various 
fatty acids is not the same. Hence, the validity of using check cells for examining the 
fatty acid status remains unclear in dietary research. In summary, cheek-cell lipid 
evaluation is of possible value in nutrition research investigations and of beneficial use 
in epidemiological research on fatty acid assessment mainly from children (Laitinen et 
al., 2006; Koletzko et al., 1999; McMurchie et al., 1984 a, b; Abraham et al., 2013). Yet, 
the amount of assessment material is very small and there is high threat of 
contamination of sample by food particles. 
1.5.2 Adipose tissue    
 
Fatty acids from subcutaneous adipose tissue has been used since the 1960s to 
measure the habitual long-term dietary fatty acid intake of human beings 
 (Hirsch et al., 1960).The adipose tissue biopsy is mostly taken using a needle and 
disposable syringe from the upper buttock (Hirsch et al., 1960). In weight stable 
individuals adipose tissue fatty acids provide the best choice for the study of long- term 
fatty acid intake (> 6 months) because of their absence of response to acute disease 
and slow turnover 2-3 years (Dayton et al., 1966). However, the fatty acid composition 
can be affected by the tissue-sampling site (Phinney et al., 1994; Malcom et al., 1989). 
Research comparing fat from outer and inner thighs and abdominal areas has shown 
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that there is greater levels of SFA in abdominal fat (Phinney et al., 1994), whereas 
PUFA levels were lowest in the abdomen, moderate in the inner thigh, and the greatest 
in the outer thigh. The observed differences were as high as 17% for PUFA and 30% 
for SFA (Phinney et al., 1994). A comparison of fatty acid patterns from two 
subcutaneous sites (abdomen and buttocks) and a deep-seated site (perirenal) from 
autopsies of a group of adults belonging to different ethnicities showed that the 
proportion of SFA were lowest in the gluteal depot and greatest in the perirenal adipose 
tissue. While MUFA were greatest in the gluteal depot, PUFA profiles, however, were 
not significantly different across these three tissue sites (Malcom et al., 1989). The 
differences in fatty acid composition from subcutaneous adipose tissues in the 
abdominal area are more evident than adipose tissue from gluteal pool in 
demonstrating the dietary n-3 LCPUFA intakes (Katan et al., 1997). As a result, the 
sampling of adipose tissue should be conducted carefully and accurately to make sure 
that the results between subjects are comparable. Even though adipose tissue is 
usually considered by most researchers as a gold standard biomarker for long-term 
dietary fatty acid alterations (>6 months), because of the complications in collecting the 
tissue specimens, adipose tissue is not a practical option for usage in routine 
population screening or large clinical research (Beynen & Katan, 1985).  
The investigation of the composition of human adipose tissue as a dependable 
biomarker of dietary fat intake was carried out in six research studies, which all chose 
Dietary assessment by Food Frequency Questionnaire (FFQ) and Gas 
chromatography (GC) to assess the fatty acid composition of human tissues. One 
research study evaluated habitual fish intake by assessing marine n-3 LCPUFA 
composition of adipose tissue only (Marckmann et al., 1995); Trans fatty acid (TFA) 
was measured in another (Clifton et al., 2004), and ALA and the risk of nonfatal acute 
myocardial infarction (MI) were evaluated in two research studies (Baylin et al., 2003; 
Campos et al., 2008). The reliability of adipose tissue as biomarker for a number of 
fatty acids was assessed by further (Baylin et al., 2002; Craig et al., 2009). All the six 
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research studies found that there was a relationship between adipose tissue 
composition and dietary fat intake as evaluated by FFQ. Case control studies on 
Australian groups indicate that adipose tissue TFA composition is associated with 
consumption of TFA from the diet (18:1n-9, r=0.66, 18:1n-10, r=0.66) (Clifton et al., 
2004). Interestingly, in mid-1996 TFA was removed from margarine, and levels of TFA 
(18:1n-9 and 18:1n-11) were higher in cases biopsied before mid-1996 (P< 0.03, P< 
0.001 respectively). It was established in the research that adipose tissue TFA levels 
(18:1n-9 and 18:1n-10) were correlated to TFA in the diet, suggesting that adipose 
tissue is a good biomarker of dietary TFA consumption (Clifton et al., 2004). Higher 
levels of ALA were found in the adipose tissue of controls in comparison to patients 
who had experienced a MI (Baylin et al., 2003). Consequently, Campos et al., (2008) 
conducted a follow-up of this research, assessing the relationship between the 
consumption of ALA and the risk for myocardial infarction MI on 1819 subjects and the 
same number of controls, showing that approximations of the proportion of ALA in 
adipose tissue correlated with dietary ALA consumption. Interesting results were 
obtained when using adipose tissue as a biomarker of habitual fish consumption, 
where the outcomes demonstrated that the marine n-3 PUFA (r=0.58) and fish 
consumption (r=0.55) were considerably associated with adipose tissue DHA content 
(P< 0.001), but were not considerably associated with EPA and DPA levels 
(Marckmann, 1995). The other two studies (Baylin et al., 2002; Craig et al., 2009) 
compared the reliability of the use of adipose tissue as a biomarker of different fatty 
acids. The first demonstrated that adipose tissue is appropriate for the evaluation of 
TFA (r=0.58) and n-6 PUFA (r=0.58), n-3 PUFA (r=0.34) consumption from dietary 
intake (Baylin et al., 2002), while the other reported the reliability of adipose tissue to 
considerably reflect EPA (r=0.41) and DHA (r=0.36) (Craig et al., 2009). In conclusion, 
the findings proposes that adipose tissue is appropriate to estimate intake of TFA and 
PUFA so long as sampling sites are similar within the study. The reliability for 
evaluating intake of MUFA and specific SFA remain unclear.  
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1.5.3 Plasma  
 
Since the 1950s plasma has been in use widely for evaluating human fatty acid status, 
(Bronte-Stewart et al., 1956; Ahrens et al., 1957). Plasma contains lipoproteins which 
contains fatty acids as well as free fatty acids bound to albumin; when measuring 
plasma fatty acids the level of phospholipids, cholesterol ester and triglycerides are 
highly variable. Plasma fatty acid levels have also provided a sensitive indicator of 
alterations in dietary consumption of LCPUFA (Dougherty et al., 1987). However, the 
strength of the relationship between the amount of LCPUFA in plasma and estimated 
dietary consumption of certain fatty acids differ for various fatty acids (Glatz et al., 
1989; Vessby, 2003). There are relatively strong relationships between the amount of 
n-3 PUFA (r=0.31), EPA (r=0.34) and DHA (r=0.41) in the diet and the proportions of 
fatty acids in plasma phospholipids (Warensjo Lemming et al., 2015). The 
relationships between the levels of fatty acids in plasma phospholipids and SFA in the 
diet are weak (r=0.15) and the relationships for MUFA are are almost nonexistent 
(r=0.05) (Ma et al., 1995). This may reflect the point that while the amounts of PUFA in 
blood lipids and human tissue are ultimately resulting from the diet (Riboli et al., 1987; 
James et al., 1993), considerable amounts of SFA and MUFA are endogenously 
synthesized in the human body (Ma et al., 1995). The short lifetime of circulating fats 
in plasma is a limitation for using plasma fatty acids as a biomarker of fatty acid status 
in human body. The levels of fatty acids in plasma only reflect the dietary fat 
composition over the last few days meals (plasma triglyceride) or (plasma 
phospholipid fatty acids and serum cholesterol ester) (Kohlmeier & Kohlmeier, 1995). 
Hence, plasma fatty acid status does not have the capability to deliver information on 










1.5.4 Whole blood 
 
For a fatty acid biomarker whole blood is an attractive alternative option when 
conducting epidemiologic studies compared with erythrocytes or plasma samples, 
because of its easier processing requirements. It was validated in a research 
conducted by Baylin et al., (2005) that fasting whole blood reflects dietary intake of LA 
and ALA, high correlations were observed between whole blood ALA and LA and 
plasma (r=0.96 and r=0.88) and adipose tissue (r=0.59 and r= 0.67) respectively 
(Baylin et al., 2005). However, whole blood fatty acid concentration is more difficult to 
interpret because the blood volume proportion that is occupied by erythrocytes 
changes with age and gender (Cirillo et al., 1992) and can be affected by factors such 
as pregnancy, cardiac and pulmonary diseases (Belo et al., 2002) and hypertension 
(Cirillo et al., 1992). Thus, the likelihood for differences in the percentage of whole 
blood composed of erythrocytes and plasma needs to be considered cautiously to 
avoid the misinterpretation the results of whole blood fatty acid (Rise et al., 2007). 
1.5.5 Erythrocytes 
 
Many investigators consider erythrocyte lipids as a reliable indicator of relatively long-
term (few weeks to few months) dietary fatty acid consumption as compared to 
plasma lipids, this is because the turnover of fatty acid status in erythrocytes is much 
slower compared to plasma (Glatz et al., 1989; Siscovik et al., 1995; Poppitt et al., 
2005). Erythrocyte fatty acid profile was not significantly affected by alterations in 
short-term (a few days) dietary consumption of EPA and DHA, when compared to the 
fatty acid profiles of plasma or platelet phospholipids or plasma free fatty acids (Von 
Schacky et al., 1985; Harris et al., 2007). The average lifespan of erythrocytes is 120 
days (Franco, 2012) significantly longer (Ebaugh et al., 1953; Prisco et al., 1991), 
less brief as compared to that of the platelets (7-10 days) (Harker et al., 2000; 
Andreoli et al., 1973) and less variable than white blood cells (hours to years).  
The mature erythrocyte does not comprise any intracellular membrane compartments 
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other than its plasma membrane component (Mikhalyov et al., 2001). Consequently, 
any lipids that may be established from the erythrocyte must originate from its lipid 
bilayer. 
The n-3 LCPUFA concentration in erythrocytes provides a good biomarker that can be 
used to measure n-3 fatty acid (Harris et al., 2004; Sullivan et al., 2006), erythrocytes 
contain a substantial concentration of n-3 LCPUFA (Arterburn et al., 2006; Burdge & 
Calder, 2006), and there is no significant fluctuation unless dietary intake of n-3 
LCPUFA is increased (Arab, 2003; Di Marino et al., 2000). Also, erythrocyte n-3 
LCPUFA levels have less inter-individual variability than plasma (Harris et al., 2004), 
reflects intake that has occurred during the past 120 days (Arab, 2003) and maintain a 
level of stability at -80°C for several years (Arab, 2003). There is evidence that a linear 
relationship can be seen between erythrocyte EPA, DHA and total n-3 LCPUFA r=0.92, 
r=0.69 and r=0.78 respectively and the intake of EPA, DHA and total n-3 LCPUFA 
(Swierk et al., 2011). Also, there is a strong relationship between the total levels of 
DHA+EPA in erythrocytes and cardiac tissues (r=0.82) (Harris et al., 2004). This makes 
extraction of fatty acids from erythrocyte membranes suitable for long-term evaluation 
of fatty acid status. 
1.6 Lipidomics  
1.6.1 Introduction 
With the rapid development of lipid research, the concept of “lipidomics” was 
introduced in the early 2000s. Lipidomics focuses on the global study of molecular 
lipids in biological systems and aims at the “full characterization of lipid molecular 
species and of their biological roles with respect to expression of proteins involved in 
lipid metabolism and function, including gene regulation” (Spener et al.,2003). 
Advances in mass spectrometry instrumentation and computational methods have 
greatly promoted the development of the lipidomics field, enabling precise identification 
and quantification of the lipidome in cells and tissues. Through the incorporation of 
multiple lipidomics techniques, lipidomics have provided insight into the functional roles 
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of subcellular membrane compartments in mammalian cells and have expanded our 
knowledge on human health and diseases (Han & Gross, 2003). 
Over past decades, the relationship between blood lipids and n-3 intake has been 
examined extensively. This has been greatly influenced by early associations between 
the consumption of fish and positive health outcomes, such as reducing the risk of 
developing heart disease (Dyerberg & Bang, 1979; Chowdhury et al., 2014). Most of 
this research has used fatty acid compositional data derived from gas chromatography 
analyses, resulting in specific parent acyl lipid species information being lost and 
limited to the fatty acid composition of lipid classes (Xu et al., 2007). Lipidomics can 
allow us to identify relationships between lipids, diet and health at the level of individual 
molecular species of complex lipids. Therefore, the metabolism of these very specific 
lipid molecules can be better characterized. The emerging literature on analysis of 
native lipids containing n-3 in biological samples include the analysis of single lipid 
classes of cell cultures (Ramanadham et al., 2000; Rucker et al., 2013), isolated 
tissues (Lamaziere et al., 2011; Murthy et al., 2002; Sjovall et al., 2015), plasma, 
erythrocytes and other circulating blood cells (Ottestad et al., 2012; Pacetti et al., 2004; 
Stanke-Labesque et al., 2008; Uhl et al., 2013). 
1.6.2 Erythrocyte lipid extraction  
There have been several popular methods for total lipid extraction including Folch et 
al., (1957), Bligh & Dyer (1959) or Rose & Oklander (1965) methods. Lipid extraction 
has been performed by using chloroform: methanol (2:1) in the Folch's method, this 
method shows high efficiency of lipid extraction however, it poses some disadvantages 
such as formation of highly pigmented (Folch et al., 1957). Bligh and Dyer have used 
chloroform, methanol and water, where the chloroform layer contained lipids and the 
methanol-water layer contained non-lipids. This method attempted to eliminate the 
centrifugation step in the lipid extraction and instead create a spontaneous phase 
separation, the proposed system seems to be more effective and time saving 
compared to Folch et al., (1957) method.  
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Alternative chloroform: methanol extractions have been discussed by Reed et al., 
(1960) and Ways & Hanahan (1964) these extraction procedure have found wide 
application with reliable results. However, there is still an issue that heme pigment is 
often extracted as well, this pigment is difficult to remove and may have catalytic 
effects on auto oxidation processes. Therefore, Rose & Oklander (1965) advised to use 
of isopropanol instead of methanol and proposed a simpler procedure employing 
chloroform: isopropanol (7:11). It is reproducible and simple method, uses a single 
extraction tube and yields an extract with slightly heme contaminated.   
At the present time, procedure allowing both hydrolysis and esterification of bound fatty 
acids are being more popular for saving the time and commonly used. Lepage & Roy 
(1986) have proposed the one-step direct transesterification and extraction procedure 
suitable for total fatty acids as well as fatty acid classes. The advantage of the method 
is no addition of antioxidants to protect unsaturated lipids (Lepage & Roy, 1984) and an 
acidic catalyst (acetyl chloride) are required. The procedure provides higher recovery of 
fatty acids compared to the Folch's method (Rodrı́guez-Palmero et al., 1998). 
Therefore, it is preferable and common method used for the analysis of biological 
samples such as erythrocytes and plasma (Ridges et al., 2001; Rodrı́guez-Palmero et 
al., 1998; Stewart et al., 2007; Goozee et al., 2017; Masood et al., 2005, Masood & 
Salem, 2008). However, whilst this method provides consistent and reliable 
measurement of fatty acids, it has a number of disadvantages. It utilises manual 
sample preparation and as such is time consuming (6 hours to prepare only 24 
samples a day). A relatively large amount of sample (400ul of erythrocytes) is required 
and this method cannot generate molecular phospholipid data as the fatty acids are 
removed from the glycerol backbone during the derivatisation steps. Furthermore, this 
method uses an extremely toxic solvent (benzene). Considerable research effort has 
been focussed on the development of efficient analytical techniques in order to reduce 
time and labour involved in the estimation of fatty acids (Masood et al., 2005; Masood 
& Salem, 2008). Thus far the focus of development has primarily been on modification 
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of the original techniques of Lepage & Roy (1986) and still using gas chromatography 
for analysis.  
The technique for lipid extraction using methyl-tert-butyl ether (MTBE) (Matyash et al., 
2008) simplifies the handling of samples and allows for automated processing of small 
amounts of biological samples. Studies have demonstrated that the use of MTBE in the 
recovery of lipid species for almost all the fundamental categories is similar to, or even 
more efficient than the Folch’s (1957) or Bligh & Dyer's (1959) methods (Matyash et al., 
2008). 
The Matyash et al., (2008) technique that substitutes the use of chloroform with MTBE 
has similar steps as those in Folch method, particularly considering that the two revolve 
around two fundamental steps. First, is the single phase lipid homogenisation of the 
biological matrix in which they are found. Second, is the solubilisation of the lipids in 
the distinct ‘organic” phase. The key distinction between the Folch et al., (1957) and 
the Matyash et al., (2008) method is that in the latter technique, the separation of the 
two phases is spontaneous once the aqueous agent has been added. Extraction of the 
layer containing the organic lipid is also much simpler, as MTBE is much less dense 
than methanol/water mixture. The organic layer containing the lipids forms at the top 
layer, thus reducing the possibility of cross-contamination with the insoluble and non-
lipid materials that often fall to the bottom layer. 
Matyash et al., (2008) devised extraction protocols specifically aimed at being used 
alongside automated robotic platforms combined with a shotgun-lipidomics approach to 
mass spectrometry. The main purpose of this was to produce techniques on the basis 
of a standard 96-well format that makes use of a two-phase solvent system similar to 
the Folch technique (Folch et al., 1957), with the only difference being that there would 
be a spontaneous separation of phases, in which case it would not be necessary to 
undertake centrifugation. Similarly, the technique comes with the use of MTBE, which 
is a much less toxic reagent, with chloroform being replaced by MTBE and methanol as 
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the primary reagent in the extracted phospholipid and fatty acids solubilisation 
(Matyash et al., 2008). 
1.6.3 Electrospray ionization mass spectrometry (ESI-MS) and lipid analysis 
The development of electrospray ionization (ESI) has revolutionized the mass 
spectrometric analysis of biomolecules, including lipids. In 1994, the first combination 
of LC and ESI-MS for phospholipids analysis was published (Kim et al., 1994). Since 
then, ESI has become the most frequently employed ionization technique in the 
lipidomics field. ESI is a soft ionization technique with minimal in-source fragmentation. 
In an ESI experiment, the liquid sample is introduced from an LC column or infusion 
pump to the probe near the orifice of a mass spectrometer. The high potential 
difference between the probe tip and the sample cone causes electroionization of the 
liquid sample. Charged droplets are generated with the help of a drying gas. The 
surface of the droplets that contains the ionized compounds will become charged, 
either positively or negatively. As the solvent evaporates, the size of the droplets is 
reduced, and, consequently, the density of charges at the droplet surface increases. 
The repulsion forces between the charges increase until there is an explosion of the 
droplet. This process repeats until analyte ions are ejected from the droplet (Kim et al., 
1994; Cole, 2000). The ESI technique allows rapid, accurate and sensitive analysis of a 
wide range of analytes from low molecular weight (less than 200 Da) polar compounds 
to biopolymers larger than 100 kDa. Generally, compounds of less than 1000 Da 
produce singly charged molecules and compounds of high molecular weight produce a 
series of multiple charged ions. The typical sample flow rates of the ESI ranges from 5 
to 20 μL/min. Nanoelectrospray today supports stable flow rates as low as 20 nL/min, 
which further increases sensitivity (Brugger, 2014). 
The use of neutral loss (NL) and precursor (PIS) scanning technology was improved 
the reliability and specificity of this methodology (Brugger et al., 1997). The use of this 
type of technology contributed to the specific identification of molecular ions (precursor 
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ions) that upon collision-induced dissociation release characteristic fragment ions. In a 
positive ion mode, the PC and SM can be easily detected and recognized as 
protonated molecular cations which upon collision-induced dissociation these ions 
generate a characteristic fragment ion of the phosphorylcholine head group having m/z 
184.1. A triple quadruple mass spectrometer using PIS m/z 184.1 allowed the 
quantitative profiling of molecular PC and SM classes at the lowest nM levels (Brugger 
et al., 1997). 
The collision-induced dissociation of cationic molecular PS and PE classes the 
particular NL of their head group moiety (e.g. neutral loss of 141 by PE species) which 
prompted their quantitative profiling by NL scanning (Brugger et al., 1997); despite the 
fact that, glycerophospholipids except PC are always negatively charged molecular 
anions. Therefore upon collision-induced separation in negative ion mode, anionic 
glycerophospholipid species generate acyl anions that relate to the fatty acid moieties 
which are attached to the glycerol phosphate backbone (Hsu & Turk, 2000a; 2000b; 
2000c; 2001). Hence, encouraging the use of PIS technology for direct profiling and 
quantitative of the fatty acid that consists of molecular glycerophospholipid classes 
(Beckedorf et al., 2002; Ekroos et al., 2002; Han et al., 2004). Furthermore, the same 
methods have been used for the molecular quantification and characterization of 
sphingolipids (Gu et al., 1997; Han, 2002; Liebisch et al., 1999). 
Recent advances in ESI-MS have enabled increased sensitivity in the detection, and 
accurate characterization, identification, and quantitation of membrane lipid species 
from biological samples. These techniques have been applied in several studies of lipid 
metabolism (Boumann et al., 2003; Boumann et al., 2004; Brooks et al., 2002; DeLong 
et al., 1999; Hunt et al., 2002), lipid trafficking (Heikinheimo & Somerharju, 2002) and 
lipid composition (Blom et al., 2001; Brugger et al., 1999; Brugger et al., 2006; Brugger 
et al., 2004; Fridriksson et al., 1999; Rodemer et al., 2003; Schneiter et al., 1999) but 
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have yet to be applied to studies in people who are at UHR of developing psychosis 
and the effect of n-3 supplementation in this population.  
1.7 n-3 index   
 
The n-3 index defined as the sum of EPA and DHA levels in erythrocytes membranes 
expressed as percent of total fatty acids was first postulated by Von Schacky & Harris 
(2004), for consideration to be used as a new risk factor to determine risk for sudden 
cardiac death.  
There have been several studies done examining which of the n-3 LCPUFA shows the 
most benefit for cardiovascular-related end-points such as nonfatal MI or even sudden 
cardiac death (Sun et al., 2008, Lee et al., 2009). It has been shown in the 
epidemiological studies and large randomized controlled clinical trials (RCTs) including 
the JELIS (Japan EPA Lipid Intervention Study), DART (diet and reinfarction trial) and 
GISSI (Gruppo Italianoperlo Studio della Sopravvivenzanell Infartomiocardico)-
Prevenzione trial), that EPA and DHA supplementation is a favourable treatment for 
both primary and in specific secondary prevention of cardiovascular disorders, 
including heart attack, atherosclerosis, cardiac arrhythmias and stroke (Kromhout et al., 
1985; Burr et al., 1989; GISSI-P, 1999; Marchioli et al., 2002; Yokoyama et al., 2007; 
Lavie et al., 2009). However, currently, the efficiency of n-3 LCPUFA in preventing 
cardiovascular disease (CVD) in adult humans has been doubted by the results of 
some RCTs, which have mentioned that low dose daily intake of DHA and EPA did not 
significantly reduce the rate of major CVD in patients with dysglycemia (Bosch et al., 
2012) and in post MI patients (Kromhout et al., 2010). In addition, the most recent 
meta-analysis (Abdelhamid et al., 2018) showed that the RCTs showed no effect of n-3 
LCPUFA on CVD mortality. However, this meta-analysis included studies with primary 
outcomes not being CVD mortality; there were lower than expected rates of death from 
CVD, most likely due to increased CVD care; and the dose of n-3 LCPUFA (particularly 
DHA) may not have been sufficiently high to demonstrate the efficacy (Meyer & Groot, 
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2017). Furthermore, not all of these studies measured the levels of n-3 LCPUFA in the 
blood. Of these studies that did measure n-3 LCPUFA in the blood, their levels only 
increased by approximately 1% which is not enough of a change to see a difference. 
Further research in this area is necessary with high enough dose of n-3 LCPUFA and 
studies should also check the n-3 LCPUFA at baseline and exclude participants with 
high levels of n-3 LCPUFA status (James et al., 2014). 
Recently, there is emerging evidence that suggests a relationship between an n-3 
index of less than 4% as an independent risk marker for major depressive disorder 
(MDD) in adults (Baghai et al., 2011; Grant et al., 2013), schizophrenia and depression 
(Parletta et al., 2016; 2017). In addition, n-3 index is starting to be utilized in other 
areas such as obesity, depression and diet quality (Burrows et al., 2011; Baghai et al., 
2011; O’Sullivan et al., 2011). However, the research available in these areas is fairly 
limited. Whilst the n-3 index has been used in cardiovascular health applications (Von 
Schacky & Harris 2007; Harris, 2008a) the use of the n-3 index as it applies to mental 
health is still novel and requires further investigation. 
1.8 n-3 LCPUFA and mental health  
 
Several studies have investigated the n-3 LCPUFA (EPA and DHA) ‘status’ of 
psychiatric patients. These studies have found that patients with major depressive 
disorder (MDD)  (Assies et al., 2010; Edwards et al., 1998; Maes et al., 1996; Peet et 
al., 1998; Riemer et al., 2010; Mcnamara et al., 2010), bipolar disorder (Mcnamara et 
al., 2010; Chiu et al., 2003; Ranjekar et al., 2003), schizophrenia (Ranjekar et al., 2003; 
Evans et al., 2003; Khan et al., 2002; Reddy et al., 2004; Parletta et al., 2016), anxiety 
disorders (Green et al., 2006) and attention deficit hyperactivity disorder (ADHD) (Chen 
et al., 2004; Colter et al., 2008; Stevens et al., 1995; Young et al., 2004) exhibit 
significant EPA and DHA deficits in erythrocytes compared with demographically 
similar healthy subjects. 
n-3 LCPUFA, particularly EPA and DHA are capable of playing a role and are seen to 
be related to brain activity (Markrides et al., 1994) as they induce electrical signals from 
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the brain cells to other parts of the body (Bourre et al., 1991; 1992). Studies have been 
conducted confirming the fact that a diet that is low in n-3 LCPUFA could quite possibly 
impair neuron growth and function (Neuringer, 1988). As a result low levels of n-3 
LCPUFA is thought considered to play an important role in mental disorders such as 
depression and dementia (Hibblen & Salem, 1995).  
By incorporating DHA into brain cell membranes, there is also an improvement in the 
fluidity of membranes, which might affect brain function because of its capability to bind 
ligands and initiate a series of signal transduction processes (Michell et al., 2003). 
Brain function is also influenced by DHA and EPA by effecting the working of 
neurotransmitters like dopamine and serotonin (Du Bois et al., 2006), where deficiency 
of n-3 LCPUFA alters the internalization of dopamine in the storage pool of the frontal 
cortex (Zimmer et al., 1998). Also, low levels of n-3 LCPUFA result in changes in the 
vesicular pool of serotonin as well as dopamine, thus inducing several regulatory 
processes such as modification of cerebral receptors in specific brain areas (Chalon, 
2006). 
The presence of n-3 LCPUFA has a critical impact on the function of the brain. DHA is 
a prime structural component of phospholipids within the neuronal cell membranes 
(Horrobin et al., 1991). Altering the lipid environment of the phospholipid bilayer can 
result in changes in the function within the activity of the receptor as well as the activity 
of other proteins embedded in the membrane (Rudin, 1981). Although EPA is not found 
in neuronal cell membranes, it still has several significant physiological functions it can 
perform, such as acting as a precursor for eicosanoids, or as acting as modulator of 
cytokines which have neurotransmitter and neuromodulatory activity (Fenton et al., 
2000). Therefore, there are numerous potential mechanisms where the presence of n-3 
LCPUFA can cause a modulation in brain function. 
It was first suggested by Rudin (1981) that n-3 LCPUFA showed potential for use in 
treating mental disorders. He suggested that the cause of mental health problems 
could be linked to a deficiency in n-3 LCPUFA, and reported that a number of patients 
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had been successfully treated with the use of flaxseed oil which is high in levels of 
ALA. Western diets since that time often show a major deficiency in n-3 LCPUFA 
intakes (Leaf & Weber, 1987; Meyer et al., 2003; Howe et al., 2006; Meyer et al., 
2016). This could possibly be linked to the increasing rate of several psychiatric 
illnesses (Weissman et al., 1996). 
People with schizophrenia were the first to take part in studies involving fish oil 
derivatives. Soon afterward, studies were done on patients exhibiting mood disorders. 
In the first study (a 3-month pilot study), a comparison was made between the effects 
of EPA-enriched oil, DHA enriched oil and corn oil when they are added to an existing 
dosage of antipsychotic medication, the patients who were studied were already 
symptomatic of schizophrenia (Peet et al., 2001). This study showed that those 
patients on high levels of EPA treatment all showed clinical improvement, while 
patients receiving treatment with DHA showed no difference in therapeutic response 
from those offered the placebo (Peet et al., 2001). Since then, studies focusing on 
schizophrenia have been directed toward effects of EPA (Emsley et al., 2002; Peet & 
Horrobin 2002; Fenton et al., 2001; Berger et al., 2004) or in some cases, on the effect 
of a mixture of EPA and DHA (Arvindakshan et al., 2003; Sivrioglu et al., 2007). No 
further studies have been done using pure DHA. An improvement in psychotic 
symptoms was found when an add-on treatment with EPA was incorporated into the 
daily lives of patients suffering from schizophrenia (Peet et al., 2001; Emsley et al., 
2002; Mellor et al., 1995; Arvindakshan et al., 2003; Sivrioglu et al., 2007). Another two 
trials showed no improvement following the use of n-3 LC-PUFA. In one trial, patients 
known to have schizoaffective disorder and those with a definitive diagnosis of 
schizophrenia were examined (Fenton et al., 2001) and one trial assessed patients with 
first episode psychosis (FEP) (Berger et al., 2007). It is not clear whether the 
differences in terms of the analysed population, dose intake or study duration time had 
an effect on the results. In a recent meta-analysis of those who clearly manifest 
schizophrenia, the addition of PUFA as a supplement to existing antipsychotic therapy 
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has shown evidence that there is no sufficient effect (Fusar-Poli & Berger, 2012). On 
the other hand, when a review of epidemiological data (Hedelin et al., 2010) was done, 
combined with a recent RCT of an emerging psychosis, the hypothesis that n-3 
LCPUFA may in fact show potential effects for prevention of the very early stages of 
psychotic disorders was supported (Amminger et al., 2010). The results of these 
findings points to the potential neuroprotective properties of n-3 LCPUFA (Berger et al., 
2007). Studies have indicated that there is a valid, positive correlation between an 
improvement of symptoms and the intake of n-3 LCPUFA; however there is a need for 
further studies involving larger and more randomized-controlled studies since the 
previous work was generally conducted with small groups. Currently, there is limited 
knowledge and only two studies investigating the relationship between those with ultra 
high risk (UHR) of developing psychosis and n-3 LCPUFA supplementation (McGorry 
et al., 2017; Amminger et al., 2010). Most of the knowledge of n-3 concentration in 
human erythrocytes comes from experiments performed using methods that are far 
less comprehensive than those currently available (Han & Gross, 2003). What remains 
unclear, however, is the molecular phospholipid data and n-3 index which relates to 
individuals with an UHR of psychosis and how this is affected by n-3 supplementation. 
1.9 The ultra high risk of psychosis period  
 
“Prodromal syndrome” is technical term used to describe the specific group of 
symptoms that are characteristic during UHR period (Simon et al., 2007), and the 
appearance of this syndrome does not qualify as a psychological or psychiatric 
diagnosis. The UHR period that precedes actual psychosis is often characterized by 
attenuated positive symptoms and a decrease in social and role function (Yung et al., 
2004; 2005; Yung & McGorry, 1996). These attenuated positive symptoms have not yet 
reached the level of conviction and impairment generally seen in the case of a formal 
psychosis diagnosis, but feelings do emerge that indicate a sense that something is 
“off” or there may also be an increase in overall suspicion. These feelings don’t occur 
with the severity exhibited in a case of formal psychosis; however these positive 
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symptoms are cause for concern and can still be jarring (Yung et al., 2004). An 
examination of UHR individuals during this time period is critical toward efforts in 
prevention and intervention. It is a fact that with early intervention, there is potential for 
help in preventing or decreasing the impact of an episode (Yung et al., 2004). During 
the mid-1990s, the suggested criteria for use in identifying individuals thought to be at 
UHR of psychotic disorder has been established (Miller et al., 2003; Miller et al., 2002; 
Yung et al., 1996; Yung et al., 2003; Yung et al., 2004). Since that time, several studies 
have offered validation of the UHR criteria, determining that young people who were 
seeking help and met the criteria went on to have a high risk of developing psychosis 
over 1–2 years (Cannon et al., 2008, Mason et al., 2004; Yung et al., 2003). 
In more recent studies, there is evidence suggesting that 36% of individuals 
categorized as UHR will progress to the point of developing a psychotic disorder within 
3 years after follow up (Fusar-Poli et al., 2012; Cannon et al., 2008; Mittal et al., 2007; 
Mittal et al., 2008). Research should be done on the biological mechanisms involved in 
psychosis, information may come forward to provide better understanding of etiological 
processes during the UHR period. Along with brain changes characteristic of healthy 
adolescence (Mittal et al., 2008; Bernard, 2014), but various environmental stressors 
can interact with these biological vulnerabilities and potentially lead to a formal 
diagnosis of psychosis. Particular environmental stressors include sexual trauma 
(Thompson et al., 2014), drug use (Carol & Mittal 2014), and problematic family 
environments (Meneghelli et al., 2011), among others. 
The uses of psychosocial (Morrison et al., 2012) and cognitive-based (Hooker, 2014) 
therapies have proven effective as early interventions during the UHR period. Very 
recent evidence indicates that interventions involving exercise may also be helpful in 
prevention, since exercise is known to help stimulate hippocampal neurogenesis, which 
has been shown a positive effects in cognitive deficits (Mittal et al., 2013). 
Several interventions using both pharmacological and psychological techniques have 
been suggested in an effort to either delay or perhaps even prevent the onset of 
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psychosis in the UHR population (Preti & Cella 2010). There is value to the use of 
antipsychotics, but their risk-benefit profile is currently unclear (McGorry et al., 2002).  
During a 12-week randomized, placebo-controlled trial that followed 81 individuals 
aged 13 to 25 years who had been diagnosed with UHR of developing psychotic 
disorder, a 12-week intervention using 1200 mg/day n-3 LCPUFA or placebo was 
followed by monitoring for a period of 40 weeks (Amminger et al., 2010). Study results 
showed a 4.9% (2 out of 41) rate of transitioning to acute psychosis in the UHR 
patients who had been treated with n-3 LCPUFA in compared to a much higher 
psychosis transition rate of 27.5% (11 out of 40) in the individuals who had received 
placebos in addition to their standard care. A follow-up of the same subjects conducted 
seven years later indicated that even the brief intervention with n-3 LCPUFA had 
caused a reduction both in the risk of progression to psychotic disorder and in actual 
cases of psychiatric morbidity (Amminger et al., 2010; 2015). No severe functional 
impairment was found in the majority of the individuals from the n-3 LCPUFA group, 
and in addition, they no longer experienced attenuated psychotic symptoms when the 
follow-up occurred (Median 6.7 years) (Amminger et al., 2010; 2015). This indicates 
that a supplementation of n-3 LCPUFA could possibly reduce the risk of a transition to 
psychosis in those at risk. In contrast, the first randomized, placebo controlled 
multicentre study for individuals aged 13 to 40 years who had been diagnosed with 
UHR of developing psychotic disorder, using 1400 mg/day n-3 LCPUFA did not 
demonstrate an advantage over placebo in the prevention of psychosis at 6 month 
(5.1% of placebo group and 6.7% of the n-3 LCPUFA group transitioned to psychosis) 
or 12 month (11.2% of placebo group and 11.5% of the n-3 LCPUFA group transitioned 
to psychosis) follow up evaluations (McGorry et al., 2017). This lower transition rate 
compared to the previous study could be due to insufficiently enriched for risk of 
transition and a high level of antidepressant treatment received by both groups 




1.10 The NEURAPRO-E randomized clinical trial 
The NEURAPRO-E study is a multicentre, randomised, controlled trial of n-3 LCPUFA 
supplementation and cognitive behavioural case management (CBCM) for patients at 
UHR of psychosis. 
A total of 304 participants meeting the ‘at-risk’ criteria were randomized to treatment 
with either n-3 LCPUFA plus CBCM or to treatment with placebo plus CBCM (see 
appendix (A) Flow chart for participant distribution). The total length of treatment was 6 
months with a follow-up assessment at 6 and 12 months post study entry. This study 
involving 10 research centres around the world Australia (Sydney, Melbourne), 
Switzerland (Basel, Zurich), Germany (Jena), Denmark (Copenhagen), Austria 
(Vienna), Singapore, Hong Kong (Pokfulam), and The Netherlands (Amsterdam). 
Inclusion and exclusion criteria for these participants has been reported previously 
(Markulev et al, 2015; McGorry et al., 2017) (See appendix (B) for more details). 
At study entry, participants were randomly assigned into either the n-3 LCPUFA plus 
CBCM group, or the placebo plus CBCM group by way of an online electronic data 
management system. Randomization was stratified based on site and total score 
according to the Montgomery- Åsberg Depression Rating Scale (MADRS) (total score 
range 0-60) (Montgomery & Asberg, 1979) since both antidepressants and depression 
may affect illness progression and UHR symptoms (McGorry et al., 2009; McGorry et 
al., 2012; Cornblatt et al., 2007; Fusar-Poli et al., 2015). 
Participants received either n-3 LCPUFA (2600 to 3000 mg of concentrated marine fish 
oil active intervention containing: 560mg of (DHA) and 840mg of (EPA) or placebo 
(2600 to 3000 mg of paraffin oil) together with clinical care with up to 20 sessions of 
CBCM for the 6-month intervention phase, after which administration of both the n-3 
LCPUFA and placebo were ceased, although patients could continue to access CBCM 
on the basis of need throughout this 6-month follow-up (Markulev et al., 2015). A total 
of 125 participants (41.1%) continued to receive CBCM after the 6-month follow-up 
visit. During the study’s first 12 months, benzodiazepine therapy was permitted for 
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anxiety and therapy using selective serotonin reuptake inhibitors was allowed for 
treatment of depression at a moderate or even severe and major level. Using any form 
of mood stabilizers or antipsychotics was not allowed at any point while the trial was 
underway, unless the withdrawal of a participant from the study took place before 12 
months and it was determined that the treatments were considered to be necessary in 
accordance with clinical guidelines (Markulev et al., 2015).  
To date, there is no data available for erythrocytes molecular phospholipids species in 
UHR cohort. In this PhD research project the aim is to investigate the UHR cohort 
erythrocytes n-3 index, fatty acids and molecular phospholipids species and this will 





















1.11 Aims and Hypothesis 
1.11.1 Hypothesis: 
 The automated extraction method coupled up with mass spectrometry will show 
no difference from the Lepage and Roy’s GC method and it will be a valid high-
throughput method for assessing n-3 index in erythrocytes. 
 The erythrocyte n-3 index, fatty acids and phospholipid molecular species will 
differ between the UHR of developing psychosis and the healthy groups. (The 
UHR of developing psychosis group will have a lower n-3 index than the healthy 
group).   
 n-3 supplementation will alter n-3 status in UHR of developing psychosis group. 
 Erythrocytes n-3 index, fatty acids and/or phospholipid molecular species, will 
predict the transition of UHR to psychosis. 
1.11.2 Research Aims 
The aims of this project were to: 
 Develop and validate a highly-automated, high-throughput technique for the 
analysis of n-3 index and molecular phospholipid profile in human erythrocytes. 
 Compare human erythrocyte n-3 index, fatty acid and phospholipids molecular 
species of individuals at high risk of developing psychosis to healthy age-
matched individuals. 
 Determine the effect of n-3 supplementation on n-3 index, fatty acids and 
phospholipid molecular species to those at high risk of developing psychosis. 
 Identify any n-3 index, fatty acids and/or phospholipids molecular species that 
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n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) have several health benefits. In 
particular, low n-3 LCPUFA status is associated with cardiovascular disease (CVD) and led 
to the development of the n-3 index which is the proportion of eicosapentaenoic acid and 
docosahexaenoic acid in the erythrocyte membranes, as a marker of CVD risk. Most 
methods used to measure the n-3 index are laborious and time consuming. Therefore, the 
aim of this study was to develop a high-throughput method for the extraction and 
measurement of erythrocyte fatty acids and the n-3 index. For sample extraction and 
quantification two methods were used; a single-step extraction, degradation and 
derivatisation method by Lepage and Roy, followed by gas chromatography flame ionization 
(GC-FID) which is commonly used and a high throughput method using an automated 
methyl tert-butyl ether extraction followed by electrospray ionization mass spectrometry. 
Both methods were first applied to the analysis of known concentrations of synthetic 
phospholipid mixtures to determine recovery and precision prior to their application in the 
analysis of human erythrocytes. The range of recoveries over five synthetic PL mixtures 
were 86.4% - 108.9% and the coefficient of variation was < 10% (within-run) and ≤ 15.2% 
(between-run). Both methods showed high correlation (R=0.993) for the n-3 index and there 
was no systematic bias in the detection of n-3 index using either method. The new high 
throughput method described here offers considerable advantages in terms of simplicity and 
throughput compared to GC-FID method and provides additional information on molecular 
phospholipid concentrations. 
 
Abbreviations CerPCho Sphingomyelin, PtdSer Phosphatidylserine, PtdEtn 
Phosphatidylethanolamine, PtdCho Phosphatidylcholine 








n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA), particularly eicosapentaenoic acid 
(20:5n-3, EPA) and docosahexaenoic acid (22:6n-3, DHA), provide several health benefits 
including enhanced cognitive function, CVD prevention and treatment of arthritis and other 
inflammatory and autoimmune disorders (Salem, 1989; Simopoulos,1999; Bakker et al., 
2003; Hibbeln et al., 2007; Marchioli et al., 2002). Conversely, insufficient n-3 LCPUFA 
intake (Meyer, 2016) has been implicated in increased risk of CVD (Mozaffarian, 2008), 
suboptimal neural development (Salem, Kim, & Yergy, 1986), psychiatric disorders (Hibbeln 
& Salem, 1995) and neurodegenerative diseases (Calon et al., 2005). 
The ‘n-3 index’ is defined as the sum of EPA and DHA levels in erythrocyte membranes 
expressed as percent of total fatty acids (Harris & Von Schacky, 2004; Harris, 2008; Von 
Schacky & Harris, 2007; Block et al., 2008). The n-3 Index in the western countries, the 
Middle East, Africa and Southeast Asia is believed to be ≤ 4%. In countries where fish 
consumption is high such as Korea, Japan and Scandinavia the average n-3 Index is ≥ 8% 
and coronary artery disease is less common (Stark et al., 2016). Most notably, it has been 
observed that an n3 index of 5% or more was associated with a 70% reduction in the risk of 
primary cardiac arrest (Siscovick et al., 1995). Also, similar results suggest that whole blood 
EPA and DHA concentration is strongly associated with a reduced risk of sudden death 
among men without evidence of prior cardiovascular disease (Albert et al., 2002). Based on 
this foundation, the n-3 index was proposed in 2004 as a marker of risk of death from CVD 
(Harris & Von Schacky, 2004; Harris, 2008) and the n-3 index has now been widely 
measured in different studies that examined not only CVD but also schizophrenia and 
depression (Parletta et al., 2016) . 
Erythrocytes have advantages over plasma since the former reflects the last few months of 
food intake (Sullivan, Williams, & Meyer, 2006; Katan et al., 1997), while plasma EPA and 
DHA status is representative of food intake over the previous few days (Arab, 2003). 
Therefore, erythrocyte fatty acids are a more reliable biomarker of long-term EPA and DHA 
status (Arab, 2003; Harris & Thomas, 2010). Specialized methods for extraction of lipids 
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from erythrocyte membranes have been developed in the past (Reed, Swisher, Marinetti, & 
Enen, 1960; Rose & Oklander, 1965) and these two methods have noted the difficulty of 
extracting lipids from erythrocytes. The MTBE method (Matyash et al., 2008) has been 
performed manually for the extraction of lipids from erythrocyte membranes (Turcot et al., 
2015, Tran et al., 2016). An automated plasma lipid extraction using the Hamilton STAR 
robotic platform has also previously been published (Surma et al., 2015). However, the 
previous MTBE methods were done manually and the automated method used plasma as 
the sample, the novelty in this thesis is the use of the automated Hamilton STAR robotic 
platform being applied to erythrocytes. Doing plasma samples on Hamilton STAR robotic 
platform is easier than erythrocytes because erythrocytes need to be lysed to be able to 
extract erythrocyte membrane lipids.   
A common method used for measuring erythrocyte membranes fatty acid concentrations 
including EPA and DHA (Ridges et al., 2001; Rodriguez-Palmero et al., 1998; Stewart et al., 
2007; Goozee et al., 2017) is the gas chromatography-based method of Lepage & Roy 
(1986). The development of efficient analytical techniques, to improve recovery of all lipid 
species, to reduce the time and amount of labour that is involved in the estimation of fatty 
acids would improve the utility of measuring the n-3 index. Accordingly, several recent 
studies have improved the throughput of gas chromatography-based fatty acid analysis 
(Masood, Salem, & Stark, 2005; Masood & Salem 2008; Glaser et al., 2010).  
The aims of this study were 1) to develop high throughput method for measuring erythrocyte  
fatty acids and n-3 index utilizing an electrospray ionization mass spectrometry (ESI-MS)-
based method and 2) to compare this new method to the commonly used Lepage and Roy 
method (GC-FID method) in terms of time, sample volume and overall cost. 
Material and Methods  
 
Chloroform, methanol and methyl tert-butyl ether (MTBE), were purchased from VWR 
International (QLD, Australia) and were high performance liquid chromatography grade or 
higher. Analytical grade ammonium acetate was obtained from Crown Scientific (New South 
Wales, Australia). Ethylenediaminetetraacetic acid (EDTA), butylated hydroxytoluene (BHT), 
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acetyl chloride, toluene and potassium carbonate (K2CO3) were all purchased from Sigma 
Aldrich (NSW, Australia). Synthetic phospholipids (PL): 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (PtdCho 16:0/18:1), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine 
(PtdCho 16:0/18:2), 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (PtdCho 
16:0/20:4), 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (PtdCho 
16:0/22:6), 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (PtdEtn 18:0/20:4), 
1-stearoyl-2- docosahexaenoyl –sn-glycero-3-phosphoethanolamine (PtdEtn 18:0/22:6), 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (PtdEtn 16:0/18:1) were purchased 
from Avanti Polar Lipids through Auspep (Victoria, Australia). 
Disposable tips used on the Hamilton-star liquid handling workstation were purchased from 
Hamilton Robotics (Reno NV, USA). 50 uL and 300 uL sizes of conductive CO-RE tips 
(without filter) were used. Twin-tec PCR (Polycarbonate) clean plates and 96-well plates 
were purchased from Eppendorf (POCD scientific, Australia).   
Preparation Synthetic PL mixtures 
 
The seven synthetic PL listed above were mixed in concentrations designed to mimic human 
erythrocyte membranes lipid levels (additional information is available in supplementary 
materials). The concentrations of PtdCho (16:0/22:6) and PtdEtn (18:0/22:6) were varied in 
order to create five synthetic PL mixtures with a range of n-3 indexes (2, 4, 6, 8 and 10 %). 
The synthetic PL stock solutions were stored at -80oC in 10 mL glass vials containing 2:1 
methanol: chloroform with 0.01 % BHT as an antioxidant. To the best of the authors’ 
knowledge, there are currently no commercially available synthetic PL species containing 
EPA and hence EPA was not used in these synthetic PL mixtures. Nevertheless, EPA is 
present at < 1% of total erythrocyte fatty acids. In comparison, DHA is usually present at ≥ 4 
% (Jackson et al., 1997) and therefore in the synthetic PL mixtures DHA was used to 
represent the n-3 fatty acids in the n-3 index. Synthetic PL mixtures were first analysed in 
order to a determine recovery and accuracy of both methods. Analysing erythrocytes with 




Human Erythrocytes  
This study was approved by the human research ethics committee at the University of 
Wollongong (HE16/016) and written consent was obtained from all participants. Participants 
were recruited from the University of Wollongong staff and students. Blood samples were 
collected into vacutainers coated with EDTA to prevent clotting and platelet clumping. This 
followed by centrifugation at 3000 rpm at 4 oC for 10 minutes and the remaining plasma and 
white blood cells removed. Aliquots 1.5 ml of erythrocytes were stored at -80 oC until 
required for analysis.  
Lipid extraction & direct transesterification 
The method for fatty acid extraction has been described previously (Ridges et al., 2001). 
Briefly, frozen (-80°C) packed erythrocytes (n=25) were thawed and 400 uL resuspended at 
room temperature in a Tris buffer, which contained 10 mM Trizma Base and 2 mM EDTA 
Na2 (pH 7.2) in polycarbonate ultracentrifuge tubes (16 × 76mm). The samples were 
capped, gently mixed and left at room temperature for 30 minutes to induce erythrolysis. 
Erythrocyte membranes were pelleted by ultracentrifugation at 49000 rpm at 4°C for 30 
minutes using a 70.1 TI rotor in a Beckman L-8 ultracentrifuge (Beckman, USA). The 
supernatant was discarded and removed, and the pelleted erythrocyte membranes were 
resuspended in 200 μL of distilled water. Aliquots (150 μL) of resuspended erythrocytes or 
synthetic PL mixtures were subjected to direct transesterification according to the method of 
Lepage and Roy (1986). Briefly, 2.2 mL of a stock solution methanol: toluene (4:1) and 
0.01% BHT with the internal standard heneicosaenoic acid 0.2 mg/ml) was added to the 150 
μL aliquots of erythrocyte membranes resuspension or synthetic PL mixtures. Following this, 
200 uL of acetyl chloride was added while vortexing at low speed. The tubes containing this 
solution were tightly sealed and heated on a heating block at 100oC for a period of 60 
minutes. The tubes were cooled to room temperature in a water bath for 15 min and 6% 
K2CO3 was added prior to centrifugation for 10 min at 3000 rpm at 4 oC. The extracted upper 
toluene phase containing fatty acid methyl esters (FAME) was then transferred into glass GC 
vials for analysis by GC-FID.  
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Gas chromatography-flame ionization detection (GC-FID)  
The gas chromatograph (GC-2010 plus, Shimadzu, Rydalmere, NSW, Australia) was fitted 
with a fused silica capillary column with 50 m x 0.25 mm internal diameter x 0.25 um film 
thickness from Agilent J & W GC Columns with the following temperature program: 150oC 
initial temperature, 10oC/min to 162.5oC, 0.4oC/min to 172.5oC and 10oC/min to 211oC, the 
injector and detector temperature were set at 250oC. The carrier gas was ultra-high purity 
hydrogen and the column flow rate was 2.0 mL/min. Column pressure was maintained at 
157.1 kPa. The split ratio was set at 20:1. One microliter of each sample was injected onto 
the column using an auto injecting unit (Shimadzu AOC-20i) and the fatty acids were 
detected using FID. The total analysis time was approximately 30 minutes per sample with 
fatty acids eluting between 2.5 and 25 minutes. The fatty acids were identified by comparing 
their retention time with known fatty acid standards (Nu-chek and Sigma, Sydney, NSW, 
Australia). After analysis, each fatty acid was quantified by comparing their peak area to the 
peak area of internal standard. 
Adaptation of a lipid extraction protocol to a robotic platform 
To assess the suitability of existing protocols to a robotic platform several key properties 
were evaluated. They were: 1) the ability of the homogeising solvent to lyse erythrocytes, 2) 
the impact of the solvent on erythrocyte clotting, 3) the ability to convert the protocol to small 
volumes (<2000 μL) to fit a 96-well plate configuration, 4) an organic phase with a lower 
density than water to allow removal of lipids from the top layer of the two-phase system, and 
5) spontaneous phase separation (removing the need to centrifuge samples). The protocol 
described by Matyash et al., (2008) appeared to fulfil many of these criteria and was chosen 
as the method used in the current investigation.  
The MTBE extraction protocol was initially tested manually using packed erythrocytes. The 
first observation made was the difficulty of pipetting packed erythrocytes from the eppendorf 
tubes in which they were stored. The second notable observation was the tendency of 
erythrocytes to form an insoluble mass upon the addition of combined MTBE and methanol. 
This was quite different from what occurs with the Lepage & Roy (1986) method where the 
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addition of Tris buffer to the packed erythrocyte causes the cellular membranes to 
immediately lyse with no sedimentation of the celluar membranes upon standing. The 
clumping suggested that the membrane bound proteins had become denatured in the 
presence of the organic solvents used. Furthermore, it was also unclear if the erythrocyte 
membranes had been effectively lysed by the addition of solvents. This was an important 
consideration as without the membrane being properly lysed, the lipids contained within the 
membrane bi-layer would not be exposed to the solvents and it would not be possible to 
solubilise the lipids in the following steps thus making the protocol ineffective for its proposed 
means. The focus of refining the MTBE protocol thus turned to how the erythrocyte 
membranes could be effectively lysed as well as preventing the “clotting”. 
After testing several solvent systems (see supplementary material), we decided to use a 150 
mM ammonium acetate solution due to its ability to lyse erythrocytes, prevent clotting and is 
compatible with MS analysis. The Matyash et al., (2008) method reports the use of large 
volumes of both the sample to be analysed and the reagents used in the protocol (matyash 
et al., 2008). The starting volume of plasma used was 200 uL to which 1.5 mL of methanol is 
added. Upon the addition of 5mL of MTBE this far exceeds the 2mL of the standard format 
96-well plates. Hence, the first amendment made to the protocol was to reduce the volumes 
used. To begin with, 10 uL was arbitrarily assigned as the volume of packed erythrocytes on 
which the extraction would be performed. It was then calculated that the ratio of specimen to 
methanol used by matyash et al., (2008) was 1:7 (sample: methanol v/v) and that the solvent 
system used comprised of MTBE: methanol: aqueous reagents in the ratio 10:3:2.9 (v/v/v). 
Applying these ratios to the new starting amount of 10 uL packed erythrocytes created a 
protocol where the highest volume reached was 1600 μL. This is in line with the proposed 
requirement for robot extraction that the highest volume reached is ≤2000 μL. This protocol 





Automated Lipid Extraction  
For ESI-MS analysis, lipids where extracted from erythrocytes (n=25) and synthetic PL 
mixtures (n=5) using the method of Matyash et al., (2008), with some modifications. In the 
automated extraction method, 290 uL of an aqueous mixture containing 150 mM Ammonium 
acetate and 2 mM EDTA was added to the wells of a 2.0 mL 96-well plate on ice. Aliquots of 
10 μL taken from the synthetic PL mixtures or erythrocytes were then added to the wells 
prior to vortexing at 800 rpm for 10 minutes. Robotic procedures were then started with all 
plates, solvents and reagents loaded onto the automated liquid handling workstation 
(Hamilton, Nevada, USA). A 300 μL aliquot of an internal standard mixture in methanol [500 
uM (PtdCho 19:0_19:0); 166.7 uM (PtdEtn 17:0_17:0); 100 uM (PtdSer 17:0_17:0); 500 uM 
(CerPCho 18:0_12:0)] was added to the wells prior to mixing and standing for 10 minutes. 
Then 1 mL of MTBE was added to the wells and mixed for 30 minutes before the mixture 
was allowed to stand for 15 minutes to allow phase separation. To ensure optimal lipid 
extraction efficiencies the sample mixing was performed by repeated aspiration and 
dispensing. Following this, 500 μL of the MTBE top phase was removed to the extraction 
plate (containing the extracted PL) and 40 μL of this extract was transferred to another 96-
well plate and diluted with 760 μL of a 2:1 (v:v) methanol: chloroform solution containing 5 
mM Ammonium acetate. A 40 μL aliquot of the diluted extract was transferred to another 96-
well plate, which was sealed with aluminum foil prior to analysis by mass spectrometry. 
Electrospray ionization mass spectrometry (ESI-MS) 
Mass spectrometry was performed utilizing a hybrid triple quadrupole linear ion trap mass 
spectrometer (QTRAP 5500 ,Sciex, MA, USA) with an automated chip-based 
nanoelectrospray source (Triversa NanoMate, Advion Biosciences, New York, USA) as 
previously described (Brown et al., 2013; Norris et al., 2015). A 10 uL aliquot of lipid extract 
diluted in methanol: chloroform (2:1 v/v) containing 5mM ammonium acetate (approximately 
10 uM) was infused into the nano-electrospray ion source. Spray parameters were a voltage 
of 1.1 kV for negative ion acquisition and 1.2 kV for positive ion acquisition and a nitrogen 
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gas pressure of 0.40 psi (Brown et al., 2013; Norris et al., 2015). Lipids were identified using 
precursor ion and neutral loss scans as show in Supplementary Table S7. Specifically, 
precursor ion scans for phosphocholine ctaions (m/z 184.1) were used to detect PtdCho and 
CerPCho species while neutral loss scans were used to detect PtdEtn species 
(phosphoethanolamine loss, 141.0 Da) and PtdSer species (phosphoserine loss, 185.0 Da) 
(Brugger et al. 1997). The identitiy of the FA component of each PL was determined using 
precursor ion scanning for each FA in negative ion mode (Supplementary Table S7).  
Ionized lipids identified with a minimum signal-to-noise ratio of 10 were included in the 
analysis. Identification and quantification was accomplished using LipidView software 
(version 1.2, Sciex, MA, USA) this included smoothing, identification, removal of isotope 
contribution from lower mass species, and correction for isotope distribution, as described 
(Brown et al., 2013; Norris et al., 2015). Quantification was performed using LipidView 
software by comparing the spectral peak area of individual lipids to their class specific 
internal standards following isotope correction. Fatty acid concentrations were then 
determined directly from PL concentration i.e. the concentration of each fatty acid is 
equivalent to the parent. For example if PtdCho 16:0_18:0 is 1.5 nmol/ml then the fatty acid 
16:0 and fatty acid 18:0 are both 1.5 nmol/ml. Isobaric phospholipids e.g. PtdCho 16:0/22:6 
and PtdCho 18:1/20:5 were resolved using fatty acid precursor ion scans. The concentration 
obtained from the head group scan was multiplied by the ratio of the relative abundance of 
each fatty acid pair to obtain the concentration of each molecular PL as described previously 
(Nealon, Blanksby, Mitchell, & Else, 2008). An excerpt (plus explanatory comments) from the 
spreadsheet where these calculations were performed is show in Supplementary Figure S1. 
A quality control (QC) sample was produced using pooled erythrocytes from healthy 
volunteers (n = 10, 5 male and 5 female) aged between 13 and 40 years. The QC aliquots 
were stored frozen at (−80 °C). With each full plate prepared (96 well plate) in the high-
throughput ESI-MS method 3 QC samples distributed in positions (2, 49 and 95) to monitor 
instrument performance and assay precision. To assess contamination and interference 3 
blank samples were processed side-by-side with analytical samples and placed in positions 
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(1, 48 and 96) of each 96-well plate. Additionally, blanks were used to correct the data by 
subtracting blank readings from sample readings.    
 
Statistics 
Statistical analyses were performed using Microsoft excel and SPSS statistics. Pearson’s 
correlation coefficient (r) was determined and tested for significance via two-tailed analysis. 
A Bland-Altman plot was produced to assess the agreement between the two methods 
(Bland & Altman, 1986; Altman & Bland, 2002; Ludbrook, 2010).  
 
 
Results and Discussion 
Recovery  
 
Extraction recovery was tested to evaluate the accuracy of the method. As is evident in table 
1 recovery and detection in both the GC-FID and the high-throughput ESI-MS methods was 
greater than 86% for most fatty acids.  
An unexpected result was the low recovery of 18:0 using the MS-based method (50.9-
61.3%) and 22:6 using both methods (66.9-85.1% for GC-FID method and 63.5-75.3% for 
ESI-MS method). Interestingly, PtdEtn (18:0/22:6), was noticeably yellow in colour inside the 
2.5 mL ampule (starting material) and low signal of PtdEtn (18:0/22:6) detected (See 
supplementary figure S2) , suggesting oxidation had occurred and may explain these 
findings. The GC-FID method measures only the fatty acids and not the whole PL molecule. 
This means that only the data for the oxidized fatty acid is altered; i.e. a lower than expected 
22:6 level was detected. This is in contrast to the high-throughput ESI-MS method, which 
measures the intact PL. Therefore, when one fatty acid is oxidized the data from both fatty 
acids is lost. In the case of oxidized PtdEtn (18:0/22:6) both 22:6 and 18:0 would be reduced 
as observed. If the concentration of PtdEtn (18:0/22:6) add to the synthetic mixtures is 
removed from the expected values, the recovery of 18:0 of using the ESI-MS method 
increases to (70.3-99.3%) and 22:6 is improved for both methods (83.7-106.4% for the GC-
FID method and 81.2-94.1% for the ESI-MS method). 
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Table 1:- Average amount of synthetic PL mixtures (nmol/ml) across a range of n-3 indexes recovered using the GC-FID and high-throughput 
ESI-MS methods (n=3 for all mixtures). 
* Synthetic PL mixtures 
(%) 
Fatty acids Expected value GC-FID method  The high-throughput ESI-MS method 
nmol/ml Mean ± SEM (%) recovery of synthetic 
PL 

















930.0 ± 24.3 
57.8 ± 0.9 
429.8 ± 15.9 
344.9 ± 2.7 
147.4 ± 7.5 







929.9 ± 10.1 
35.5 ± 0.2 
406.5 ± 11.5 
396.0 ± 2.6 
132.8 ± 5.5 





















927.0 ± 17.8 
64.9 ± 1.9 
423.1 ± 3.3 
347.8 ± 10.8 
141.9 ± 4.4 







890.1 ± 13.9 
36.9 ± 2.0 
400.3± 7.8 
341.3 ± 3.1 
125.5 ± 1.9 





















 827.0 ± 7.8                      
67.9 ± 1.7                        
386.7 ±3.2                       
316.7 ± 2.2                    
128 ± 1.6                      
 80.3 ± 1.2                        
 88.9%                          
96.6%                     
94.9%                          
94.9%                          
92.4%                          
66.9%                           
 893.4 ± 3.0                            
40 ± 0.9                          
401.2 ± 4.5                      
329.1 ± 6.2                            
125.4 ± 2.8                           
77.9 ± 0.9                                       
 96.1%                           
57.2%                                   
98.4%                             
98.7%                             
90.3%                                

















907.4 ± 19.1 
75.8 ± 3.1 
384.2 ± 9.9 
313.7 ± 1.6 
121.0 ± 6.1 







855.3 ± 4.7 
41.9 ± 0.4 
374.2 ± 6.4 




























896.3 ± 3.6 
83.9 ± 0.4 
367.9 ± 2.6 
303.6 ± 1.4 
125.6 ± 8.5 







879.3 ± 8.6 
41.8 ± 1.6 
360.2 ± 5.3 
294.0 ± 4.6 
118.5 ± 0.5 











Precision was assessed by estimating within-run and between-run %CV for both methods as 
shown in Table 2.  
The within-run %CV of each fatty acid in each synthetic PL mixture for both the GC-FID 
method and the high-throughput ESI-MS methods were calculated for n=3 (Table 2). The 
within-run precision for high-throughput ESI-MS method was less than 10% and this is 
comparable to the GC-FID method. The high-throughput ESI-MS method also shows 
comparable results for within-run precision with previously published work using gas 
chromatography-flame ionization detection (GC-FID) fatty acid analysis (CV < 8% and < 
14%) (Glaser et al., 2010; Lin et al., 2012) and gas chromatography/mass spectrometry 
analysis GC-MS (CV <14%) (Quehenberger, Armando, & Dennis, 2011). 
Measurement of between-run precision was calculated for samples of synthetic PL mixtures 
(n=3/day) over one month (Table 2). The between-run %CV in high-throughput ESI-MS 
method was slightly higher (≤ 15.2%) compared to the between-run coefficient of variation (≤ 
13.9%) observed in GC-FID method. Also, the between-run coefficient of variation observed 
in the high-throughput ESI-MS method was comparable to that of the method used GC-FID 
and GC-MS fatty acid analysis (CV <16% and <17%) (Lin et al., 2012; Quehenberger, 
Armando, & Dennis, 2011). The QC samples intra-assay precision (within the batch) ranged 
from 0.90% to 17.4% of 19 batches and the average inter-assay precision (batch-to-batch) 
ranged from 6.9% to 20% of 19 batches. (See supplementary material table S9 for fatty 
acids QC samples concentration data).  
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GC-FID method  The high-throughput ESI-MS method 
Mean nmol/ml ± SEM (within-run 
%CV) 
Mean nmol/ml ± SEM (between-run 
%CV) 
Mean nmol/ml ± SEM (within-run 
%CV) 









930.0 ± 24.3 (4.4) 
57.8 ± 0.9  (2.6) 
429.8 ± 15.9  (6.3) 
344.9 ± 2.7  (1.3) 
147.4 ± 7.5  (8.7) 
27.8 ± 0.2  (1.2) 
962.1 ± 36.4 (11.9) 
59.4 ± 1.5  (7.9) 
443.3 ± 16.5  (11.8) 
362.9 ± 3.0  (2.6) 
145.0 ± 5.5  (11.9) 
27.6 ± 1.0 (11.4) 
 929.9 ± 10.1 (1.8) 
 35.5 ± 0.2 (0.9) 
 406.5 ± 11.5 (4.8) 
 396.0 ± 2.6 (1.1) 
 132.8 ± 5.5 (7.0) 
 30.1 ± 0.9 (5.1) 
 831.6 ± 22.2 (8.4) 
 36.5 ± 0.4 (3.5) 
 375.8 ± 8.9 (7.5) 
 335.8 ± 14.2 (13.4) 
 127.4 ± 3.4 (8.4) 








927.0 ± 17.8  (3.3) 
64.9 ± 1.9  (4.9) 
423.1 ± 3.3  (1.3) 
347.8 ± 10.8  (5.3) 
141.9 ± 4.4  (5.3) 
56.5 ± 1.9  (5.7) 
924.8 ± 18.0  (6.2) 
65.8 ± 2.5  (12.0) 
420.7 ± 4.0  (3.0) 
352.1 ± 10.0  (8.9) 
136.7 ± 5.0  (11.6) 
55.0 ± 1.5  (8.6) 
 890.1 ± 13.9 (2.7) 
 36.9 ± 2.0 (9.2) 
 400.3± 7.8 (3.3) 
 341.3 ± 3.1 (1.5) 
 125.5 ± 1.9 (2.6) 
 59.9 ± 1.7 (4.8) 
 843.4 ± 19.8 (7.5) 
 35.9 ± 1.3 (11.4) 
 379.8 ± 11.1 (9.2) 
 327.9 ± 10.4 (10.0) 
 113.4 ± 3.1 (8.6) 








827.0 ± 7.8 (1.6)                                      
67.9 ± 1.7 (4.3)                                                   
386.7 ±3.2 (1.4)                                     
316.7 ± 2.2 (2.6)                                    
128 ± 1.6 (2.1)                                               
80.3 ± 1.2 (2.5)                                                  
 
835.2 ± 8.9 (3.4)                                    
70.9 ± 2.8 (12.5)                                     
397.5 ± 4.1 (3.3)                                
325.1 ± 3.7 (3.6)                                   
130.1 ± 1.9 (4.6)                               
81.2 ± 3.1 (12.1)                                 
 893.4 ± 3.0 (0.6)                                  
40.0 ± 0.9 (3.8)                           
401.2 ± 4.5 (1.9)                           
329.1 ± 6.2 (3.2)                              
125.4 ± 2.8 (3.8)                                
77.9 ± 0.9 (1.9)                                         
 
 905.5 ± 5.5 (1.9)                                                             
41.7  ± 2.0 (15.2)                                                           
395.1 ± 8.4 (6.7)                                                                    
309.7 ± 9.5 (9.7)                                                            
119.0 ± 5.5 (14.6)                                                                   











907.4 ±19.1  (3.6) 
75.8 ± 3.1  (6.9) 
384.2 ± 9.9  (4.4) 
313.7 ± 1.6  (0.9) 
121.0 ± 6.1  (8.6) 
136.2 ± 8.0 (10.0) 
 
929.4 ± 20.2  (6.9) 
76.9 ± 3.4  (13.9) 
379.6 ± 10.5  (8.7) 
323.2 ± 1.9  (1.9) 
118.3 ± 5.0  (13.4) 
132.2 ± 5.8  (13.9) 
 
 855.3 ± 4.7 (0.2) 
 41.9 ± 0.4 (1.6) 
 374.2 ± 6.4 (2.9) 
 301.2 ± 1.7 (0.9) 
 120.1± 0.8 (1.1) 
 101.7±1.9 (3.2) 
 
 778.9 ± 20.9 (8.5) 
 40.5 ± 1.9 (14.8) 
 334.5 ± 11.2 (10.6) 
 283.6 ± 6.6 (7.4) 
 105.8 ± 4.6 (13.7) 












896.3 ± 3.6  (0.7) 
83.9 ± 0.4  (0.6)                                                  
367.9 ± 2.6  (1.2) 
303.6 ± 1.4  (0.6) 
125.6 ± 6.5  (8.8)                                               
149.1 ± 1.7  (1.9) 
 
900.9 ± 4.5  (1.6) 
84.8 ± 1.2  (4.5) 
364.9 ± 2.9  (2.5) 
307.9 ± 1.5  (1.5) 
118.2 ± 5.1  (13.6) 
144.3 ± 2.4  (5.3) 
 
 
 879.3 ± 8.6(1.7) 
 41.8 ± 1.6 (6.5) 
 360.2 ± 5.3 (2.5) 
 294.0 ± 4.6 (2.7) 
 118.5 ± 0.5 (0.7) 
 148.4 ± 5.2 (5.9) 
 
 813.4 ± 21.5 (8.4) 
 42.6 ± 1.9 (14.0) 
 341.7 ± 14.9 (13.8) 
 261.7 ± 10.2 (12.3) 
 106.4 ± 4.1 (12.2) 
 146.2 ± 4.9 (10.6) 
 
Coefficient of variation (%CV). SEM, standard error of the mean. Within run %CV (n=3); between run %CV (n= 3/day over one month).* See supplementary materials 
(Tables S1 to S5) for additional Synthetic PL mixtures information.
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Measurement of erythrocyte fatty acids and n-3 index using two methods 
There is a strong correlation (R= 0.993) between the GC-FID method and the high 
throughput ESI-MS method when assessing n-3 index over a range of 2-10% (figure 1). 
 
Figure 1: Correlation between the GC-FID method and the high throughput ESI-MS method 
using erythrocyte samples (n=25) over an n-3 index range of 2-10%. The line of best fit is y = 
1.01567x. R= 0.993.   
 
There was good agreement between the two methods across the range of n-3 index (2-10 
%) with all points plotted falling within both the upper and lower limits of agreement (95% CI) 
as shown in figure 2. There was no systematic bias in the detection of n-3 index extracted 
using either method. To the best of the authors’ knowledge, this is the first validation study 
using Bland-Altman plot in comparing the difference between the two methods measuring 
fatty acids. The reporting of correlation coefficients can be misleading as correlations 
measure the strength of a relationship between two methods rather than the level of 
agreement between the results yielded by two methods (Bland & Altman, 1986). As 
described by Bland and Altman (1986) a significant correlation is expected if two measures 
are measuring same thing. As such, studies validating a novel method against a reference 
method should be interpreted with caution where validity is measured and reported by way 
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Figure 2:  Bland-Altman plot of the difference between the two methods (the high throughput 
ESI-MS method minus GC-FID method) against their mean of n-3 index (%) using 
erythrocytes (n=25). The line of best fit (dashed line) is y = 02 + -0.01x (R² = 0.015). {95 % 
confidence interval = Mean difference ± (STD of difference * 1.96)} STD = 0.235. 
 
The concentration of erythrocytes fatty acids as determined by the GC-FID method and the 
high throughput ESI-MS method are presented in Table 3. The difference between the two 
methods was less than 10% with exception for fatty acid 22:4, where the difference was 
37.5%. The abundance of fatty acid 22:4 is relatively low. The amount of 22:4 measured by 
the GC-FID method detects the total fatty acid amount obtained from all PL species in a 
single GC peak. This is advantageous as it improves signal -to-noise and therefore 
sensitivity of fatty acid with low relative abundance. Because 22:4 is of relatively low total 
abundance and was bound to several different PL species, the signal obtained by ESI-MS 
was further diluted. This results in a decreased signal-to-noise and therefore, some 22:4 
containing PLs were below the limit of quantification and are not included in the MS totals 
(but would be included in the GC analysis). 
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Table 3: comparison of erythrocytes fatty acids concentrations using GC-FID method and 




(Mean ± SEM) 
GC-FID method (Mean 
± SEM) corrected 
 
high throughput 
ESI-MS method  
(Mean ± SEM) 
Difference 
% 
16:0 331.8 ± 8.4 460.3 ± 8.6 464.9 ± 7.3 N/A* 
17:0 16.6 ± 0.8 - 18.1 ± 0.8 -8.6 
18:0 232.9 ± 6.2 263.8 ± 5.5 269.3 ± 7.1 N/A* 
24:0 37.7 ± 2.1 93.5 ± 2.9 85.0 ± 2.6 N/A* 
16:1 4.9 ± 0.8 - 4.6 ± 0.7 6.3 
18:1 186.5 ± 4.4 198.0 ± 3.3 207.3 ± 3.9 N/A* 
24:1 49.5 ± 1.8 122.7 ± 3.6 122.7 ± 3.6 N/A* 
18:2 155.1 ± 6.9 - 158.1 ± 6.4 -1.9 
20:3 23.8 ± 1.6 - 22.9 ± 1.6 3.9 
20:4 201.7 ± 5.2 - 195.7 ± 4.3 3.0 
20:5 9.8 ± 1.1 - 9.9 ± 1.2 -1.0 
22:4 37.6 ± 1.6 - 25.7 ± 1.9 37.5 
22:5 31.5 ± 1.6 - 31.1 ± 1.5 1.3 
22:6 67.6 ± 3.3 - 66.7 ± 3.2 1.3 
Corrected data shown in bold, Values (V), Difference % = |V 1 − V 2| / (V 1 +V 2) / 2 × 100. (V1 GC-FID results) 
& V2 ESI-MS results). N/A* (the difference % was not calculated because the data has been corrected using the 
new method). 
 
Sample derivatization is required to improve fatty acid volatility (Brondz, 2002). Nowadays, 
procedures allowing simultaneous hydrolysis and methylation of bound fatty acids are 
becoming more and more popular. Lepage & Roy (1986) have proposed the one-step direct 
transesterification procedure suitable for fatty acid classes. The analysis of fatty acid methyl 
esters (FAME) from erythrocyte membranes may be differentially affected by the method of 
lipid extraction. Rodrı́guez-Palmero coworkers compared direct (Lepage & Roy) and 
conventional esterification (Folch) methods and found that the direct method has substantial 
advantages over the conventional method in terms of reduce contamination and increased 
throughput. However, the transesterification of amides from sphingomyelin (CerPCho) is less 
efficient than that of esters from glycerophospholipids (Christie & Han, 2012); this results in 
an underestimation of fatty acids bound to CerPCho when using the GC-FID method 
described here.  
To determine the transesterification efficiency of sphingomyelin using the Lepage and Roy 
method CerPCho 24:1 was added to the synthetic PL mixture shown in table S5. This 
mixture was then subjected to both the GC and MS methods described earlier and the 
results shown in the supplementary material (Table S6). A very low recovery (45%) was 
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obtained using the GC-FID method compared to 98% recovery using the high-throughput 
ESI-MS method. In order to account for this underestimation a correction factor was 
determined and applied as follows. Five erythrocytes samples were selected at random and 
the concentration of fatty acid 24:1 obtained from the high-throughput ESI-MS method (123 
nmol/ml blood) was divided by the fatty acid 24:1 concentration determined by the GC-FID 
method (49.5 nmol/ml blood). This produced a correction factor of 2.48. Fatty acid 24:1 was 
chosen to calculate the correction factor as it was found exclusively bound to CerPCho in 
erythrocytes. To correct for fatty acids exclusive to CerPCho, i.e. 24:1 and 24:0 the GC-FID 
data was simply multiplied by 2.48 (the correction factor). 
For fatty acids bound to both phospholipids and CerPCho (16:0, 18:0 and 18:1) further 
calculations were required to determine the corrected fatty acid concentrations. They were; 
1) dividing the concentration of CerPCho bound fatty acid by the total  fatty acid 
concentration (both determined by ESI-MS) for 16:0, 18:0 and 18:1 in every sample to obtain 
the proportion of CerPCho fatty acid, 2) multiplying the GC data by this proportion to obtain 
the approximate CerPCho fatty acid concentration, 3) multiplying the calculated CerPCho 
fatty acid concentration by the correction factor (2.48), and 4) adding the corrected CerPCho 
fatty acid concentration to the PL fatty acid concentration. A step-by step example of this 
calculation is provided in the supplementary material. The result of applying the correction 
factor to 16:0, 18:0, 18:1, 24:0 and 24:1 concentrations determined by GC-FID are shown in 
Table 3. 
As shown in the table 4 the new method is cheaper than the GC-FID method with several 
other advantages e.g. throughput is increased by almost 8 times; sample and reagent 
volumes can be reduced four-fold and additional information, i.e. phospholipid class and 







Table 4: comparison between methods using GC-FID method and high throughput ESI-MS 
method. 
 GC-FID method high throughput ESI-MS method 
Number of samples per 
day 
24 samples per day 186 samples per day 
Time needed for sample 
preparation 
Approximately 6 hours 
to prepare 24 samples 
Approximately 6 hours to prepare 
186 samples 




Only fatty acids 
 
Fatty acids  
PL classes 
Quantity of solvents used 
per sample 
8 ml Approximately 2 ml 
Cost per sample $ 50 $ 20 
 
The throughput ESI-MS method does however, have limitations. First the diluting of signal 
from low relative abundance fatty acids across several PL species can hinder their detection. 
Second, the double bond location cannot be determined, e.g., this method is unable to 
determine whether 22:5 docosapentaenoic acid is 22:5n-3 or 22:5n-6 or if 18:1 is 18:1n-9 or 
18:1n-7. While several MS-based methods for determining double bond position have been 
developed they are not yet amenable to high-throughput, quantitative anlysis (Hancock et al. 
2017). Nevertheless, future addition of such techniques will further enhance the analysis of 
FAs and the n-3 index. Additionally, pipetting of 10 uL of packed erythrocytes introduced 
variation between samples (data not shown), as pipetting this volume of packed cells is 
difficult. Given that sample volume is generally not limited in this process, the initial starting 
volume of erythrocytes could easily be increased to further reduce variability between 
sample measurements. This could possibly be achieved using the robotic system to initially 
pipette a larger cell volume and perform hemolysis prior to aliquoting a small volume of the 
lyzed cell mixture for extraction. 
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In conclusion, the high throughput ESI-MS method described here allows the determination 
of human erythrocyte fatty acid concentration and n-3 index from low sample volumes. The 
method is convenient, simple, low in cost and significantly increases throughput compared to 
the reference GC-FID method. Consequently, the method is well suited for application in 
epidemiological studies and large clinical trials. 
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The amount of each phospholipid (PL) standard stock solutions added to create the 
five synthetic PL mixtures.  
 
Table S1: Amount of each synthetic PL stock solutions added to create 2% synthetic PL 
mixtures. 
 
Table S2: Amount of each synthetic PL stock solutions added to create 4% synthetic PL 
mixtures.   
 
Table S3: Amount of each synthetic PL stock solutions added to create 6% synthetic PL 












Synthetic PL standards  uMolar % total phospholipids 
PtdEtn 16:0/18:1 80.8 8.1 
PtdCho 16:0/18:1  363.8 36.4 
PtdCho 16:0/18:2 363.8 36.4 
PtdEtn 18:0/20:4 50.5 5.1 
PtdCho 16:0/20:4 101.1 10.1 
PtdEtn 18:0/22:6 8.0 0.8 
PtdCho 16:0/22:6 32.0 3.2 
Synthetic PL standards  uMolar % total phospholipids 
PtdEtn 16:0/18:1 77.5 7.7 
PtdCho 16:0/18:1  348.6 34.9 
PtdCho 16:0/18:2 348.6 34.9 
PtdEtn 18:0/20:4 48.4 4.8 
PtdCho 16:0/20:4 96.8 9.7 
PtdEtn 18:0/22:6 16.0 1.6 
PtdCho 16:0/22:6 64.0 6.4 
Synthetic PL standards  uMolar % total phospholipids 
PtdEtn 16:0/18:1 74.1 7.4 
PtdCho 16:0/18:1  333.5 33.3 
PtdCho 16:0/18:2 333.5 33.3 
PtdEtn 18:0/20:4 46.3 4.6 
PtdCho 16:0/20:4 92.6 9.3 
PtdEtn 18:0/22:6 24.0 2.4 
PtdCho 16:0/22:6 96.0 9.6 
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Table S4: Amount of each synthetic PL stock solutions added to create 8% synthetic PL 
mixtures.    
 
Table S5: Amount of each synthetic PL stock solutions added to create 10% synthetic PL 





























Synthetic PL standards  uMolar % total phospholipids 
PtdEtn 16:0/18:1 70.7 7.1 
PtdCho 16:0/18:1  318.3 31.8 
PtdCho 16:0/18:2 318.3 31.8 
PtdEtn 18:0/20:4 44.2 4.4 
PtdCho 16:0/20:4 88.4 8.8 
PtdEtn 18:0/22:6 32.0 3.2 
PtdCho 16:0/22:6 128.0 12.8 
Synthetic PL standards  uMolar % total phospholipids 
PtdEtn 16:0/18:1 67.4 6.7 
PtdCho 16:0/18:1  303.2 30.3 
PtdCho 16:0/18:2 303.2 30.3 
PtdEtn 18:0/20:4 42.1 4.2 
PtdCho 16:0/20:4 84.2 8.4 
PtdEtn 18:0/22:6 40.0 4.0 
PtdCho 16:0/22:6 160.0 16.0 
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Example of the correction applied to 16:0, 18:0 and 18:1 concentration determined by 
GC. The example provided here is for 18:0 in a single sample. This procedure was 
repeated for 16:0, 18:0 and 18:1 in every sample.  
1) Determine the proportion of CerPCho 18:0 from MS data.  
     [CerPCho 18:0 (MS)] / [total 18:0 (MS)] = proportion of CerPCho 18:0 (MS) 
     (0.95 nmol/ml) / (6.91 nmol/ml) = 0.14 
2) Estimate the concentration of CerPCho 18:0 obtained by GC. 
0.14 X [18:0 (GC)] = [CerPCho 18:0 (GC)] 
            0.14 X 213.8 nmol/ml = 29.9 nmol/ml 
3) Correct the concentration of CerPCho 18:0 obtained by GC 
     29.9 nmol/ml X correction factor = corrected [CerPCho 18:0 (GC)] 
     29.9 nmol/ml X 2.48 = 74.2 nmol/ml 
4) Add corrected CerPCho 18:0 concentration to the PL 18:0 concentration to determine 
corrected total 18:0 concentration by GC. 
([18:0 (GC)] – [CerPCho 18:0 (GC)])+ corrected [CerPCho 18:0 (GC)] = corrected [18:0 
(GC)]  




Sphingomyelin fatty acids transesterification experiment 
An experiment was conducted to examine the extraction recovery of sphingomyelin fatty 
acids using two methods; namely the Lepage and Roy transesterification as used in the GC-
FID method and the new high throughput ESI-MS method. CerPCho 24:1 was selected and 
added to the synthetic PL mixture shown in table S5. The results are shown in table S6 and 
it clearly shows that 24:1 (sphingomyelin fatty acids) are not completely transesterified using 
the Lepage and Roy method as there was only a 45% recovery.  






GC-FID method  The high-throughput ESI-MS method 
















870.4 ± 17.3 
85.4 ± 0.5 
361.9 ± 6.4 
278.6 ± 4.6 
111.9  ± 5.4 
154.6 ±  17.3 








880.2 ± 11.9 
45.7 ± 1.0 
360.2 ± 3.7 
297.7 ± 6.2 
116.5  ± 1.9 
150.0 ± 5.8 









Footnote of abbreviations; * due to oxidation of PtdEtn (18:0/22:6) as described the expected 







Table S7: Targeted ion scans used to acquired phospholipid data. 
Lipid  Ion  Scan DP EP CE CXP  Mass range (Da)       
Head group scans 
PtdCho/CerPCho [M+H]+ PI 184.1 100 10 47  8 640-1000 
PtdEtn [M+H]+ NL141.0 100 10 30  8 685-950 
PtdSer [M+H]+ NL 185.0 100 10 30  8 755-965 
 
Fatty acyl chain scans 
16:1 [M-H]¯ PI 253.2 -100 -10 -55 -11 600-900 
16:0 [M-H]¯ PI 255.2 -100 -10 -55 -11 600-900 
17:0 [M-H]¯ PI 269.3 -100 -10 -55 -11 560-900 
18:2 [M-H]¯ PI 279.2 -100 -10 -40 -11 600-900 
18:1 [M-H]¯ PI 281.3 -100 -10 -55 -11 600-900 
18:0 [M-H]¯ PI 283.3 -100 -10 -55 -11 600-900 
19:0 [M-H]¯ PI 297.3 -100 -10 -55 -11 600-900 
20:5 [M-H]¯ PI 301.2 -100 -10 -40 -11 500-1000 
20:4 [M-H]¯ PI 303.2 -100 -10 -40 -11 600-1000 
20:3 [M-H]¯ PI 305.2 -100 -10 -40 -11 600-1000 
22:6 [M-H]¯ PI 327.2 -100 -10 -40 -11 700-1000 
22:5 [M-H]¯ PI 329.2 -100 -10 -40 -11 700-1000 
22:4 [M-H]¯ PI 331.2 -100 -10 -40 -11 700-1000 
24:0 [M-H]¯ PI 365.3 -100 -10 -40 -11 740-1040 
24:1 [M-H]¯ PI 363.3 -100 -10 -40 -11 740-1040 
Scan rate for positive ion mode was 200 Da/s, for negative ion mode 1000 Da/s. Mass shifting was 
prevented in negative ion mode by increasing number of summed scans. PI Precursor ion, NL neutral 





Table S8: Justification for Cost per sample for GC-FID method and ESI-MS method. 
Items GC-FID method ESI-MS method 
Materials and consumables $ 28.0  $ 10.0  
Maintenance contributions and initial cost $ 22.0  $ 10.0  






















Table S9: Fatty acids concentrations (nmol/ml blood) in QC samples (n=57). Values are 





Mean ± SEM (%CV) 
16:0 454.3 ± 12.5 (13.4%) 
17:0 17.6 ± 1.1 (13.7%) 
18:0 257.7 ± 1.7 (8.3%) 
24:0 83.9 ± 1.3 (19.7%) 
16:1 4.4 ± 0.1 (14.9%) 
18:1 206.9 ± 10.9 (13.8%) 
24:1 104.0 ± 0.5 (7.5%) 
18:2 146.5 ± 3.3 (13.3) 
20:3 22.2 ± 0.3 (17.2%) 
20:4 187.9 ± 2.3 (10.0%) 
20:5 5.7 ± 0.1 (15.5%) 
22:4 21.7 ± 2.2 (17.9%) 
22:5 29.8 ± 1.2 (10.7%) 




















Figure S1: An example of spread sheet used to calculate the fatty acids levels from PL 
individual species detected from ESI-MS method.
PL species Sample #1 Sample #2 Sample #3
PtdCho 16:0 -16:0 0.3067 0.4257 0.4061
PtdCho 16:0 -16:1 0.0529 0.0559 0.0840
PtdCho 16:0 -17:0 0.0223 0.0440 0.0404
PtdCho 16:0 -18:0 0.0670 0.1240 0.0692
PtdCho 16:0 -18:1 1.4029 1.9089 1.7042
PtdCho 16:0 -18:2 2.4135 2.5645 2.4609
PtdCho 17:0 -18:1 0.0577 0.0829 0.0991
PtdCho 17:0 -18:2 0.0571 0.1042 0.1010
PtdCho 18:0 -18:0 0.0218 0.0307 0.0192
PtdCho 18:0 -18:1 0.2411 0.3723 0.4016
PtdCho 18:0 -18:2 0.5075 0.7984 0.8687
PtdCho 18:1 -18:1 0.1741 0.2029 0.2515
PtdCho 18:1 -18:2 0.2553 0.3664 0.4422
PtdCho 16:0 -20:3 0.3944 0.2256 0.2142
PtdCho 16:0 -20:4 0.7541 0.9201 0.6681
PtdCho 16:0 -20:5 0.0323 0.0865 0.0774
PtdCho 18:0 -20:4 0.3001 0.4022 0.3045
PtdCho 18:1 -20:4 0.1172 0.1923 0.1533
PtdCho 16:0 -22:6 0.2240 0.3027 0.2285
PtdCho 18:0 -22:6 0.0488 0.0681 0.0758
PtdEtn 16:0 -18:1 0.9952 1.6980 1.1877
PtdEtn 16:0 -18:2 0.4094 0.5437 0.4861
PtdEtn 18:0 -18:0 0.0107 0.0206 0.0135
PtdEtn 18:0 -18:1 0.2436 0.2933 0.2676
PtdEtn 18:0 -18:2 0.2253 0.2728 0.2325
PtdEtn 18:1 -18:1 0.2107 0.3383 0.3201
PtdEtn 18:1 -18:2 0.2692 0.4544 0.4678
PtdEtn 16:0 -20:3 0.0805 0.0813 0.0891
PtdEtn 16:0 -20:4 0.6756 0.9784 0.6669
PtdEtn 16:0 -20:5 0.0391 0.0648 0.0584
PtdEtn 17:0 -20:4 0.1052 0.1373 0.1044
PtdEtn 17:0 -20:5   0.1183 0.1675 0.1294
PtdEtn 18:0 -20:4 0.4480 0.5038 0.4570
PtdEtn 16:0 -22:4 0.2259 0.2528 0.1547
PtdEtn 16:0 -22:5 0.1216 0.2065 0.1147
PtdEtn 18:1 -20:4 0.3976 0.5620 0.4405
PtdEtn 16:0 -22:6 0.3658 0.4774 0.3093
PtdEtn 17:0 -22:5 0.0595 0.0761 0.0590
PtdEtn 18:0 -22:6 0.1188 0.1370 0.1001
PtdSer 18:0 -18:0 0.0047 0.0056 0.0067
PtdSer 18:0 -18:1 0.2237 0.1789 0.2599
PtdSer 18:0 -20:4 1.3874 1.6430 1.6171
PtdSer 18:0 -22:5 0.2739 0.3720 0.2826
PtdSer 18:0 -22:6 0.4162 0.6404 0.4840
CerPCho 16:0 2.5708 3.6073 3.3175
CerPCho 18:0 0.3409 0.5706 0.4763
CerPCho 18:1 0.1172 0.2077 0.1788
CerPCho 24:0 2.5009 2.9584 2.0206
CerPCho 24:1 3.1676 4.1307 3.6350
Fatty acids Sample #1 Sample #2 Sample #3
16:0 11.5 15.0 12.7
16:1 0.1 0.1 0.1
17:0 0.4 0.6 0.5
18:0 4.9 6.5 6.0
18:1 4.7 6.8 6.3
18:2 4.1 5.1 5.1
20:3 0.5 0.3 0.3
20:4 4.2 5.3 4.4
20:5 0.2 0.3 0.3
22:4 0.2 0.3 0.2
22:5 0.5 0.7 0.5
22:6 1.2 1.6 1.2
24:0 2.5 3.0 2.0
24:1 3.2 4.1 3.6
Fatty acids Sample #1 Sample #2 Sample #3
16:0 458.4 599.7 509.7
16:1 2.1 2.2 3.4
17:0 16.8 24.5 21.3
18:0 196.7 259.6 239.0
18:1 187.7 273.5 252.2
18:2 165.5 204.2 202.4
20:3 19.0 12.3 12.1
20:4 167.4 213.6 176.5
20:5 7.6 12.8 10.6
22:4 9.0 10.1 6.2
22:5 18.2 26.2 18.3
22:6 46.9 65.0 47.9
24:0 100.0 118.3 80.8
24:1 126.7 165.2 145.4
Individual PL species 
concentration 
(nmol/10 uL of packed 
RBCs) determined by 
mass spectrometry as 
described in methods.
Individual fatty acid 
concentration 
(nmol/10 uL of packed 
RBCs) calculated 
from the sum of each 
individual PL species 
that contains that FA. 
If the PL contained 2 
moles of the FA, e.g. 
PtdCho 16:0-16:0 it 
was added twice.
To convert FA 
concentration from 
nmol/10 uL of packed 
RBCs to nmol/mL of 
blood the FA 
concentration obtained 
for 10 uL of packed 
RBCs was multiplied 
by 40 (x 100 to obtain 
mL of RBCs then x 0.4 
to convert to whole 










Testing solvents for lysing erythrocyte membranes 
a) The TRIS-Aliquot method 
In 2 mL glass vials, 10 μL of packed erythrocytes were added to 240 μL of TRIS-HCl. 
Following this, the tubes were vortexed for two minutes before a 25 μL aliquot was taken. 
The aliquot was dispensed into a new tube to which 75 μL of 200 mM ammonium acetate 
and 90 μL of methanol were added prior to a further 2 minutes of vortexing. Following this, 
300 μL of MTBE was added and tubes were vortexed again for 2 minutes after which they 
were left to stand for 1 minutes to allow phase separation. After phase separation had 
occurred, 300 μL of the upper lipid containing phase was removed and dried under nitrogen 
at 37oC. The dried lipid were then reconstituted to 150 μL using 2:1 methanol: chloroform 
and were stored at -20 oC until ready to be analysed. Prior to mass spectrometric analysis, 
extracts were diluted using 2:1 methanol: chloroform solution containing 5 mM ammonium 
acetate as spray solvent.  
          
b) Adding ammonium acetate first 
In 2 mL eppendorf tube, 10 uL of packed erythrocytes were added to 100 μL of an aqueous 
mixture containing 150 mM ammonium acetate and 2 mM EDTA before being vortexed. 
Following this, 100 μL of methanol was added and vortexed for 2 minutes. After that 400 μL 
of MTBE was added and vortexed for 2 minutes. 400 μL of the supernatant was removed 
and dried under nitrogen at 37oC and then reconstituted with 200 μL of 2:1 methanol: 
chloroform solution containing 5 mM ammonium acetate. Lipid extracts were stored at -20 oC 
until ready for analysis.  
 
c) TRIS-buffered ammonium chloride 
TRIS-buffered ammonium chloride was firstly optimised to PH 7.4 by the addition 
hydrochloric acid. As per methods above, 10 μL of packed erythrocytes were added to 100 
μL of the TRIS-buffered ammonium chloride and mixed by repeated aspirating/dispensing. 




followed by further 2 minutes of vortexing. To each tube, 400 μL of MTBE was then added 
and each tube was again vortexed for 2 minutes. The upper phase was extracted, placed in 
a new glass vial and dried under nitrogen at 37oC and then reconstituted with 300 μL of 2:1 
methanol: chloroform and then stored at -20 oC until ready for analysis.  
 
d) Adding methanol first 
The method carried out was analogous to those previously described with some minor 
adjustments to reagent order and times for vortexing. Briefly, 10 μL of packed erythrocytes 
were added to 120 μL of methanol containing 0.01% BHT in eppendorf tubes and vortexed 
for 10 minutes. Following this, 400 μL of MTBE was added and the tubes underwent another 
10 minutes vortex before phase separation was initiated by addition 100 μL of 5 mM 
ammonium acetate. Lipid extracts were stored at -20 oC until ready for analysis.  
 
This study demonstrated that adding ammonium acetate as first reagent to packed 
erythrocytes produced quality mass spectra when analysed using ESI-MS. Having the 
erythrocytes suspended in aqueous mixture containing ammonium acetate and EDTA 
enable the methanol to interface more readily with the packed erythrocytes than if they were 
not in suspension. Further to this, the uniform solution created by suspending the packed 
erythrocytes in ammonium acetate and EDTA makes their analysis considerably more 
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People classified as ultra high risk (UHR) of developing psychosis have reduced cellular 
membrane n-3 and n-6 polyunsaturated fatty acids. We aimed to compare n-3 index, fatty 
acids and molecular phospholipid species from erythrocytes of people with UHR (n =285) 
with age-matched healthy controls (n =120). The molecular phospholipid and fatty acid 
composition of erythrocytes for both groups were determined by mass spectrometry. Lower 
proportions of polyunsaturated fatty acids were observed in the UHR group compared to 
healthy controls; specifically, eicosapentaenoic acid was 29.3% lower, docosahexaenoic 
acid 27.2% was lower, arachidonic acid 15.8% was lower and the n-3 index 26.9% lower in 
the UHR group compared to healthy group. Conversely, the proportion of nervonic acid was 
64.4% higher in the UHR group compared to healthy controls. At a lipid class level, the UHR 
group had higher concentrations of sphingomyelin 16% and lower concentrations 
phosphatidylethanolamine 46% compared to healthy group. Of the 49 individual molecular 
phospholipid components studied here, twenty seven phospholipid species were lower in the 
UHR group. In conclusion, there are clear differences in the proportions of erythrocyte fatty 
acids and phospholipids between UHR and healthy controls and UHR had higher 
concentrations of SM and lower concentrations of PE. These differences may represent a 
promising prodromal risk biomarker in the UHR population to aid clinical diagnosis. 














Psychosis is a term used to describe a number of psychological symptoms that impact on a 
person’s perception of reality or understanding, and affects approximately 1% of the 
population.1,2 It is severely disabling and has a major socioeconomic impact.3 In the past two 
decades criteria were introduced for identifying people in the prodromal phase that have an 
ultra high risk (UHR) of developing psychosis.4-8 People classified as UHR of developing 
psychosis are usually young people who experience brief limited psychotic symptoms, 
attenuated psychotic symptoms or possess a key risk factor (e.g. first degree relative with 
psychosis and schizotypal personality disorder) in addition to a decline in psychosocial 
functioning.4,9 A recent meta-analysis of UHR found that the proportion of people who 
transitioned to psychosis increased with time, i.e. 18% by 6 months, 22% by 1 year, 29% by 
2 years and 36 by 3 years.10 These values are consistent with evidence that some UHR 
patients develop psychosis after the first 24 months following presentation when the 
transition risk is thought to be maximal.11,12 
Polyunsaturated fatty acid (PUFA) deficiency may underlie the physiological and clinical 
phenomena observed in some neuropsychiatric diseases, particularly in schizophrenia.13 It 
has been reported that people at UHR of psychosis14 and patients with schizophrenia15-18 
have low levels of n-3 and n-6 PUFA. This is supported by a meta-analysis that compared 
the erythrocyte fatty acids composition of 429 schizophrenia patients and 444 healthy 
controls.19 This study found that the schizophrenia patients had lower levels of erythrocyte 
docosahexaenoic acid (DHA, 22:6), docosapentaenoic acid (DPA, 22:5), eicosapentaenoic 
acid (EPA, 20:5) and arachidonic acid (AA, 20:4). Several studies have also found a low 
(≤4%) n-3 index (the sum of EPA and DHA levels in erythrocytes membranes expressed as 
percent of total fatty acids)20, 21 in individuals at UHR of developing psychosis14 and other 







The PUFA content, specifically DHA, of erythrocyte membranes reflects their content in the 
brain r=0.8625 and therefore, erythrocyte membrane DHA represents an ideal target in 
psychotic patients. Erythrocytes also have less inter-individual variability compared to 
plasma26; it reflects dietary intake that has occurred during the past 120 days27, 28 and 
maintains stability at -80C for several years29,30 and is therefore an ideal tissue/sample to 
investigate.   
Currently, little is known about the molecular phospholipid species and associated fatty acids 
in people at UHR of psychosis and which of these lipid species are altered compared to 
healthy people. The aim of this study was to quantify and compare the erythrocyte fatty 
acids, n-3 index and molecular phospholipid species from people at UHR of developing 
psychosis to aged matched healthy controls. 




This study was approved by the human research ethics committees at the University of 
Wollongong (HE 16/018) and the University of Melbourne (2008.628).   
 
UHR participants 
The NEURAPRO-E study is a double-blind, placebo-controlled, randomized clinical trial to 
determine whether treatment with n-3 LCPUFA in combination with a high-quality 
psychosocial intervention (cognitive behavioural case management [CBCM]) is more 
effective than placebo plus CBCM. UHR participants were recruited between March 1, 2010 
and September 30, 2014 from Melbourne, Sydney, Hong Kong, Vienna, Basel, Winterthur, 
Copenhagen, Amsterdam, Singapore and Jena.29, 30 Inclusion and exclusion criteria for these 
participants have been reported previously. 29, 30 20 mL of blood collected into vacutainers 
coated with EDTA as antioxidant at baseline and the 6-month time point. The packed 
erythrocytes were processed (centrifuged and aliquoted according to the guidelines in the 
Neurapro-E Pathology Manual) frozen erythrocyte samples were transported to the 




evidence that shows the samples stable for 3.5 years at -80°C31. The UHR samples 
collected 2014 and samples run completed by 2017 which is within 3.5 years. 
 
Healthy control participants, screening questionnaire and blood sampling 
125 healthy control participants were recruited between October 2016 and March 2017 from 
the University of Wollongong staff, their children and undergraduate students to achieve 
similar age range to the UHR participants, namely 13-40. All participants were assigned a 
study number and data regarding their sex, age, weight, height and smoking were recorded. 
Inclusion criteria of the healthy control group were age between 13-40 years, no psychiatric 
history, no family history of psychiatric illness and no drug use. The healthy subjects were 
screened using the 16-item Version of the Prodromal Questionnaire PQ-16.32 A score of 6 
or more indicates a risk of psychosis and was used as an exclusion criterion.33 Five 
participants were excluded from this study due to their ages being over 40 years old and no 
participants were excluded due to psychiatric symptoms or history. 
After an 8 hour overnight fast, blood samples were collected into vacutainers coated with 
ethylenediaminetetraacetic acid (EDTA) as antioxidant and to prevent clotting. The blood 
samples were subjected to centrifugation at 3000 rpm at 4 oC for 10 minutes. The 
supernatant of plasma and white blood cells were removed and the packed erythrocytes 
were aliquots of 1.5 ml and stored at -80 oC until required for analysis. 
Materials 
High performance liquid chromatography (HPLC) grade or higher methyl tert-butyl ether 
(MTBE), chloroform and methanol were purchased from VWR International (QLD, Australia). 
Butylated hydroxytoluene (BHT), and ethylenediaminetetraacetic acid (EDTA) were 
purchased from Sigma Aldrich (NSW, Australia). Analytical grade ammonium acetate was 
obtained from Crown Scientific (New South Wales, Australia). Phospholipid internal 
standards were purchased from Avanti Polar Lipids through Auspep (Victoria, Australia) and 
consisted of dinonadecanoyl phosphatidylcholine (PC 19:0/19:0); diheptadecanoyl 




17:0/17:0); N-lauroyl-D-erythro-sphinganylphosphorylcholine (SM d18:0/12:0).  
Twin-tec PCR plates and 96-well plates were purchased from Eppendorf (POCD scientific, 
Australia). Two types of disposable conductive CO-RE tips (without filter) in 50 uL and 300 
uL sizes were used and purchased from Hamilton Robotics (Reno NV, USA).    
Lipid extraction  
 Both healthy control & UHR of psychosis erythrocyte samples were extracted using the 
automated extraction method described previously.34 In brief, 290 uL an aqueous mixture 
containing 2 mM EDTA and 150 mM Ammonium acetate was added to the wells of a 2.0 mL 
96-well plate on ice. A 10 μL aliquot of packed erythrocytes was added to the wells and the 
plate mixed using a vortex at 800 rpm for 10 minutes. Robotic procedures were then started 
with all reagents, solvents and plates loaded onto the automated liquid handling station 
(Hamilton, Nevada, USA). A 300 μL aliquot of an internal standard mixture in methanol [500 
uM (PC 19:0/19:0); 166.7 uM (PE 17:0/17:0); 100 uM (PS 17:0/17:0); 500 uM (SM 
18:0/12:0)] was added to the wells prior to mixing and standing for 10 minutes. 1 mL of 
MTBE was added to the wells and mixed for 30 minutes before the mixture was allowed to 
stand for 15 minutes to allow phase separation. Following this, 500 μL of the MTBE top 
phase was removed to the extraction plate (containing the extracted phospholipids) and 40 
μL of extract was transferred to another 96-well plate and diluted with 760 μL of a 2:1 (v:v) 
methanol/chloroform solution containing 5 mM Ammonium acetate. A 40 μL aliquot of the 
diluted extract was transferred to another 96-well plate which was sealed with aluminium foil 
prior to analysis by mass spectrometry. 
Electrospray ionization mass spectrometry (ESI-MS) 
Mass spectrometry was performed utilizing a hybrid triple quadrupole linear ion trap mass 
spectrometer (QTRAP 5500 AB Sciex, MA, USA) with an automated chip-based 
nanoelectrospray source (Triversa NanoMate, Advion Biosciences, New York, USA) as 
previously described.34, 35, 36 A 10 uL aliquot of lipid extract diluted in methanol: chloroform 
(2:1 v/v) containing 5mM ammonium acetate (approximately 10 uM) was infused into the 




acquisition and 1.1 kV for negative ion acquisition and a nitrogen gas pressure of 0.40 psi.35, 
36 Lipids were identified using precursor ion and neutral loss scans as previously 
described.35, 36 
Ionized lipids identified with a minimum signal-to-noise ratio of 10 were included in the 
analysis. Identification and quantification was accomplished using LipidView software 
(version 1.2, Sciex, MA, USA) this included smoothing, identification, removal of isotope 
contribution from lower mass species, and correction for isotope distribution, as described.35, 
36 Quantification was performed using LipidView software by comparing the spectral peak 
area of individual lipids to their class specific internal standards following isotope correction.  
Statistical analysis  
 
Microsoft™ Excel software (Microsoft Corp., California, USA) was used for the basic 
statistical analyses including mean, median, interquartile range (IQR), standard deviation 
and standard error of the mean. All variables were not normally distributed thus the Mann-
Whitney U-test was used to estimate the significance of these variables between UHR and 
healthy groups. Categorical data were analyzed using chi-square. Correction for multiple 
comparisons was performed using the Bonferroni method; P values measuring < 0.0008 was 
considered to be statistically significant. Statistical analyses were completed using SPSS 
















Baseline characteristics of UHR and healthy controls 
 
Of the 304 participants that started the Neurapro-E study30, 285 participants completed the 
study and 19 participants were either not eligible or lost to follow-up. The control group 
consisted of 120 age matched healthy participants. The baseline characteristics of each 
group are presented in table 1. 









Age median (IQR-1, IQR-3) 18 (16 , 22) 17 (16 , 20) 0.195 
Sex male n (%) 129 (50.4%) 61 (51%) 0.305 
Body mass index Kg/m2 (IQR-1, IQR-3) 23 (20 , 26.7)* 21.7 (19.8 , 25.2) 0.012 
Smoking n (%) 110 (38.6%) 25 (20.8%) 0.001 
* BMI is for 252 of the 285 participants. “Ultra high risk (UHR) of developing psychosis; Interquartile 
range (IQR)”. 
 
Fatty acids and n-3 index 
The fatty acid composition of erythrocytes and the n-3 index of UHR and healthy controls are 
shown in table 2. A number of fatty acids, i.e. 17:0, 18:0, 18:2, 20:4, 20:5, 22:4; 22:5 and 
22:6 were lower in the UHR group compared to healthy controls. The n-3 index was also 
lower in the UHR group than the healthy controls. In contrast, UHR participants had higher 











Table 2. Individual erythrocyte fatty acid composition from healthy (n=120) and people at 




Median (First, Third quartile) 
UHR group 






16:0 31.37 (30.49 , 32.39) 32.31 (30.65 , 34.24) 2.9%↑ <0.0001 
16:1 0.20 (0.13 , 0.31) 0.21 (0.14 , 0.29) 5.0% 0.936 
17:0 1.35 (1.24 , 1.52) 1.28 (1.18 , 1.40) 5.2%↓ <0.0001 
18:0 14.38 (13.77 , 14.89) 12.99 (11.98, 13.94) 9.7%↓ <0.0001 
18:1 15.49 (14.43 , 16.63) 16.62 (15.51 , 17.73) 7.3%↑ <0.0001 
18:2 12.89 (11.63 , 14.04) 12.04 (10.49 , 13.53) 6.6%↓ <0.0001 
20:3 0.86 (0.63 , 1.09) 0.81 (0.65 , 0.98) 5.8% 0.884 
20:4 10.95 (10.11 , 11.64) 9.22 (7.52 , 10.11) 15.8%↓ <0.0001 
20:5 0.75 (0.63 , 0.88) 0.53 (0.45 , 0.63) 29.3%↓ <0.0001 
22:4 0.37 (0.30 , 0.47) 0.31 (0.14 , 0.45) 16.2%↓ <0.0001 
22:5 1.16 (1.03 , 1.31) 1.05 (0.83 , 1.31) 9.5%↓ <0.0001 
22:6 3.34 (2.83 , 3.92) 2.43 (1.94 , 2.91) 27.2%↓ <0.0001 
24:0 2.19 (1.41 , 3.94) 3.95 (2.98 , 5.15) 80.4%↑ <0.0001 
24:1 3.40 (2.26 , 6.16) 5.59 ( 4.27 , 7.27) 64.4%↑ <0.0001 
  n-3 index 4.09 (3.59 , 4.65) 2.99 (2.49 , 3.54) 26.9%↓ <0.0001 
P-values were calculated by using Mann-Whitney U-test; statistical significance shown in bold. ↑ 

























As shown in figure1, the erythrocyte membranes of the UHR group and the healthy controls 
showed similar proportions of phosphatidylcholine (PC) and phosphatidylserine (PS), but a 
lower percentage of phosphatidylethanolamine (PE) and a higher percentage of 
sphingomyelin (SM). Investigating the concentrations (nmol/10ul erythrocyte) for these four 
classes shows similar results with lower PE (3.57±0.26 vs. 6.63±0.45, p<0.0001) and higher 
SM (6.36±0.57 vs. 5.50±0.32, p<0.0001) concentrations in the UHR group compared to 
healthy controls. No differences in the concentrations of PC (7.48±0.69 vs. 8.95±0.37, 





















Figure 1. Percentage of the four major phospholipid classes within the human erythrocyte 
membranes of healthy controls (A) and UHR (B). Values are mean ± SEM for the entire 
cohort (n=120 for healthy group & 285 for UHR group). “PC, phosphatidylcholine; PE, 














42 ± 0.2  
*Total PE
25 ± 0.1  
Total PS
10 ± 0.3        
*Total SM
23 ± 0.8          
B) Ultra-high risk of psychosis group
Total PC
41 ± 0.2  
*Total PE
18 ± 0.1  
Total PS
9 ± 0.5        
*Total SM




Molecular phospholipids  
Phosphatidylcholine (PC)  
A comparison of the individual PC molecules from erythrocytes from UHR and healthy 
controls expressed as percentage of the total phospholipids is shown in table 3. Although 
there was no difference in total PC concentration twelve of the twenty PC species were 
different between the two groups. 
Of the two major PC species in human erythrocytes in both UHR and healthy controls, there 
was a lower proportion of PC (16:0_18:2) and higher proportion of PC (16:0_18:1) in UHR 
compared to the healthy controls. The other less abundant PC species such as PC 
(16:0_20:4), PC (16:0_20:5), (16:0_22:6), PC (18:0_22:6), PC (18:0_20:4), PC (18:1_18:2), 
PC (18:1_20:4) were lower in UHR compared to healthy controls. Conversely, PC 
(16:0_16:0), PC (16:0_17:0), PC (18:0_18:1) conributed a lower proportion of total 
phospholipids in healthy compared to UHR groups (see table 3). It should be noted however, 




Table 3. Individual species of phosphatidylcholine content of erythrocyte membranes from 
healthy (n=120) and people at UHR of developing psychosis (n= 285) (results are express 




Median (First, Third quartile) 
 
UHR group 






PC 16:0_16:0 1.72 (1.59 , 1.96) 2.10 (1.81 , 2.77 ) 22.0%↑ <0.0001 
PC 16:0_16:1 0.35 (0.23 , 0.55) 0.35 (0.24 , 0.49) 0.0% 0.717 
PC 16:0_17:0 0.11 (0.08 , 0.16) 0.24 (0.12 , 0.30) 118.0% ↑ <0.0001 
PC 16:0_18:0 0.39 (0.29 , 0.48) 0.42 (0.31 , 0.56) 7.7% 0.0114 
PC 16:0_18:1 8.60 (7.35 , 9.62) 9.84 (8.42 , 11.44) 14.4%↑ <0.0001 
PC 16:0_18:2 11.90 (10.18 , 13.47) 11.00 (8.81 , 13.64) 7.6%↓ <0.0001 
PC 16:0_20:3 1.08 (0.76 , 1.44) 0.96 (0.70 , 1.31) 11.1% 0.033 
PC 16:0_20:4 3.31 (2.85 , 3.82) 2.82 (2.08 , 3.47) 14.8%↓ <0.0001 
PC 16:0_20:5 0.38 (0.30 , 0.52) 0.25 (0.17 , 0.33) 34.2%↓ <0.0001 
PC 16:0_22:6 1.26 (0.98 , 1.53) 0.84 (0.62 , 1.04) 33.3%↓ <0.0001 
PC 17:0_18:1 0.43 (0.37 , 0.48) 0.42 (0.36 , 0.48) 2.3% 0.264 
PC 17:0_18:2 0.45 (0.39 , 0.54) 0.46 (0.35 , 0.57) 2.2% 0.405 
PC 18:0_18:0 0.12 (0.07 , 0.30) 0.10 (0.06 , 0.15) 16.7% 0.010 
PC 18:0_18:1 1.81(1.60 , 2.07) 2.09(1.72 , 2.43) 15.5%↑ <0.0001 
PC 18:0_18:2 3.90 (3.29 , 4.55) 3.64 (2.93 , 4.42) 6.7% 0.002 
PC 18:0_20:4 1.51 (1.30 , 1.77) 1.39 (1.08 , 1.68) 7.9%↓ <0.0001 
PC 18:1_18:1 0.87 (0.67 , 1.13) 1.12 (0.77 , 1.49) 28.7% 0.005 
PC 18:1_18:2 1.53 (1.15 , 1.80) 1.35 (0.97 , 1.64) 11.8%↓ <0.0001 
PC 18:1_20:4 0.79 (0.64 , 0.94) 0.60 (0.47 , 0.71) 24.1%↓ <0.0001 
P-values were calculated by using Mann-Whitney U-test; statistical significance shown in bold. ↑ 











Table 4 compares the PE measured in UHR and healthy erythrocytes. The lower abundance 
of total PE in the UHR group is reflected in the molecular PE species with all but PE 




Table 4. Individual species of phosphatidylethanolamine content of erythrocyte membranes 
from healthy (n=120) and people at UHR of developing psychosis (n= 285) (results are 




Median (First, Third quartile) 
UHR group 







PE 16:0_18:1 5.37 (4.60 , 5.95) 4.16 (3.79 , 4.64) 22.5%↓ <0.0001 
PE 16:0_18:2 2.08 (1.76 , 2.51) 1.60 (1.38 , 1.86) 23.1%↓ <0.0001 
PE 16:0_20:3 0.29 (0.21 , 0.48) 0.30 (0.20 , 0.51) 3.4% 0.685 
PE 16:0_20:4 3.15 (2.68 , 3.72) 2.43 (2.12 , 2.73) 22.9%↓ <0.0001 
PE 16:0_20:5 0.30 (0.22 , 0.44) 0.18 (0.13 , 0.23) 40.0%↓ <0.0001 
PE 16:0_22:4 0.63 (0.53 , 0.81) 0.53 (0.23 , 0.74) 15.9%↓ <0.0001 
PE 16:0_22:5 0.61 (0.46 , 0.78) 0.40 (0.22 , 0.55) 34.4%↓ <0.0001 
PE 16:0_22:6 1.54 (1.28 , 2.05) 1.00 (0.76 , 1.23) 35.1%↓ <0.0001 
PE 17:0_20:4 0.48 (0.41 , 0.55) 0.39 (0.31 , 0.46) 18.8%↓ <0.0001 
PE 17:0_20:5 0.59 (0.51 , 0.67) 0.45 (0.39 , 0.52) 23.7%↓ <0.0001 
PE 17:0_22:5 0.26 (0.22 , 0.32) 0.21 (0.17 , 0.25) 19.2%↓ <0.0001 
PE 18:0_18:0 0.09 (0.05 , 0.16) 0.08 (0.06 , 0.11) 11.1% 0.015 
PE 18:0_18:1 1.15 (0.98 , 1.30) 0.96 (0.84 , 1.07) 16.5%↓ <0.0001 
PE 18:0_18:2 0.90 (0.77 , 1.12) 0.75 (0.65 , 0.88) 16.7%↓ <0.0001 
PE 18:0_20:4 1.90 (1.62 , 2.22) 1.19 (0.59 , 1.67) 37.4%↓ <0.0001 
PE 18:0_22:6 0.48 (0.40 , 0.61) 0.32 (0.23 , 0.39) 33.3%↓ <0.0001 
PE 18:1_18:1 1.10 (0.86 , 1.51) 0.84 (0.66 , 1.05) 23.6%↓ <0.0001 
PE 18:1_18:2 1.66 (1.25 , 1.99) 1.18 (0.85 , 1.50) 28.9%↓ <0.0001 
PE 18:1_20:4 1.79 (1.48 , 2.17) 1.40 (1.07 , 1.67) 21.8%↓ <0.0001 
P-values were calculated by using Mann-Whitney U-test; statistical significance shown in bold. ↑ 










The PS species detected in this study and their percentage of the total phospholipids is 
shown in table 5. Only five PS species were quantified, with an increased percentage of PS 
(18:0_18:0) and a lower percentage of PS (18:0_20:4) and PS (18:0_22:6) in the UHR group 
compared to the healthy group. 
 
Table 5. Individual species of phosphatidylserine content of erythrocyte membranes from 
healthy (n=120) and people at UHR of developing psychosis (n= 285) (results are express 




Median (First, Third quartile) 
UHR group 






PS 18:0_18:0 0.03 (0.01 , 0.07) 0.11 (0.10 , 0.14) 266.7%↑ <0.0001 
PS 18:0_18:1 1.06 (0.92 , 1.23) 1.00 (0.82 , 1.20) 5.6% 0.080 
PS 18:0_20:4 5.82 (5.29 , 6.29) 5.16 (3.85 , 6.12) 11.3%↓ <0.0001 
PS 18:0_22:5 1.13 (1.00 , 1.27) 1.17 (0.94 , 1.36) 3.5% 0.329 
PS 18:0_22:6 2.07 (1.59 , 2.43) 1.61 (1.19 , 2.00) 22.2%↓ <0.0001 
P-values were calculated by using Mann-Whitney U-test; statistical significance shown in bold. ↑ 




Sphingomyelin (SM)  
Erythrocytes SM results are shown in table 6. The higher percentage of total SM observed in 
the UHR group (figure 1) is reflected in the higher contribution of SM 16:0, SM 18:0, SM 24:0 
and SM 24:1 to total phospholipids. The lowest SM species measured (SM 18:1) contributed 
a similar proportion of total phospholipids to both groups. 
Table 6. Individual species of sphingomyelins content of erythrocyte membranes from 
healthy (n=120) and people at UHR of developing psychosis (n= 285) (results are express 




Median (First, Third quartile) 
UHR group 






SM 16:0 9.17 (7.62 , 11.32) 10.63 (9.18 , 13.45) 15.9%↑ <0.0001 
SM 18:0 1.12 (0.93 , 1.67) 1.60 (1.32 , 2.23) 42.9%↑ <0.0001 
SM 18:1 0.53 (0.43 , 0.65) 0.55 (0.45 , 0.79) 3.8% 0.010 
SM 24:0 3.88 (2.57 , 6.62) 6.77 (5.23 , 8.42) 74.5%↑ <0.0001 
SM 24:1 6.05 (4.12 , 10.18) 9.63 (7.44 , 11.79) 59.2%↑ <0.0001 
P-values were calculated by using Mann-Whitney U-test; statistical significance shown in bold. ↑ 




Discussion   
 
To the authors knowledge this is the first study to compare the molecular phospholipid 
composition of human erythrocytes from individual at UHR of developing psychosis with that 
from age-matched healthy individuals.  
A striking finding of this study was the large difference in the level of phospholipid classes 
between the UHR patients and healthy controls. In particular, the UHR group had an 
approximately 46% lower concentration of PE and 16% higher concentration of SM in their 
erythrocyte membranes. Interestingly, both Keshavan et al. 37 and Ponizovsky et al.38 report 
similar lower levels of PE and increased levels of SM in the erythrocytes of schizophrenia 
patients compared to healthy individuals. In fact, reduced PE levels in erythrocytes of 
schizophrenia patients is a common finding37-44 and has also been observed in fibroblasts45 
and postmortem brain tissue.46 There are however, two studies that did not detect 
differences in erythrocyte phospholipid classes in patients with schizophrenia47  and in 
hippocampus of individuals with schizophrenia and with bipolar disorder 48 the possible 
reason for there was no differences observed in these two studies might come from 
diagnostic or biological differences between populations or laboratory methodologies. 
 
Previous findings in schizophrenic patients suggest there are two possible mechanisms that 
lead to a decrease in the erythrocyte levels of PE. First, decreased phosphomonoesters 
including phosphoethanolamine (precursors of membrane phospholipids) in the brains of 
schizophrenic patients49, 50 suggests a decrease in PE synthesis. Second, elevated levels of 
phospholipase A2 (PLA2) in erythrocytes of schizophrenia and UHR patients23, 51-56 and 
phosphodiesters, particularly glycerophosphoethanolamine (breakdown products of 
membrane phospholipids) in the brains of schizophrenic patients50 suggests an increase in 
the breakdown of PE. Elevated levels of SM may represent compensatory changes in the 
metabolism of phospholipids. The inverse relationship between PE and SM is compatible 






Of the 49 individual molecular phospholipids reported here (Tables 3, 4, 5 and 6), twenty 
seven were lower in proportion and nine were higher in proportion in the UHR group 
compared to healthy controls. All twenty seven phospholipids that were lower in the UHR 
group were glycerophospholipids and most contained PUFA. Of the phospholipids that were 
higher in the UHR group all were choline containing (PC and SM), with the exception of PS 
(18:0_18:0) that contributes approximately 0.1% or less of total erythrocyte phospholipids. 
The abnormality in phospholipid composition in UHR may be related to alterations in lipid 
metabolism as commonly observed in schizophrenia patients.16, 57, 58, 59 Evidence from brain 
studies using 32P Magnetic Resonance Spectroscopy (MRS) suggests there is a decreased 
synthesis of membrane phospholipids and an altered molecular composition of synaptic 
vesicles in the prefrontal cortex adolescents at genetic risk for schizophrenia.60  
The large differences in erythrocyte fatty acids composition is another striking finding in the 
present study. The long chain PUFA, in particular AA, EPA and DHA were much lower in 
UHR subjects compared to healthy subjects. While similar differences have been reported in 
schizophrenia 15-19, 59 and UHR14 patients previously we can now confirm that these 
differences are not the result of changes to specific molecular phospholipids as all fifteen 
phospholipids containing these fatty acids were found to be lower in UHR subjects. PUFA 
reductions in schizophrenia patients may in part be due to increased levels of oxidative 
stress; increased breakdown or decreased incorporation of these fatty acids into 
erythrocytes membrane15 disturbances in PUFA metabolism occur during the early stages of 
schizophrenia61 and also those at UHR of psychosis in general.62  
Another interesting finding is the elevated level of nervonic acid (NA) in the UHR group. 
Again, this has been reported in schizophrenia patients previously.63 Unlike the differences 
observed in PUFA however, the difference observed in NA in the current study is due to 
changes in a single molecular phospholipid, i.e. SM 24:1. NA is an abundant 
monounsaturated fatty acid present in the brain and the nervous system and helps to 




effects on white matter integrity observed in schizophrenia.64, 66  
The n-3 index was 2.99% in the UHR group vs. 4.09% in the healthy group. This result is in 
agreement with earlier observations that found a low n-3 index (3.1%) in UHR subjects.67 
Additionally, low n-3 index has been reported in people diagnosed with depression and 
schizophrenia68 and adolescents at UHR for bipolar disorder.24 This suggests that low n-3 
index is common in individuals with psychological disorders and may be present prior to 
illness onset. 
The alterations of erythrocyte phospholipids and fatty acids in UHR of psychosis may be 
expected to result in changes to their aggregability. Erythrocyte aggregability, i.e., their 
ability to form multicellular aggregates, plays a major role in blood flow. Erythrocytes in the 
presence of plasma proteins, most importantly fibrinogen, may aggregate to form rouleaux 
formations.69,70 Currently, no studies have been conducted in people with the UHR 
population investigate to this phenomenon; however, limited studies have reported increased 
erythrocyte aggregation among schizophrenic patients with mainly negative symptoms.71,72,73 
This suggests that the relationship between negative symptoms and erythrocyte aggregation 
was not due to extracellular factors, but rather to changes in the cell membrane. Erythrocyte 
aggregation can contribute to circulatory slowdown, especially in the microcirculation74, 
which may exacerbate cerebral white matter deficiencies in different brain regions. 
 
There is evidence to suggest that food components such as antioxidants, n-3 PUFA and B 
vitamins can influence mental health and modulate brain function.75 Disturbances in the 
metabolism of n-3 and n-6 PUFA are commonly seen in patients with schizophrenia, but it 
remains unclear whether poor dietary habits play a role in the development of disease in 
susceptible individuals. Interestingly, it has been recently reported that UHR individuals have 
a significantly lower consumption of n-3 PUFA than healthy individuals.76, 77 A low level of n-3 
PUFA in the brain is associated with reduced neuronal membrane fluidity78, which affects 
glutamatergic, dopaminergic and serotonergic neurotransmission79, 80, 81 and increases the 




schizophrenia in susceptible individuals.13  
The strengths of this study include a large sample in a group of people with UHR of 
psychosis and it utilized a new analytical technique for high throughput of erythrocyte 
samples for the assessment of phospholipid species, fatty acids and the n-3 index.34 A 
limitation in this study was that the healthy control group was from a single geographical 
location compared to people at UHR of psychosis which included people from different cities 
around the world and the confounders were not considered in this study. Also, the analytical 
method is not able to assign the correct position of the double bond in the carbon chain of 
the fatty acids e.g., this method is unable to determine whether 22:5 docosapentaenoic acid 
is 22:5n-3 or 22:5n-6 or if 18:1 is 18:1n-9 or 18:1n-7. Despite this limitation, the current study 
findings indicate that those in the UHR group have markedly different molecular 
phospholipids, fatty acids and n-3 index profile in comparison to healthy control individuals. 
 
In conclusion, the present investigation has identified large differences in n-3 index, fatty 
acids and phospholipids between healthy and UHR of psychosis groups. UHR of psychosis 
group had higher concentrations of SM and lower concentrations of PE. These differences 
may represent a promising prodromal risk biomarker in UHR to assist clinical diagnosis and 
warrant further investigation in future studies. 
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n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) are necessary for optimum mental 
health, with recent studies showing low n-3 LCPUFA in people with ultra-high risk (UHR) of 
developing psychosis. The aim of this study was to evaluate the effect of n-3 
supplementation on erythrocyte membranes of UHR participants. 225 UHR participants 
completed the 6 month intervention and 114 were randomized to fish oil capsules containing 
840mg of EPA and 560mg of DHA, and 111 were randomized to placebo capsules 
containing paraffin oil. Blood samples were taken at baseline and post intervention.  Mass 
spectrometry was used to analyse the molecular phospholipids and fatty acid composition of 
erythrocytes for both groups. The n-3 index was significantly increased form 3.0% to 4.12% 
after 6 months of receiving n-3 capsules. Fish oil capsules significantly increased the 20:5, 
22:6 and most of 22:5 containing species of PC, PE and PS by 11.8%-50.0% and 
significantly decreased 18:2, 20:3, 20:4, 22:4 containing species of PC, PE and PS by 7.4%-
42.9%. The SM 16:0, SM 18:0 and SM 18:1, however, significantly increased by 25.9%, 
31.3% and 27.3% respectively after 6 months of receiving placebo capsules. n-3 
supplementation increased n-3 index and PUFA in phospholipid molecular species but one 
limitation is the lack of compliance of the groups with taking their daily supplementation. 
 














Several studies have investigated the health benefits of consuming n-3 long chain 
polyunsaturated fatty acids (n-3 LCPUFA) predominantly focusing on their protective effects 
against such diseases as inflammatory diseases (e.g., arthritis) (Gillies et al., 2012), 
cardiovascular diseases (Marik & Varon, 2009), Alzheimer’s disease (van Gelder et al., 
2007) and depression (Hibbeln & Salem, 1995; Hibbeln, 2009; Parletta et al., 2017). 
 
Lower levels of PUFA are frequently observed in the erythrocyte membranes of patients with 
schizophrenia compared to healthy people (Carver et al., 2001; Khan et al., 2002; 
Arvindakshan et al., 2003; Peet et al., 2004; Parletta et al., 2016). PUFA deficiencies in 
neuronal membranes can be the result of the decreased incorporation or increased release 
of PUFA within membrane phospholipids (Pawelczyk et al., 2015). Both processes were 
found to be defective in schizophrenia patients (Pawelczyk et al., 2015).  
 
Supplementation with n-3 LCPUFA can prevent a transition to psychosis in people at UHR of 
developing psychosis (Amminger et al., 2010, 2015). Study results showed 4.9% (2 out of 
41) of patients treated with n-3 LCPUFA (700 mg of EPA and 480 mg of DHA) transitioned to 
psychosis compared to 27.5% (11 out of 40) of individuals treated with placebo supplements 
in addition to their standard care (Amminger et al., 2010). No severe functional impairment 
was found in the majority of the individuals from the n-3 group, and in addition, they no 
longer experienced attenuated psychotic symptoms at follow-up (Median, 6.7 years) 
(Amminger et al., 2010; 2015). This indicates that supplementation with n-3 LCPUFA could 
possibly reduce the risk of a transition to psychosis in those at ultra-high risk. High 
erythrocyte PUFA levels in schizophrenia patients are associated with reduced psychotic 
symptoms, better function, and improved myelin integrity (Amminger et al., 2012, 2015; 
Zhang et al., 2011; Peters et al., 2013). Research studies have shown that n-3 LCPUFA 
have neuroprotective and anti-inflammatory properties (Pandya et al., 2013; Smesny et al., 




release of arachidonic acid and the production of inflammatory eicosanoids and cytokines 
(Szefel et al., 2015). Nevertheless, n-3 LCPUFA therapeutic effects are complex and not 
fully understood.  
The PUFA content of erythrocyte membranes reflects the distribution in the brain (Kuratko & 
Salem, 2009) and therefore is an ideal sample to study. Erythrocyte PUFA have advantages 
over plasma PUFA since there is less inter-individual variability compared to plasma PUFA, 
more stable biomarker (Arab, 2003; Harris & Thomas, 2010) and reflects the last few months 
of food intake (Sullivan et al., 2006).  
Previous research investigating supplementation with n-3 LCPUFA in people with UHR 
compared to placebo supplementation identified increased erythrocyte n-3 LCPUFA levels 
and reduced transition to psychosis (Amminger et al., 2010). Nevertheless, this study was 
limited in the number of participants and lacks information on erythrocyte molecular 
phospholipid species. The aim of the present study was to investigate the effect of n-3 
LCPUFA supplementation on the n-3 index, fatty acids and molecular phospholipids species 
in erythrocytes samples from people diagnosed with UHR of developing psychosis 
compared to placebo supplementation. 
 
Material & methods 
Ethics and Subjects recruitment  
The NEURAPRO-E study is a double-blind, placebo-controlled, randomized clinical trial of n-
3 LCPUFA supplementation for participants at UHR of developing psychosis (McGorry et al., 
2017). The participants at UHR of developing psychosis were diagnosed and recruited 
between March 2010 and September 2014 from different cities around the world (Melbourne, 
Sydney, Hong Kong, Vienna, Basel, Winterthur, Copenhagen, Amsterdam, Singapore and 
Jena) as described in previously published reports (Markulev et al., 2015; Mcgorry et al., 
2017). Study characteristics such as exclusion and inclusion criteria have previously been 




in appendix (B). This study was approved by the human research ethics committee at the 
University of Melbourne (2008.628). The trial is registered as ACTRN 12608000475347 with 
The Australian New Zealand Clinical Trials Registry.      
Study intervention and randomization 
This trial was a double-blind, randomized placebo- controlled trial. Participants were 
randomized at entry to one of two treatment groups: n-3 PUFAs plus CBCM or placebo plus 
CBCM. There was equal allocation to the two treatment groups. The randomization was 
stratified by site and total score <21 or ≥21 on the Montgomery Asberg Depression Rating 
Scale (MADRS) (Montgomery, 1979) as both depression and antidepressants may impact 
on prodromal symptoms and illness progression. 
As previously described by (McGorry et al., 2017), participants were treated for a 6 month 
period with a daily dose of gelatin capsules containing either n-3 LCPUFA or the placebo 
control. Bottles of capsules were distributed to participants with each capsule containing 
either (a) 2600 to 3000 mg of concentrated marine fish oil (active intervention: 560mg of 
(DHA) 22:6n-3 and 840mg of (EPA) 20:5n-3, equivalent to approximately 1400 mg of n-3 
LCPUFA per day) or (b) 2600 to 3000 mg of paraffin oil (placebo control). Paraffin oil was 
specifically chosen as placebo because it does not contain PUFAs and has no impact on n-3 
PUFA metabolism. Placebo capsules were carefully matched in appearance and flavour with 
the active treatment to preserve blinding. The placebo capsules also contained the same 
amount of vitamin E as the fish oil capsules, and approximately 1% fish oil to mimic taste. 
This dose was similar to that described in a previous study (Amminger et al., 2010) and 
higher than dose recommended for people who diagnosed with cardiovascular disease 1000 
mg/day of n-3 LCPUFA (NHFA, 2008). 
Materials 
High performance liquid chromatography (HPLC) grade or higher of chloroform, methyl tert-
butyl ether (MTBE) and methanol were purchased from VWR International (QLD, Australia). 
Phospholipid internal standards were purchased from Avanti Polar Lipids (Victoria, Australia) 




diheptadecanoyl phosphatidylethanolamine (PE17:0/17:0); diheptadecanoyl 
phosphatidylserine (PS 17:0/17:0); N-lauroyl-D-erythro-sphinganylphosphorylcholine (SM 
d18:0/12:0). Ethylenediaminetetraacetic acid (EDTA) and butylated hydroxytoluene (BHT) 
were purchased from Sigma Aldrich (NSW, Australia). Analytical grade ammonium acetate 
was purchased from Crown Scientific (New South Wales, Australia). 96-well plates and twin-
tec PCR plates were purchased from Eppendorf (POCD scientific, Australia). Two types of 
disposable conductive CO-RE tips (without filter) in 50 uL and 300 uL sizes were used and 
purchased from Hamilton Robotics (Reno NV, USA). 
Lipid extraction  
Erythrocyte samples were extracted using an automated extraction method described 
previously (Alqarni et al., 2018), In brief, 290 uL of aqueous ammonium acetate 150 mM with 
2 mM EDTA was added to the wells of a 2.0 mL, 96-well plate cooled on ice. A 10 μL aliquot 
of packed erythrocyte samples was added to the wells before the plate was mixed using a 
vortex at 800 rpm for 10 minutes. Solvents, sample plates and reagents were loaded onto 
the liquid handling workstation (Hamilton, Nevada, USA) where the following steps were 
performed. First, a 300 μL aliquot of an internal standard mixture in methanol [500 uM (PC 
19:0/19:0); 166.7 uM (PE 17:0/17:0); 100 uM (PS 17:0/17:0); 500 uM (SM 18:0/12:0)] was 
added to the wells prior to mixing and standing for 10 minutes. Next, 1000 uL of MTBE was 
added to the samples and mixed for 30 minutes before the mixture was allowed to stand for 
15 minutes to allow phase separation. Following this, 500 μL of the MTBE top phase was 
removed to the extraction plate (containing the extracted phospholipids) and 40 μL of extract 
was transferred to another 96-well plate and diluted with 760 μL of a 2:1 (v:v)  
methanol/chloroform solution containing 5 mM ammonium acetate. A 40 μL aliquot of the 
diluted extract was transferred to another 96-well plate which was sealed with aluminium foil 







Electrospray ionization mass spectrometry ESI-MS  
Mass spectra were acquired using a chip based nanoelectrospray ionization source 
(Triversa NanoMate, Advion Biosciences, New York, USA) coupled to a hybrid linear ion 
trap-triple quadruple mass spectrometer (QTRAP 5500 AB Sciex, MA, USA) as previously 
described (Alqarni et al., 2018; Brown et al., 2013; Norris et al., 2015). A 10 uL aliquot of 
lipid extract diluted in methanol: chloroform (2:1 v/v) containing 5mM ammonium acetate 
(approximately 10 uM) was infused into the nano-electrospray ion source. The delivery gas 
was nitrogen at a pressure of 0.40 psi and spray voltage of 1.1 kV and 1.2 kV for negative 
and positive ion acquisition, respectively (Brown et al., 2013; Norris et al., 2015). 
Lipids were identified using precursor ion and neutral loss scans as previously described 
(Brown et al., 2013; Norris et al., 2015). 
Data were analyzed using LipidView software (version 1.2, Sciex, MA, USA), this included 
identification, smoothing, correction for isotope distribution, and removal of isotope 
contribution from lower mass species (Brown et al., 2013; Norris et al., 2015). Ionized lipids 
identified with a minimum signal-to-noise ratio of 10 were included in the analysis. 
Quantification was achieved using LipidView software by comparing the spectral peak area 
of individual lipids to their class specific internal standards after isotope correction. 
 
Statistical analysis  
Statistical analyses were carried out using SPSS software (version 19.0 SPSS. Inc), and 
results presented as median and interquartile range (IQR). All variables were not normally 
distributed thus the Wilcoxon signed-rank test (for paired samples) and the Mann-Whitney U 
test (for unpaired samples) were used to compare means. Categorical data were analyzed 
using chi-square and Mann-Whitney U test was used to calculate the significance of 
continuous variables. For multiple comparisons the P-values were corrected using the 








Characteristics of participants 
 
A total of 304 participants at UHR of developing psychosis were randomized to either n-3 
LCPUFA or placebo group in this study (McGorry et al., 2017). Seventy-nine participants 
were lost to follow-up during the study and 225 completed the 6-month period (McGorry et 
al., 2017). The participant characteristics for each group are presented in table 1. As shown 
in table 1 there were no differences in participant characteristics between n-3 LCPUFA or 
placebo groups at baseline. 
Table 1: Characteristics of the study participants at UHR of developing psychosis at 
baseline after randomisation to the n-3 LCPUFA and placebo groups. 
General characteristics 








Age median (IQR-1, IQR-3) 17 (16,22) 17 (16,21) 
0.564 
Sex male n (%) 59 (51.8%) 43 (38.7%) 
0.050 
Body mass index Kg/m2 (IQR-1, IQR-3) 23 (20 , 26.5)* 23 ( 20.5 , 27.1)* 
0.961 
Smoking n (%) 40 (35.1%) 43 (38.7%) 
0.570 
* 22 participants BMI information missed (10 from placebo group and 12 from n-3 LCPUFA group).  
 
Pre versus post n-3 LCPUFA and placebo supplementation. 
Table 2 shows the fatty acid results from the n-3 LCPUFA and placebo groups. Out of the 14 
fatty acids measured four fatty acids (18:2, 20:3, 20:4, 22:4) were decreased and three fatty 
acids (20:5, 22:5, 22:6) were increased in n-3 LCPUFA supplementation group after 6 
months of supplementation. Additionally, the n-3 index increased by 37.3% in the n-3 
LCPUFA supplementation group while no change was observed in the placebo group after 6 
months of supplementation with paraffin oil (Table 2).  
As shown in table 3, no change from baseline was observed in total erythrocyte PC, PE or 
PS after 6 months of supplementation with either n-3 LCPUFA or placebo. Interestingly, total 





The individual phospholipid molecules PC, PE, PS and SM expressed as nmol/10ul 
erythrocytes are shown in table 4. Out of a total of 20 PC species, seven species (PC 
16:0_18:1, PC 16:0_18:2, PC 17:0_18:2, PC 18:0_18:2, PC 16:0_20:3, PC 16:0_20:4 and 
18:0_20:4) decreased by 12.8%, 13.7%, 22.2%, 20.3%, 20.3%, 22.6%, 29.6%, respectively 
and three species (PC 16:0_20:5, PC 16:0_22:6 and PC 18:0_22:6) increased by 50.0%, 
11.8%, 40.0%, respectively in the n-3 LCPUFA supplementation group while the placebo 
group showed no difference post dose. Similar changes were seen with both PE and PS 
species. Eight PE species (PE 16:0_18:2, PE 18:1_18:2, PE 16:0_20:3, PE 16:0_20:4, PE 
17:0_20:4, PE 18:0_20:4, PE 16:0_22:4, PE 18:1_20:4) decreased by 9.1%, 24.0%, 28.6%, 
10.4%, 25.0%, 7.4%, 33.3%, 10.7%, respectively and four PE species (PE 16:0_20:5, PE 
16:0_22:5, PE 16:0_22:6, PE 18:0_22:6) increased by 50.0%, 12.5%, 36.8%, 33.3%, 
respectively in the n-3 LCPUFA supplementation group. PS 18:0_20:4 decreased by 14.4% 
and PS 18:0_22:6 increased by 31.3% after 6 months of n-3 LCPUFA supplementation. No 
changes were observed post placebo dose for PC, PE and PS species (Table 4). SM 
species did not shows any significant changes in n-3 LCPUFA group however, three SM 
species (SM 16:0, SM 18:0, SM 18:1) significantly increased by 25.9%, 31.3%, 27.3% 
respectively after 6 months of supplementation with placebo.  
After 6 months of n-3 LCPUFA supplementation PC n-3 LCPUFA increased by 43.0% from 
3.30% to 4.72% of total PC and similar increase was observed in PE n-3 LCPUFA by 32.6% 
from 10.08% to 13.37% of total PE and PS n-3 LCPUFA by 33.4% from 17.58% to 23.46% 





Table 2: Erythrocyte fatty acids of UHR of developing psychosis groups (n-3 LCPUFA and placebo).  









n-3 LCPUFA group (n=114) Placebo group  (n=111) 
Median (IQR)    
 Pre  
supplementation 
Median (IQR)    






Median (IQR)    
 Pre 
 supplementation 







16:0 423.45 (405.30 , 450.21) 434.41 (422.30 , 458.93) 0.567 2.60% 430.53 (407.11 , 455.77) 433.43(411.26 , 462.62) 0.248 0.67% 
16:1 2.86 (2.05 , 4.05) 2.39 (1.57 , 3.65) 0.035 16.40% 2.57 (1.76 , 3.66) 2.66 (1.88 , 3.92) 0.380 3.50% 
17:0 17.03 ( 15.69 , 18.68) 16.72 (14.90 , 18.80) 0.474 1.80% 16.52 (15.18 , 17.86) 16.69 (15.24 , 19.33) 0.056 1.02% 
18:0 171.29 (159.57 , 184.72) 175.44 (162.85 , 184.71) 0.072 2.40% 171.16 (155.07 , 182.49) 175.03 (160.93 , 188.73) 0.016 2.26% 
18:1 218.76 (203.09 , 233.48) 222.87 (207.79 , 240.75) 0.069 1.87% 218.13 (203.97 , 230.74) 220.17 (206.49 , 234.19) 0.780 0.94% 
18:2 155.89 (139.60 , 177.04) 152.25 ( 127.79 , 165.71) <0.0001 2.33%↓ 159.03 (135.74 , 177.09) 146.83 (136.24 , 170.22) 0.133 7.67% 
20:3 10.56 ( 8.81 , 12.38 ) 8.25 (6.81 , 10.41) <0.0001 21.88%↓ 11.01 (8.46 , 13.00) 8.61 (7.26 , 11.26) 0.003 21.79% 
20:4 121.38(98.56 , 131.89) 111.26 (101.95 , 122.60) <0.0001 8.33%↓ 123.07 (98.09 , 135.53) 123.23 (106.04 , 134.10) 0.783 0.13% 
20:5 7.31 (6.32 , 8.30) 9.60 (7.15 , 14.84) <0.0001 31.32%↑ 6.72 (5.60 , 8.36) 7.47 (6.17 , 9.90) 0.005 11.16% 
22:4 4.35 (2.33 , 5.95 ) 3.85 (1.39 , 4.87) <0.0001 11.49%↓ 4.22 (1.82 , 5.85) 4.19 (1.42 , 5.74) 0.568 0.71% 
22:5 13.99 (11.43 , 17.03) 16.76 (13.45 , 19.55) <0.0001 19.79%↑ 13.28 (10.47 , 17.11) 14.51 (11.68 , 16.36) 0.635 9.26% 
22:6 32.41 (26.18 , 40.04) 45.95 (31.07 , 53.83) <0.0001 41.77%↑ 33.14 (26.34 , 38.45) 36.44 (27.95 , 43.13) 0.396 9.95% 
24:0 54.07 (39.69 , 68.46) 60.31 (42.45 , 70.63) 0.131 11.54% 51.79 (39.53 , 68.81) 57.62 (44.67 , 81.08) 0.017 11.25% 
24:1 73.62 (55.84 , 97.07) 83.52 (64.43 , 105.04) 0.045 13.45% 74.31 (56.42 , 97.66) 85.41 (63.81 , 111.83) 0.011 14.94% 




Table 3: Different PL classes distribution in erythrocyte membranes pre and post supplementation with (n-3 LCPUFA and placebo) in UHR of 
developing psychosis groups.  
Phospholipid 
Classes 
n-3 LCPUFA group (n=114) Placebo group  (n=111) 
 Median (IQR)    
 Pre 
supplementation 







Median (IQR)    
 Pre 
supplementation 







PC 8.33 ( 6.47 , 9.46) 6.93 (6.18 , 8.20) 0.259 16.8% 8.06 (6.48 , 9.22) 7.59 (6.75 , 8.89) 0.499 5.8% 
PE 3.74 (3.39 , 4.22) 3.79 (3.27 , 4.14) 0.302 1.3% 3.49 (3.16 , 4.15)  4.11 (3.34 , 4.68) 0.001 17.8% 
PS 1.87 (1.57 , 2.05) 1.83 (1.62 , 2.02) 0.824 2.1% 1.81 (1.53 , 2.02)  1.96 (1.68 , 2.14)  0.099 8.3% 
SM 5.74 (4.84 , 7.44) 6.31 (5.19 , 7.25) 0.228 9.9% 5.66 (4.88 , 7.29) 6.96 (5.62 , 8.22)  <0.0001 22.9%↑ 




Table 4: Erythrocyte PL species of UHR of developing psychosis groups (n-3 LCPUFA and placebo). 
Phospholipids 
n-3 LCPUFA group (n=114) Placebo group  (n=111) 
Median (IQR)    
 Pre 
supplementation 







Median (IQR)    
 Pre 
supplementation 







PC 16:0_16:0 0.42 (0.35 , 0.55) 0.38 (0.34 , 0.47) 0.153 9.5% 0.41 (0.36 , 0.52) 0.42 (0.35 , 0.51) 0.964 2.4% 
PC 16:0_16:1 0.07 (0.05 , 0.10) 0.06 (0.04 , 0.09) 0.047 14.3% 0.07 (0.04 , 0.09) 0.07 (0.05 , 0.09) 0.534 ↔ 
PC 16:0_17:0 0.05 (0.03 , 0.06) 0.05 (0.03 , 0.06) 0.943 ↔ 0.04 (0.02 , 0.06) 0.05 (0.03 , 0.06) 0.006 25.0% 
PC 16:0_18:0 0.08 ( 0.06 , 0.11) 0.07 (0.06 , 0.10) 0.200 12.5% 0.08 (0.06 , 0.11) 0.08 (0.06 , 0.10) 0.995 ↔ 
PC 16:0_18:1 1.96 (1.64 , 2.29) 1.71 (1.45 , 2.05) <0.0001 12.8%↓ 1.93 (1.67 , 2.18) 1.90 (1.61 , 2.20) 0.911 1.6% 
PC 16:0_18:2 2.11 (1.70 , 2.63) 1.82 (1.52 , 2.22) <0.0001 13.7%↓ 2.21 (1.67 , 2.67) 1.95 (1.71 , 2.42) 0.548 11.8% 
PC 16:0_20:3 0.21 (0.14 , 0.26) 0.12 (0.09 , 0.16) <0.0001 42.9%↓ 0.19 (0.14 , 0.27) 0.15 (0.12 , 0.23) 0.021 21.0% 
PC 16:0_20:4 0.53 (0.41 , 0.69) 0.41 (0.31 , 0.53) <0.0001 22.6%↓ 0.56 (0.42 , 0.69) 0.48 (0.36 , 0.63) 0.003 14.3% 
PC 16:0_20:5 0.04 (0.03 , 0.07) 0.06 (0.04 , 0.10) <0.0001 50.0%↑ 0.05 (0.03 , 0.07) 0.04 (0.03 , 0.06) 0.139 20.0% 
PC 16:0_22:6 0.17 (0.12 , 0.19) 0.19 (0.13 , 0.25) <0.0001 11.8%↑ 0.17 (0.12 , 0.22) 0.15 (0.11 , 0.20) 0.101 11.8% 
PC 17:0_18:1 0.08 (0.07 , 0.09) 0.07 (0.06 , 0.08) 0.002 12.5% 0.07 (0.06 , 0.09) 0.08 (0.07 , 0.09) 0.081 14.3% 
PC 17:0_18:2 0.09 (0.07 , 0.11) 0.07 (0.06 , 0.09) <0.0001 22.2%↓ 0.09 (0.07 , 0.12) 0.08 (0.07 , 0.10) 0.962 11.1% 
PC 18:0_18:0 0.02 (0.01 , 0.03) 0.02 (0.01 , 0.03) 0.473 ↔ 0.02 (0.01 , 0.03) 0.02 (0.01 , 0.04) 0.616 ↔ 
PC 18:0_18:1 0.41 (0.33 , 0.48) 0.36 (0.29 , 0.44) 0.002 12.2% 0.40 (0.34 , 0.48) 0.39 (0.33 , 0.48) 0.873 2.5% 
PC 18:0_18:2 0.74 (0.60 , 0.88) 0.59 (0.47 , 0.75) <0.0001 20.3%↓ 0.70 (0.57 , 0.85) 0.65 (0.54 , 0.82) 0.432 7.1% 
PC 18:0_20:4 0.27 (0.21 , 0.34) 0.19 (0.15 , 0.24) <0.0001 29.6%↓ 0.27 (0.21 , 0.32) 0.25 (0.18 , 0.29) 0.003 7.4% 
PC 18:0_22:6 0.05 (0.03 , 0.07) 0.07 (0.04 , 0.09) <0.0001 40.0%↑ 0.05 (0.03 , 0.07) 0.04 (0.03 , 0.07) 0.161 20.0% 
PC 18:1_18:1 0.21 (0.16 , 0.29) 0.20 (0.14 , 0.26) 0.379 4.8% 0.22 (0.15 , 0.29) 0.23 (0.17 , 0.27) 0.542 4.5% 
PC 18:1_18:2 0.25 (0.20 , 0.33) 0.23 (0.18 , 0.32) 0.695 8% 0.25 (0.18 , 0.33) 0.25 (0.19 , 0.34) 0.179 ↔ 






Table 4: (continued) 
Phospholipids 
n-3 LCPUFA group (n=114) Placebo group  (n=111) 
Median (IQR)    
 Pre 
supplementation 







Median (IQR)    
 Pre 
supplementation 







  PE 16:0_18:1 0.84 (0.76 , 0.95) 0.85 ( 0.76 , 0.91) 0.243 1.2% 0.82 (0.74 , 0.93) 0.89 (0.80 , 0.95) 0.120 8.5% 
PE 16:0_18:2 0.33 (0.28 , 0.39) 0.30 (0.24 , 0.34) <0.0001 9.1%↓ 0.29 (0.26 , 0.35) 0.34 (0.28 , 0.39) 0.210 17.2% 
PE 16:0_20:3 0.07 (0.04 , 0.11) 0.05 (0.04 , 0.09) <0.0001 28.6%↓ 0.06 (0.04 , 0.12) 0.06 (0.04 , 0.10) 0.862 ↔ 
PE 16:0_20:4 0.48 (0.43 , 0.55) 0.43 (0.37 , 0.47) <0.0001 10.4%↓ 0.48 (0.41 , 0.55) 0.51 (0.38 , 0.57) 0.743 6.3% 
PE 16:0_20:5 0.04 (0.03 , 0.04) 0.06 (0.04 , 0.10) <0.0001 50.0%↑ 0.03 (0.02 , 0.04) 0.04 (0.03 , 0.07) 0.652 33.3% 
PE 16:0_22:4 0.12 (0.05 , 0.16) 0.08 (0.03 , 0.12) <0.0001 33.3%↓ 0.09 (0.04 , 0.15) 0.10 (0.03 , 0.14) 0.713 11.1% 
PE 16:0_22:5 0.08 (0.05 , 0.12) 0.09 (0.06 , 0.14) <0.0001 12.5%↑ 0.07 (0.04 , 0.10) 0.08 (0.05 , 0.12) 0.021 14.3% 
PE 16:0_22:6 0.19 (0.16 , 0.25) 0.26 (0.18 , 0.35) <0.0001 36.8%↑ 0.19 (0.14 , 0.24) 0.25 (0.16 , 0.37) 0.010 31.7% 
PE 17:0_20:4 0.08 (0.06 , 0.09) 0.06 (0.04 , 0.08) <0.0001 25.0%↓ 0.07 (0.06 , 0.09) 0.08 (0.06 , 0.09) 0.296 14.3% 
PE 17:0_20:5 0.09 (0.08 , 0.10) 0.08 (0.06 , 0.14) 0.915 11.1% 0.08 (0.07 , 0.11) 0.09 (0.08 , 0.14) 0.195 12.5% 
PE 17:0_22:5 0.04 (0.03 , 0.05) 0.04 ( 0.03 , 0.05) 0.055 ↔ 0.03 (0.03 , 0.05) 0.04 (0.03 , 0.06) 0.199 33.3% 
PE 18:0_18:0 0.02 (0.01 , 0.02) 0.02 (0.01 , 0.05) 0.758 ↔ 0.01 (0.01 , 0.02) 0.01 (0.01 ,0.03) 0.920 ↔ 
PE 18:0_18:1 0.19 (0.17 , 0.22) 0.20 (0.17 , 0.22) 0.738 5.3% 0.19 (0.16 , 0.21) 0.22 (0.18 , 0.24) 0.007 15.8% 
PE 18:0_18:2 0.17 (0.14 , 0.19) 0.14 (0.12 , 0.17) 0.005 17.6% 0.15 (0.12 , 0.17) 0.17 (0.13 , 0.18) 0.054 13.3% 
PE 18:0_20:4 0.27 (0.11 , 0.35) 0.25 (0.12 , 0.30) <0.0001 7.4%↓ 0.19 (0.11 , 0.33) 0.27 (0.12 , 0.36) 0.074 42.1% 
PE 18:0_22:6 0.06 (0.05 , 0.08) 0.08 (0.06 , 0.09) <0.0001 33.3%↑ 0.06 (0.04 , 0.08) 0.07 (0.05 , 0.09) 0.245 16.7% 
PE 18:1_18:1 0.17 (0.13 , 0.20) 0.16 (0.13 , 0.19) 0.224 5.90%  0.16 (0.13 , 0.21) 0.17 (0.13 , 0.21) 0.816 6.3% 
PE 18:1_18:2 0.25 (0.17 , 0.30) 0.19 (0.13 , 0.26) <0.0001 24.0%↓ 0.22 (0.16 , 0.28) 0.24 (0.16 , 0.29) 0.168 9.1% 
PE 18:1_20:4 0.28 (0.23 , 0.33) 0.25 (0.16 , 0.29) <0.0001 10.7%↓ 0.27 (0.18 , 0.33) 0.29 (0.17 , 0.35) 0.739 7.4% 





Table 4: (continued) 
Phospholipids 
n-3 LCPUFA group (n=114) Placebo group  (n=111) 
Median (IQR)    
 Pre 
supplementation 







Median (IQR)    
 Pre 
supplementation 







PS 18:0_18:1 0.20 (0.16 , 0.24) 0.22 (0.19 , 0.27) 0.001 10.0% 0.20 (0.16 , 0.24) 0.23 (0.19 , 0.28) 0.010 15.0% 
PS 18:0_20:4 1.04 (0.69 , 1.19) 0.89 (0.75 , 1.02) <0.0001 14.4%↓ 0.97 (0.57 , 1.21) 1.08 (0.87 , 1.25) 0.100 11.3% 
PS 18:0_22:5 0.24 (0.19 , 0.27) 0.24 (0.20 , 0.28) 0.861 ↔ 0.23 (0.17 , 0.27) 0.23 (0.19 , 0.26) 0.519 ↔ 
PS 18:0_22:6 0.32 (0.23 , 0.40) 0.42 (0.28 , 0.50) <0.0001 31.3%↑ 0.33 (0.24 , 0.39) 0.32 (0.23 , 0.41) 0.446 3.0% 
SM 16:0 2.19 (1.85 , 2.75) 2.49 (2.11 , 2.82) 0.038 13.7% 2.08 (1.83 , 2.67 ) 2.62 (2.23 , 3.07) <0.0001 25.9%↑ 
SM 18:0 0.32 (0.26 , 0.44) 0.38 (0.29 , 0.44) 0.159 18.8% 0.32 (0.25 , 0.45 ) 0.42 (0.33 , 0.52) <0.0001 31.3%↑ 
SM 18:1 0.11 (0.09 , 0.16) 0.13 (0.09 , 0.15) 0.195 18.2% 0.11 (0.09 , 0.16) 0.14 (0.11 , 0.18) <0.0001 27.3%↑ 
SM 24:0 1.39 (1.06 , 1.73) 1.39 (1.02 , 1.65) 0.900 ↔ 1.31 (0.95 , 1.72) 1.48 (1.16 , 2.02) 0.015 12.9% 
SM 24:1 1.91 (1.49 , 2.36) 1.96 (1.55 , 2.39) 0.629 2.6% 1.89 (1.41 , 2.37) 2.20 (1.73 , 2.79) 0.018 16.4% 
















 Effect of n-3 LCPUFA supplementation  
 
After 6 months of supplementation, 20:5 (2.64 vs. 1.01, p<0.0001), 22:6 (13.72 vs. 1.74, 
p<0.0001) and the n-3 index (1.12 vs. 0.19, p<0.0001) were higher in the n-3 LCPUFA group 
compared to the placebo group (Table 5).      
 
There were no differences in phospholipid class totals between the two groups after the 6 
month of intervention period (Table 6), however there were concentration differences in 8 out 
of 49 molecular species (Table 7) PC 16:0_20:3 (-0.06 vs. -0.02, p<0.0001), PE 16:0_20:4 (-
0.07 vs. 0.02, p<0.0001) and PE 17:0_20:4 (-0.02 vs. 0.002, p<0.0001) were lower in n-3 
LCPUFA group and PC 16:0_20:5 (0.01 vs. -0.004, p<0.0001), PC 16:0_22:6 (0.01 vs. -
0.02, p<0.0001), PC 18:0_22:6 (0.01 vs. -0.004, p<0.0001), PE 16:0_20:5 (0.02 vs. 0.01, 
p<0.0001), PS 18:0_22:6(0.06 vs. -0.01, p<0.0001) were higher in n-3 LCPUFA group 



















Table 5: Comparison the effects of n-3 LCPUFA vs. placebo on fatty acids in UHR of 
developing psychosis groups. 
 Fatty acids n-3 LCPUFA group (n=114) Placebo group  (n=111) P value 
16:0 Change      15.18  (-10.57 , 33.61) Change    8.25   (-23.82 , 28.94) 0.122 
16:1 Change     -0.47    (-1.73 , 0.84) Change    0.06   (-0.96 , 1.33) 0.034 
17:0 Change     -0.56    (-2.94 , 2.46) Change    0.74   (-2.05 , 3.07) 0.050 
18:0 Change      4.06    (-11.26 , 22.26) Change    9.11   (-8.93 , 23.26) 0.469 
18:1 Change      5.02    (-13.44 , 25.13) Change    2.37   (-20.19 , 20.21) 0.332 
18:2 Change     -7.58    (-25.61 , 9.87) Change   -5.54   (-27.98 , 18.49) 0.590 
20:3 Change     -2.18    (-4.86 , 0.40) Change   -1.20   (-4.08 , 1.81) 0.151 
20:4 Change     -6.30    (-23.07 , 14.69) Change   -1.48   (-17.24 , 21.47) 0.151 
20:5 Change      2.64    (-0.05 , 6.98) Change   1.01    (-1.66 , 4.78) <0.0001 
22:4 Change     -1.05    (-2.99 , 1.09) Change   -0.44   (-2.06 , 2.35) 0.063 
22:5 Change      1.86    (-4.74 , 6.13) Change    0.74   (-4.41 , 4.30) 0.327 
22:6 Change      13.72  (-3.16 , 23.97) Change    1.74   (-8.63 , 13.09) <0.0001 
24:0 Change      3.68    (-14.02 , 23.48) Change    9.29   (-10.50 , 24.29) 0.465 
24:1 Change      6.69    (-18.04 , 33.04) Change    9.50   (-10.14 , 31.22) 0.642 
n-3 index Change      1.12    (-0.20 , 2.24) Change    0.19   (-0.55 , 1.27) <0.0001 




Table 6: Comparison the effect of n-3 LCPUFA vs. placebo supplementation on molecular 




n-3 LCPUFA group (n=114) Placebo group  (n=111) P value 
PC Change    -0.89 (-2.14 , 0.11) Change     0.29 (-1.52, 1.14) 0.001 
PE Change    -0.03 (-0.73, 0.51) Change     0.33 (-0.25 , 0.98) 0.002 
PS Change    -0.03 (-0.31 , 0.29) Change     0.12 (-0.32 , 0.49) 0.129 
SM Change     0.36 (-0.84 , 1.21) Change     0.87 (-0.07 , 2.43) 0.008 




Table 7: Comparison the effect of n-3 LCPUFA vs. placebo on molecular PL species in UHR 
of developing psychosis groups. 
Phospholipids n-3 LCPUFA group (n=114) Placebo group  (n=111) 
P  
value 
PC 16:0_16:0 Change      -0.01     (-0.09 , 0.08) Change          0.02     (-0.10 , 0.09) 0.341 
PC 16:0_16:1 Change      -0.01     (-0.04 , 0.02) Change          0.001   (-0.25 , 0.03) 0.063 
PC 16:0_17:0 Change       0.0002 (-0.02 , 0.01) Change          0.01     (-0.004 , 0.02) 0.031 
PC 16:0_18:0 Change      -0.01     (-0.3 , 0.01) Change         -0.0001 (-0.02 , 0.03) 0.362 
PC 16:0_18:1 Change      -0.22     (-0.48 , 0.15) Change          0.03     (-0.34 , 0.39) 0.011 
PC 16:0_18:2 Change      -0.16     (-0.71 , 0.10) Change         -0.07     (-0.47 , 0.26) 0.002 
PC 16:0_20:3 Change      -0.06     (-0.13 , -0.01) Change         -0.02     (-0.07 , 0.04) <0.0001 
PC 16:0_20:4 Change      -0.11     (-0.25 , -0.01) Change         -0.09     (-0.18 , 0.05) 0.120 
PC 16:0_20:5 Change       0.01     (-0.01 , 0.05) Change         -0.004   (-0.02 , 0.01) <0.0001 
PC 16:0_22:6 Change       0.01     (-0.04 , 0.09) Change         -0.02     (-0.06 , 0.02) <0.0001 
PC 17:0_18:1 Change      -0.01     (-0.02 , 0.01) Change          0.01     (-0.01 , 0.02) 0.001 
PC 17:0_18:2 Change      -0.01     (-0.04 , 0.01) Change         -0.001   (-0.02 , 0.02) 0.013 
PC 18:0_18:0 Change      0.001    (-0.01 , 0.01) Change          0.001   (-0.01 , 0.01) 0.389 
PC 18:0_18:1 Change      -0.04     (-0.14 , 0.03) Change          0.01     (-0.07 , 0.06) 0.026 
PC 18:0_18:2 Change       -0.11    (-0.33 , 0.03) Change         -0.03     (-0.16 , 0.11) 0.007 
PC 18:0_20:4 Change       -0.07    (-0.14 , -0.002) Change         -0.03     (-0.09 , 0.04) 0.012 
PC 18:0_22:6 Change        0.01    (-0.02 , 0.03) Change        -0.004    (-0.02 , 0.01) <0.0001 
PC 18:1_18:1 Change       -0.01    (-0.08 , 0.07) Change         0.01      (-0.07 , 0.09) 0.342 
PC 18:1_18:2 Change       -0.01    (-0.07 , 0.07) Change         0.01      (-0.05 , 0.09) 0.146 
PC 18:1_20:4 Change       -0.01    (-0.05 , 0.03) Change        -0.01      (-0.04 , 0.02) 0.232 
PE 16:0_18:1 Change       -0.02    (-0.08 , 0.05) Change         0.05      (-0.04 , 0.13) 0.049 
PE 16:0_18:2 Change       -0.03    (-0.09 , 0.003) Change         0.02      (-0.03 , 0.09) 0.001 
PE 16:0_20:3 Change       -0.02    (-0.05 , 0.02) Change        -0.001    (-0.38 , 0.04) 0.244 
PE 16:0_20:4 Change       -0.07    (-0.15 , -0.001) Change         0.02      (-0.07 , 0.09) <0.0001 
PE 16:0_20:5 Change        0.02    (-0.002 , 0.07) Change         0.01      (-0.01 , 0.03) <0.0001 
PE 16:0_22:4 Change       -0.03    (-0.10 , 0.01) Change        -0.01      (-0.08 , 0.05) 0.002 
PE 16:0_22:5 Change        0.01    (-0.04 , 0.07) Change         0.01      (-0.04 , 0.06) 0.542 
PE16:0_22:6 Change        0.05    (-0.02 , 0.18) Change         0.04      (-0.03 , 0.16) 0.747 
PE 17:0_20:4 Change       -0.02    (-0.03 , 0.002) Change         0.002    (-0.01 , 0.02) <0.0001 
PE 17:0_20:5 Change       -0.01    (-0.03 , 0.03) Change         0.01      (-0.02 , 0.07) 0.007 
PE 17:0_22:5 Change       -0.002  (-0.01 , 0.01) Change         0.002    (-0.01 , 0.02) 0.025 




Table 7: (continued) 
Phospholipids n-3 LCPUFA group (n=114) Placebo group  (n=111) 
P  
value 
PE 18:0_18:1 Change        -0.002    (-0.02 , 0.02) Change          0.01     (-0.01 , 0.05) 0.005 
PE 18:0_18:2 Change        -0.02      (-0.06 , 0.02) Change          0.004   (-0.03 , 0.05) 0.001 
PE 18:0_20:4 Change        -0.02      (-0.13 , 0.09) Change          0.05     (-0.07 , 0.15) 0.057 
PE 18:0_22:6 Change         0.01      (-0.01 , 0.04) Change          0.01     (-0.01 , 0.04) 0.743 
PE 18:1_18:1 Change        -0.01      (-0.05 , 0.02) Change          0.002   (-0.03 , 0.04) 0.317 
PE 18:1_18:2 Change        -0.04      (-0.11 , 0.04) Change          0.01     (-0.07 , 0.08) 0.001 
PE 18:1_20:4 Change        -0.04      (-0.12 , 0.02) Change          0.01     (-0.11 , 0.10) 0.008 
PS 18:0_18:0 Change        -0.001    (-0.01 , 0.01) Change          0.001   (-0.01 , 0.01) 0.895 
PS 18:0_18:1 Change         0.01      (-0.03 , 0.11) Change          0.03     (-0.02 , 0.09) 0.581 
PS 18:0_20:4 Change        -0.13      (-0.27 , 0.08) Change          0.03     (-0.16 , 0.29) 0.019 
PS 18:0_22:5 Change        -0.001    (-0.05 , 0.04) Change          0.001   (-0.06 , 0.05) 0.654 
PS 18:0_22:6 Change         0.06      (-0.04 , 0.18) Change         -0.01     (-0.09 , 0.07) <0.0001 
SM 16:0 Change         0.15      (-0.17 , 0.50) Change          0.41     (0.03 , 0.81) 0.004 
SM 18:0 Change         0.02      (-0.03 , 0.09) Change          0.07     (0.01 , 0.15) 0.009 
SM 18:1 Change         0.01      (-0.02 , 0.03) Change          0.02    (0.003 , 0.04) 0.087 
SM 24:0 Change        -0.03      (-0.35 , 0.32) Change          0.23    (-0.09 , 0.52) 0.011 
SM 24:1 Change        -0.42      (-0.41 , 0.57) Change          0.26    (-0.15 , 0.77) 0.044 
















Discussion     
It is known that phospholipids are the major component of the lipid bilayer of the cell 
membrane, molecular species composition affect cell membrane fluidity, function, and the 
activity of membrane bound proteins (Alberts et al., 2002). To the authors knowledge this is 
the first study on erythrocyte phospholipid molecular species and the effect of a 6-month 
intervention of n-3 LCPUFA supplementation compared to placebo supplementation in 
people at UHR of psychosis. 
Supplementation with n-3 LCPUFA resulted in an increase in n-3 index, all n-3 LCPUFA and 
in all phospholipid molecular species containing n-3 LCPUFA in people at UHR of psychosis, 
and this is largely replacing n-6 LCPUFA. This is in line with previous observations with 
using cod liver oil containing 3000 mg of n-3 fatty acids and daily supplement of fatty fish 
containing 3000 mg of n-3 fatty acids in healthy subjects (Popp-snijders et al., 1984; 1986). 
The increases in the n-3 LCPUFA (EPA and DHA) with corresponding decreases in n-6 
LCPUFA vary depending on the dose and period of supplementation (Blonk et al., 1990; 
Katan et al., 1997; Sanders & Roshanai, 1983). The changes in the incorporation observed 
in PC, PE and PS n-3 LCPUFA are probably due to the different pathways of renewal of 
erythrocyte phospholipids (Popp-snijders et al., 1984), phospholipids on the inside of the 
erythrocyte membrane are renewed via acylation of lysophospholipids (Renooij et al., 1974, 
1976), whereas phospholipids on the outside are renewed by exchange of phospholipids 
between red cell membrane and plasma lipoproteins (Reed, 1968).  
Despite the changes observed in individual phospholipid molecular species, there were no 
effects of n-3 LCPUFA supplementation on erythrocyte phospholipid PC, PE, PS and SM 
totals seen in this study. Similar observation have been reported in healthy populations 
(Popp-snijders et al., 1984; 1986). In contrast SM levels increased during the 6 months 
supplementation with placebo capsules. We previously observed an increased in erythrocyte 
SM concentration in subjects at UHR of psychosis compared to controls (chapter 3). The 
data here may indicate that n-3 LCPUFA supplementation helps to maintain and limit the 




The fish oil supplements in the current study contained 840 mg + 560 mg of EPA and DHA. 
EPA increased by as much as 29.0% and DHA increased by 39.2% following fish oil 
supplementation. A recent study on a UHR population found that EPA increased by 200% 
while DHA only increased by 43.1% following 12 weeks of daily supplementation with 700 
mg EPA and 480 mg DHA (Smesny et al., 2014) (Figure 1). This controversial result could 
be due to the participants’ lack of compliance. Previous studies have also shown that the 
uptake of DHA into erythrocyte membranes is more variable than that of EPA (Katan et al., 
1997; Cao et al., 2006; Pipingas et al., 2014).  
 
Figure 1: Comparison of % of changes of EPA and DHA between two studies on n-3 
LCPUFA supplementation in people at UHR of developing psychosis. (a) Current study n-3 
LCPUFA supplementation containing 840 mg of EPA and 560 mg of DHA for 6 months 
period. (b) Previous study (Smesny et al., 2014) n-3 LCPUFA supplementation contain 700 
mg of EPA and 480 mg of DHA for 3 months period.  
  
The increase in n-3 index after 6 months of n-3 LCPUFA supplementation from 3.0% to 
4.10% was much lower than that observed in previous studies that administered EPA+DHA 
for up to 12 months (Katan et al., 1997; Cao et al., 2006; Browning et al., 2012; Flock et al., 
2013) (Figure 2). An n-3 index increase from 4.3% to 9.5% with 1800 mg/day of (EPA 60% 
+DHA 40%) over a period of 5 months (Flock et al., 2013), and a similar n-3 index increase 
of 5.9% to 11.4% was observed in older healthy adults supplemented with 1900 mg/day of 












(a) Current study (840 mg of EPA) (560 mg of DHA)














supplemented with approximately 2000 mg/day of (EPA 85% +DHA 15%) for a year saw 
increase in the n-3 index by from 5.5% to 9.5% (Katan et al., 1997); furthermore, an n-3 
index increase from 4.3% to 7.8% with 2200 mg/day of (EPA 60% +DHA 40%) over a period 
of 2 months was also observed (Cao et al., 2006) (Figure 2). These studies suggest that, in 
addition to duration of intake and dose, the relative proportions of EPA and DHA may affect 




Figure 2:  Comparison of the n-3 index measured in different studies with different doses (a) 
1400 mg/day of n-3 LCPUFA for 6 months period. (b) 1200 mg/day of n-3 LCPUFA for 3 
months period. (c) 1800 mg/day of n-3 LCPUFA for 5 months period. (d) 1900 mg/day of n-3 
LCPUFA for 12 months period. (e) 2200 mg/day of n-3 LCPUFA for 2 months period. (f) 
2000 mg/day of n-3 LCPUFA for 12 months period.  
 
There is one study that investigated 1200 mg/day of (EPA 59.3% +DHA 40.7%) in people 
with UHR of developing psychosis and this resulted in n-3 index increase of 3.2% to 5.4% 
over a period of 3 months (Smesny et al., 2014). The current study used a similar dose but 
double the duration and resulted in a much lower increase in n-3 index. In the current study 
the commitment to intake capsules every day only 43.1% in the n-3 LCPUFA group and 
41.1% in the placebo (McGorry et al., 2017) compared to 81.4% adherence to daily intake in 
the n-3 group and 75.4% in the placebo group in a previous study (Amminger et al., 2010). 
































(e) Cao et al.,
2006
(f) Katan et al.,
1997




increase in the n-3 index. In this study, a similar number of participants at UHR of developing 
psychosis transitioned to psychosis from both the n-3 treated (17 out of 153) and placebo 
groups (15 out of 151) (McGorry et al., 2017). The possible reasons for this lower transition 
rate 11.5% from the n-3 and 11.2% from placebo groups could be due to the high level of 
antidepressant treatment received by both groups and the sample may have been 
insufficiently enriched for risk of transition (McGorry et al., 2017).   
Whilst dietary intake of n-3 LCPUFA is associated with erythrocyte levels of n-3 LCPUFA, 
dietary intake was not measured in this study for the following reasons. Firstly dietary intake 
methodology is not as robust as measuring the levels of n-3LCPUFA in erythrocyte 
membranes (Meyer et al., 2013). Secondly, dietary intake of n-3 LCPUFA is reported to be 
low (Meyer, 2016) and the intake levels are approximately 4 fold lower than the 
supplemental levels of 1.4g per day. Therefore measuring levels of n-3 LCPUFA in 
erythrocyte membranes is superior to measuring dietary intake on n-3 LCPUFA. 
There is emerging evidence that suggests there is a relationship between an n-3 index of 
less than 4% and risk for major depressive disorder (MDD) in adults (Baghai et al., 2011) 
and possibly healthy adolescents (Grant et al., 2013), and also in adolescents at ultra-high 
risk for bipolar disorder (Mcnamara et al., 2016). However, it should be noted that the 
research available in these areas is limited as this is only the second study investigating n-3 
index in people at UHR of psychosis (Smesny et al., 2014). 
In conclusion, daily supplementation for 6 months with 1400 mg/day of n-3 LCPUFA led to 
higher n-3 incorporation into erythrocytes. The increase was lower than previously reported 
likely due to low commitment to intake of daily capsules by both groups.  In spite of this, we 
found that n-3 LCPUFA is incorporated into phospholipid molecular species of all classes at 
the expense of n-6 LCPUFA. As a result the total concentrations of these phospholipid 
classes were not altered. 
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People at ultra-high risk (UHR) of developing psychosis have approximately 30% chance of 
developing the illness within three years. The aim of this study was to identify potential 
biomarkers such as n-3 index, fatty acids and/or molecular phospholipid species that may be 
a predictor of psychosis for people at UHR of developing psychosis. 304 people with UHR of 
developing psychosis were enrolled for the NEURAPRO-E study and 285 people completed 
this study. From 285 people 29 people developed psychoses (UHR-T, Transition) and 256 
did not developed psychosis (UHR-NT, non-transition) in 12 months. There were no 
differences in the n-3 index, fatty acids or molecular phospholipid species observed between 
those that did and did not transition to psychosis. In conclusion, none of the assessed n-3 
index, fatty acids and molecular phospholipid species predict transition to psychosis in those 
at UHR of developing psychosis. 
 



















Ultra-High Risk (UHR) is a term used to identify individuals considered to be at ‘ultra high 
risk of developing psychosis’ (Yung et al., 1996). The concept of clinical UHR of developing 
psychosis has been developed to facilitate early detection and intervention and is defined by 
a cluster of subthreshold psychotic symptoms affecting perception e.g., hallucinations and 
thinking e.g., magical thinking or odd beliefs; or trait risk factors, such as a family history of 
psychosis, accompanied by impairment in day-to-day function (Yung et al., 2005). Recent 
meta-analysis shows that less than 30% of people at UHR of developing psychosis will have 
transitioned to psychosis 3 years after identification (Fusar-Poli et al., 2012A).  
 
Previous work has identified biological and clinical predictors for transition from UHR to 
psychosis. Clinical features such as impaired premorbid psychosocial functioning, a history 
of substance use, traumatic experiences, duration of symptoms, gender and age are all 
associated with an increased transition risk (Nelson et al., 2013; Yung et al., 2004; Strobl et 
al., 2012; Dragt et al., 2011). Dynamic clinical factors include psychotic symptoms and the 
extent of baseline mood (Yung et al., 2005; Thompson et al., 2013). Additionally, specific 
patterns of cognitive function, in particular deficits in emotional processing, memory and 
verbal fluency (Fusar-Poli et al., 2012B; Allott et al., 2014) as well as impaired general 
function are associated with a higher transition risk to psychosis (Strobl et al., 2012; 
Velthorst et al., 2013). Biological predictors include abnormalities of functional and structural 
electrophysiology, e.g. significant smaller duration mismatch negativity amplitudes (dMMN) 
in people at risk of mental state than healthy controls and frontal delta activity was correlated 
with negative symptoms in UHR patients who later transitioned to psychosis (Sumiyoshi et 
al., 2013; Lavoie et al., 2012), pituitary gland enlargement (Garner et al., 2005) and genetic 
markers such as neuregulin 1 (NRG1) (Bousman et al., 2013). 
 
Low erythrocyte levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are 




is defined as the sum of EPA and DHA levels in erythrocytes membranes expressed as 
percent of total fatty acids (Harris & Von Schacky, 2004; Harris, 2008). Recently, several 
studies have also found low n-3 index (≤4%) in individuals at UHR of developing psychosis 
(Rice et al., 2015) and patients diagnosed with different psychotic disorders such as major 
depressive disorder (MDD) (Baghai et al., 2011), bipolar disorder (McNamara et al., 2016), 
schizophrenia and depression (Parletta et al., 2016). 
In order to ameliorate, prevent or delay the onset of a psychotic disorder, efforts have been 
made to identify people at high clinical risk of developing a psychotic disorder. We previously 
observed marked differences in erythrocyte n-3 index, fatty acids and molecular 
phospholipids species in people with UHR of developing psychosis compared to age 
matched healthy controls (chapter 3). Specifically, in people with UHR of developing 
psychosis; i) the n-3 index was 26.9% lower, ii) Phosphatidylethanolamine (PE) was reduced 
by 46%, sphingomyelin (SM) was increased by 16%, and iii) various molecular phospholipids 
species were either primarily lower or higher. The aim of this study was to identify a potential 
biomarker (n-3 index, any fatty acids and/or any molecular phospholipid species) to predict 
transition to psychosis for people at UHR of developing psychosis. 
 
Material & methods 
Ethics and Subjects recruitment  
The NEURAPRO-E study is a double-blind, placebo-controlled, randomized clinical trial of n-
3 fatty acids therapy for participants at UHR developing psychosis (McGorry et al., 2017). 
The subjects diagnosed with UHR of developing psychosis were recruited between March 
2010 and September 2014 (Markulev et al, 2015; McGorry et al., 2017). Inclusion and 
exclusion criteria for these participants has been reported previously (Markulev et al, 2015; 
McGorry et al., 2017) and are shown in appendix (B). This study was approved by the 







High performance liquid chromatography (HPLC) grade or higher of methanol, methyl tert-
butyl ether (MTBE) and chloroform were purchased from VWR International (QLD, 
Australia). Analytical grade ammonium acetate was obtained from Crown Scientific (New 
South Wales, Australia). Ethylenediaminetetraacetic acid (EDTA), butylated hydroxytoluene 
(BHT) were all purchased from Sigma Aldrich (NSW, Australia). Phospholipid internal 
standards were purchased from Avanti Polar Lipids through Auspep (Victoria, Australia) and 
consisted of [dinonadecanoyl phosphatidylcholine (PC 19:0/19:0); diheptadecanoyl 
phosphatidylethanolamine (PE17:0/17:0); diheptadecanoyl phosphatidylserine (PS 
17:0/17:0); N-lauroyl-D-erythro-sphinganylphosphorylcholine (SM d18:0/12:0)]. Two types of 
disposable conductive CO-RE tips (without filter) in 50 uL and 300 uL sizes were used and 
purchased from Hamilton Robotics (Reno NV, USA). 96-well plates and Twin-tec PCR plates 
were purchased from Eppendorf (POCD scientific, Australia).   
   
Lipid extraction  
Erythrocyte samples were extracted using the automated extraction method described 
previously (Alqarni et al., 2018), 290 uL of an aqueous mixture containing 2 mM EDTA and 
150 mM ammonium acetate was added to the wells of a 2.0 mL 96-well plate on ice. 10 μL 
of packed erythrocyte samples was added to the wells, the plate were mixed using a vortex 
at 800 rpm for 10 minutes. Robotic procedures were then started with all reagents, solvents 
and plates loaded onto the automated liquid handling station (Hamilton, Nevada, USA). A 
300 μL aliquot of an internal standard mixture in methanol [500 uM (PC 19:0/19:0); 166.7 uM 
(PE 17:0/17:0); 100 uM (PS 17:0/17:0); 500 uM (SM 18:0/12:0)] was added to the wells prior 
to mixing and standing for 10 minutes. 1 mL of MTBE was added to the wells and mixed for 
30 minutes before the mixture was allowed to stand for 15 minutes to allow phase 
separation. Following this, 500 μL of the MTBE top phase was removed to the extraction 
plate (containing the extracted phospholipids) and 40 μL of extract was transferred to 




containing 5 mM ammonium acetate mixture. A 40 μL aliquot of the diluted extract was 
transferred to another 96-well plate which was sealed with aluminium foil prior to analysis by 
mass spectrometry. 
 
Electrospray ionization mass spectrometry ESI-MS 
Nanoelectrospray ionization mass spectrometry was performed using a hybrid triple 
quadrupole linear ion trap mass spectrometer (QTRAP 5500 AB Sciex, MA, USA) with an 
automated chip-based nanoelectrospray source (Triversa NanoMate, Advion Biosciences, 
New York, USA) as previously described (Brown et al., 2013; Norris et al., 2015). A 10 uL 
aliquot of lipid extract diluted in methanol: chloroform (2:1 v/v) containing 5 mM ammonium 
acetate (approximately 10 uM) was infused into the nano-electrospray ion source. Spray 
parameters were a voltage of 1.2 kV for positive ion acquisition and 1.1 kV for negative ion 
acquisition and a nitrogen gas pressure of 0.40 psi (Brown et al., 2013; Norris et al., 2015). 
Lipids were identified using precursor ion and neutral loss scans as previously described 
(Brown et al., 2013; Norris et al., 2015).  
Ionized lipids identified with a minimum signal-to-noise ratio of 10 were included in the 
analysis. Identification and quantification was accomplished using lipidview software (version 
1.2, Sciex, MA, USA) this included smoothing, identification, removal of isotope contribution 
from lower mass species, and correction for isotope distribution, as described (Brown et al., 
2013; Norris et al., 2015). Quantification was performed using LipidView software (AB 
SCIEX) by comparing the spectral peak area of individual lipids to their class specific internal 










Statistical analysis  
 
Simple logistic regression was used to evaluate the association between erythrocyte n-3 
index, fatty acids and molecular phospholipids species between Transition (UHR-T) and 
non-transition (UHR-NT). Given that there were no differences between confounder factors 
age, sex, BMI and smoking this was performed as unadjusted model. Categorical data were 
analyzed using chi-square and Mann-Whitney U test was used to calculate the significance 
of continuous variables. P-values were corrected for multiple comparisons using the 
Bonferroni method with P < 0.0008 considered statistically significant. The statistical 
























Participants Characteristics  
304 people at UHR of developing psychosis were recruited for NEURAPRO-E study 
(McGorry et al., 2017) and 285 people completed this study. From 285 people 29 people 
developed psychoses (UHR-T, Transition) and 256 did not developed psychosis (UHR-NT, 
non-transition) in 12 months. The participants baseline characteristics of each group are 
presented in table 1 and there were no significant differences between (UHR-T, Transition) 
and (UHR-NT, non-transition) groups.  










Age median (IQR-1, IQR-3) 18 (16,21) 17 (16,20) 0.803 
Sex male n (%) 118 (46.1%) 11 (37.9%) 0.403 
 
Body mass index Kg/m2 (IQR-1, IQR-3) 23 (20.2 , 26.8)* 22 (19.7 , 26.5)* 0.539 
Smoking n (%) 99 (38.7%) 11 (37.9%) 0.938 
 
* 31 participants BMI information missed (29 from UHR-NT group and 2 from UHR-T group). 
 
Identification of n-3 index and fatty acids associated with ultra-high-risk of developing 
psychosis   
 
Logistic regressions were performed for n3 index and all fatty acids. The n-3 index did not 
shown any association with transition to psychosis. Similarly From 14 fatty acids none were 







Figure 1: A logistic regression was performed to identify fatty acids and the n-3 index 
associated with UHR-T (n=29) vs. UHR-NT cases (n=256). Circle show odds ratio, lines are 
95% confidence intervals. Fatty acids with odds ratio > 1.0 has increased likelihood of 
transition to psychosis. Fatty acids with odds ratio < 1.0 has reduced likelihood of transition 






















Identification of molecular phospholipid species associated with ultra-high-risk of 
developing psychosis 
 
None of the 4 major phospholipid classes phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS) and sphingomyelin (SM) were 
associated with transition to psychosis (Figure 2 and Supplementary table S2). Also, none of 
the 49 phospholipid species showed any association with transition to psychosis in those at 
ultra-high risk (Figures 3, 4, 5, 6 and Supplementary table S3). 
 
 
Figure 2: A logistic regression was performed to identify phospholipid classes (PC, PE, PS, 
SM) associated with UHR-T (n=29) vs. UHR-NT cases (n=256). Circle show odds ratio, lines 
are 95% confidence intervals. Species with odds ratio > 1.0 has increased likelihood of 
transition to psychosis. Species with odds ratio < 1.0 has reduced likelihood of transition to 











Figure 3: A logistic regression was performed to identify molecular phospholipid species 
(PC) associated with UHR-T (n=29) vs. UHR-NT cases (n=256). Circle show odds ratio, 
lines are 95% confidence intervals. Species with odds ratio > 1.0 has increased likelihood of 
transition to psychosis. Species with odds ratio < 1.0 has reduced likelihood of transition to 




















Figure 4: A logistic regression was performed to identify molecular phospholipid species 
(PE) associated with UHR-T (n=29) vs. UHR-NT cases (n=256). Circle show odds ratio, lines 
are 95% confidence intervals. Species with odds ratio > 1.0 has increased likelihood of 
transition to psychosis. Species with odds ratio < 1.0 has reduced likelihood of transition to 



















Figure 5: A logistic regression was performed to identify molecular phospholipid species 
(PS) associated with UHR-T (n=29) vs. UHR-NT cases (n=256). Circle show odds ratio, lines 
are 95% confidence intervals. Species with odds ratio > 1.0 has increased likelihood of 
transition to psychosis. Species with odds ratio < 1.0 has reduced likelihood of transition to 

























Figure 6: A logistic regression was performed to identify molecular phospholipid species 
(SM) associated with UHR-T (n=29) vs. UHR-NT cases (n=256). Circle show odds ratio, 
lines are 95% confidence intervals. Species with odds ratio > 1.0 has increased likelihood of 
transition to psychosis. Species with odds ratio < 1.0 has reduced likelihood of transition to 



















Discussion    
In this large study of people at UHR of developing psychosis, no measures of 
erythrocyte lipids were associated with the transition to psychosis. Noteworthy is the 
fact that, the power of study was reduced because of low number of UHR transitioned 
into psychosis (UHR-T, Transition (n=29)).   
While we were not able to find any association between n-3 index, fatty acids or 
molecular phospholipid species and transition to psychosis previous studies have 
identified clinical features, such as poor life functioning, subthreshold positive 
symptoms (Yung et al., 2003; Cannon et al., 2008; Ruhrmann et al., 2010) and severity 
of negative symptoms (Yung et al., 2003; Piskulic et al., 2012; Velthorst et al., 2009) as 
well as neuroimaging markers such as pituitary volumes and insula (Garner et al., 
2005; Takahashi et al., 2009) whole-brain neuroanatomical abnormalities (Koutsouleris 
et al., 2009) and thickness of anterior cingulate cortex and corpus callosum (Fornito et 
al., 2008; Walterfang et al., 2008) as predictive markers of transition to psychosis in 
those at ultra-high risk. Additionally, genetic variation in two neuregulin 1 (NRG1) 
haplotype-tagging single nucleotide polymorphisms (htSNPs) (rs12155594 and 
rs4281084)  provides a promising factor for differentiating between (UHR-NT) and 
(UHR-T) individuals, the risk of transitioning to psychosis increased by 1.5 fold in 
people who carried rs12155594 and/or rs4281084 allele (Bousman et al., 2013). 
 
Previously, we have observed differences in erythrocyte n-3 index, fatty acids and 
molecular phospholipid species between individuals at UHR of developing psychosis 
and healthy subjects (Chapter 3). Specifically, total PE was reduced by 46% as was a 
16% increase in the concentration of SM (Chapter 3). Furthermore, the n-3 index was 
low in people with UHR of developing psychosis compared to healthy (McNamara, 
2011; Rice et al., 2015). This suggests that the n-3 index, fatty acids and molecular 
phospholipids deficiencies may be present prior to illness onset and may be useful as a 




Interestingly, three SM species (SM 16:0, SM 24:0 and SM 24:1) shows close to 
significant and these species with odds ratio has high likelihood of transition to 
psychosis, this suggest that SM may be an important biomarker to investigate and this 
cohort worth following up and investigate with more (UHR-T, Transition), whether SM is 
a predictor.   
 
 
         Healthy vs. UHR of psychosis                           UHR-NT vs. UHR-T 
 















Figure 7: Timeline for the findings between healthy vs. UHR of psychosis and between 
UHR-NT (non-transition) vs. UHR-T, (Transition). 
 
 
In conclusion, the data from this study suggest that neither the n-3 index, fatty acids or 
molecular phospholipid species predict transition to psychosis in people at ultra-high 
risk. 
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 Low n-3 index in UHR of 
psychosis. 
 Low fatty acids in UHR of 
psychosis 
 Various molecular 
phospholipids species were 
either primarily lower or 
higher in UHR of psychosis. 
 High SM and low PE in UHR 
of psychosis.  
 
 
 No differences were found 
between (UHR-NT) and 
(UHR-T) across the n-3 
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Table S1: Erythrocytes fatty acids and n-3 index associated with ultra high risk of developing psychosis UHR-NT (256) UHR-T (29) (results are 
express as % of total fatty acids). 
 Median (IQR) UHR-NT Median (IQR) UHR-T OR (95% CI) 
UHR-NT, non-transition cases (n=256) 
vs. 
UHR-T, Transition (n=29) 
P value 
16:0 32.38 (30.64 , 34.24) 31.81 (31.04 , 34.92) 1.02 (0.86 , 1.19) 0.849 
16:1 0.21 (0.14 , 0.29) 0.22 ( 0.15 , 0.29) 0.31 (0.01 , 8.58) 0.489 
17:0 1.27 (1.17 , 1.39) 1.33 (1.21 , 1.41) 1.81 (0.33 , 9.89) 0.491 
18:0 13.07 (11.99 , 13.99) 12.48 (11.82 , 13.59) 0.85(0.65 , 1.11) 0.239 
18:1 16.61 (15.62 , 17.67) 16.75 (15.28 , 17.93) 1.00 (0.84 , 1.20) 0.954 
18:2 12.30 (10.58 , 13.57) 11.06 (9.91 , 12.11) 0.83 (0.69 , 1.00) 0.059 
20:3 0.81 (0.66 , 0.98) 0.78 (0.58 , 0.92) 0.44 (0.10 , 1.92) 0.171 
20:4 9.22 (7.78 , 10.08) 8.84 (5.99 , 10.28) 0.91 (0.79 , 1.05) 0.234 
20:5 0.53 (0.45 , 0.63) 0.51 (0.44 , 0.63) 0.70 (0.08 , 5.82) 0.746 
22:4 0.30 (0.14 , 0.46) 0.31 (0.09 , 0.43) 0.30 (0.05 , 1.82) 0.192 
22:5 1.04 (0.83 , 1.31) 1.09 (0.72 , 1.21) 0.93 (0.57 , 1.52) 0.778 
22:6 2.44 (1.96 , 2.88) 2.32 (1.72 , 2.97) 0.98 (0.66 , 1.45) 0.940 
24:0 3.93 (2.95 , 5.01) 5.31 (3.31 , 6.04 ) 1.14 (0.97 , 1.35) 0.100 
24:1 5.49 (4.21 , 7.18) 7.00 (4.99 , 8.59) 1.11 (0.99 , 1.24) 0.065 
n-3 index 3.00 (2.47 , 3.52) 2.77 (2.24 , 3.65) 0.97 (0.69 , 1.38) 0.904 
A logistic regression was performed to identify fatty acids and n-3 index associated with UHR-T, Transition (n=29) vs. UHR-NT, non-transition cases (n=256). Odds 


















Table S2: Erythrocytes molecular phospholipids classes associated with ultra high risk of developing psychosis UHR-NT (256) UHR-T (29) 
(results are express as % of total phospholipids).  
 
 
Phospholipids Median (IQR) UHR-NT Median (IQR) UHR-T OR (95% CI) 
UHR-NT, non-transition cases (n=256) 
vs. 
UHR-T, Transition (n=29) 
P value 
PC    41.67 (33.50 , 47.63)    34.80   (30.59 , 42.06)  1.04 (0.99 , 1.08) 0.070 
PE   18.48 (16.48 , 20.83)    18.62   (14.32 , 21.37)  1.00 (0.92 , 1.10) 0.927 
PS           9.45   (7.96 , 10.28)           8.59     (6.67 , 9.92)  1.09 (0.94 , 1.27) 0.230 
SM   28.45 (24.55 , 35.79)     36.63   (25.59 , 42.23)                       1.03 (0.99 , 1.07) 0.045 
A logistic regression was performed to identify molecular phospholipids classes associated with UHR-T, Transition (n=29) vs. UHR-NT, non-transition cases (n=256). 

























Table S3: Erythrocytes molecular phospholipids species associated with ultra high risk of developing psychosis UHR-NT (256) UHR-T (29) 
(results are express as % of total phospholipids).  
Phospholipids Median (IQR) UHR-NT Median (IQR) UHR-T OR (95% CI) 
UHR-NT, non-transition cases (n=256) 
vs. 
UHR-T, Transition (n=29) 
P value 
PC 16:0_16:0 2.11 (1.83 , 2.77) 1.88 (1.63 , 2.28) 0.64 (0.35 , 1.19) 0.160 
PC 16:0_16:1 0.35 (0.24 , 0.51) 0.34 (0.25 , 0.44) 0.39 (0.05 , 2.79) 0.349 
PC 16:0_17:0 0.23 (0.11 , 0.30) 0.27 (0.17 , 0.32) 0.13 (0.02 , 2.33) 0.255 
PC 16:0_18:0 0.43 (0.31 , 0.56) 0.36 (0.27 , 0.47) 0.18 (0.02 , 1.50 ) 0.113 
PC 16:0_18:1 9.84 (8.58 , 11.41) 9.37 (7.64 , 11.57) 0.93 (0.79 , 1.10) 0.406 
PC 16:0_18:2 11.31 (8.94 , 13.79) 9.59 (7.43 , 11.52) 0.88 (0.78 , 1.00) 0.057 
PC 16:0_20:3 0.97 (0.72 , 1.34) 0.79 (0.58 , 1.20) 0.54(0.21 , 1.35) 0.186 
PC 16:0_20:4 2.87 (2.18 , 3.47) 2.17 (1.74 , 2.92) 0.67 (0.47 , 0.95) 0.024 
PC 16:0_20:5 0.25 (0.18 , 0.33) 0.20 (0.15 , 0.32) 0.06 (0.02 , 1.59) 0.093 
PC 16:0_22:6 0.85 (0.63 , 1.06) 0.78 (0.46 , 0.92) 0.51 (0.18 , 1.47) 0.215 
PC 17:0_18:1 0.42 (0.36 , 0.48) 0.41 (0.36 , 0.47) 0.94 (0.11 , 7.90) 0.957 
PC 17:0_18:2 0.46 (0.36 , 0.57) 0.44 (0.33 , 0.52) 0.55 (0.06 , 5.19) 0.606 
PC 18:0_18:0 0.10 (0.06 , 0.14) 0.14 (0.06 , 0.37) 2.17 (0.95 , 4.95) 0.063 
PC 18:0_18:1 2.09 (1.73 , 2.45) 1.96 (1.53 , 2.12) 0.54 (0.28 , 1.04) 0.063 
PC 18:0_18:2 3.73 (2.94 , 4.45) 3.16 (2.88 , 3.79) 0.73 (0.52 , 1.02) 0.071 
PC 18:0_20:4 1.39 (1.11 , 1.71) 1.15 (0.95 , 1.52) 0.55 (0.27 , 1.11) 0.095 
PC 18:0_22:6 0.25 (0.19 , 0.33) 0.21 (0.13 , 0.30) 0.06 (0.02 , 1.65) 0.095 
PC 18:1_18:1 1.14 (0.78 , 1.52) 1.05 (0.77 , 1.25) 1.03 (0.73 , 1.47) 0.849 
PC 18:1_18:2 1.39 (0.98 , 1.66) 1.11 (0.94 , 1.38) 0.46 (0.19 , 1.12) 0.087 
PC 18:1_20:4 0.62 (0.48 , 0.71) 0.54 (0.39 , 0.67) 0.20 (0.04 , 1.03) 0.054 
PE 16:0_18:1 4.16 (3.78 , 4.64) 4.13 (3.89 , 4.52) 1.06 (0.66 , 1.71) 0.798 
PE 16:0_18:2 1.60 (1.37 , 1.87) 1.68 (1.44 , 1.78) 1.01 (0.48 , 2.09) 0.988 
PE 18:0_18:0 0.07 (0.06 , 0.11) 0.07 (0.06 , 0.11) 2.09 (0.29 , 4.17) 0.119 
PE 16:0_20:3 0.28 (0.19 , 0.51) 0.32 (0.25 , 0.44) 0.78 (0.21 , 2.95) 0.717 
PE 16:0_20:4 2.43 (2.13 , 2.74) 2.46 (1.89 , 2.69) 0.88 (0.53 , 1.46) 0.625 
PE 16:0_20:5 0.18 (0.13 , 0.23) 0.19 (0.14 , 0.24) 1.47 (0.04 , 4.63) 0.212 
PE 16:0_22:4 0.53 (0.24 , 0.75) 0.54 (0.16 , 0.71) 0.45 (0.15, 1.34) 0.153 
PE 16:0_22:5 0.39 (0.23 , 0.55) 0.43 (0.22 , 0.55) 0.78 (0.18 , 3.45) 0.741 
PE 16:0_22:6 0.99 (0.76 , 1.23) 0.99 (0.74 , 1.14) 1.00 (0.43 , 2.36) 0.994 




Table S3: Cont. 
Phospholipids Median (IQR) UHR-NT Median (IQR) UHR-T OR (95% CI) 
UHR-NT, non-transition cases (n=256) 
vs. 
UHR-T, Transition (n=29) 
P value 
PE 17:0_20:5 0.44 (0.39 , 0.51) 0.43 (0.35 , 0.49) 0.78 (0.07 , 8.82) 0.842 
PE 17:0_22:5 0.21 (0.17 , 0.25) 0.22 (0.15 , 0.24) 0.72 (0.01 , 4.09) 0.897 
PE 18:0_18:1 0.96 (0.84 , 1.07) 0.95 (0.83 , 1.04) 1.02 (0.16 , 6.41) 0.986 
PE 18:0_18:2 0.76 (0.65 , 0.89) 0.75 (0.67 , 0.83) 0.73 (0.12 , 4.18) 0.726 
PE 18:0_20:4 1.12 (0.59 , 1.66) 1.37 (0.61 , 1.77) 1.31 (0.73 , 2.34) 0.368 
PE 18:0_22:6 0.32 (0.24 , 0.39) 0.29 (0.19 , 0.40) 0.37 (0.02 , 7.24) 0.509 
PE 18:1_18:1 0.84 (0.66 , 1.05) 0.89 (0.68 , 1.02) 1.18 (0.36 , 3.89) 0.785 
PE 18:1_18:2 1.18 (0.85 , 1.50) 1.15 (0.93 , 1.42) 1.01 (0.47 , 2.17) 0.987 
PE 18:1_20:4 1.40 (1.09 , 1.66) 1.34 (1.03 , 1.68) 0.89 (0.44 , 1.82) 0.760 
PS 18:0_18:0 0.11 (0.09 , 0.14) 0.12 (0.09 , 0.15) 1.64 (0.21 , 4.08) 0.805 
PS 18:0_18:1 1.01 (0.85 , 1.20) 0.92 (0.74 , 1.17) 0.66(0.27 , 1.65) 0.377 
PS 18:0_20:4 5.22 (3.88 , 6.13) 4.95 (1.53 , 5.92) 0.90 (0.76 , 1.07) 0.237 
PS 18:0_22:5 1.18 (0.95 , 1.36) 1.12 (0.87 , 1.24) 0.94 (0.67 , 1.33) 0.740 
PS 18:0_22:6 1.63 (1.20 , 1.99) 1.33 (1.04 , 2.04) 1.05 (0.77 , 1.45) 0.749 
SM 16:0 10.56 (9.12 , 13.10) 12.96 (9.87 , 14.66) 1.11 (1.01 , 1.22) 0.035 
SM 18:0 1.58 (1.32 , 2.19) 2.03 (1.32 , 2.37) 1.49 (0.89 , 2.49) 0.124 
SM 18:1 0.55 (0.45 , 0.77) 0.69 (0.49 , 0.89) 0.94 (0.15 , 2.84) 0.105 
SM 24:0 6.73 (5.15 , 8.09) 8.55 (5.77 , 9.59) 1.12 (0.97 , 1.25) 0.068 
SM 24:1 9.47 (7.37 , 11.56) 11.36 (8.70 , 13.53) 1.09 (0.99 , 1.19) 0.058 
A logistic regression was performed to identify molecular phospholipids classes associated with UHR-T, Transition (n=29) vs. UHR-NT, non-transition cases (n=256). 















Summary and conclusion 
 
Consumption of n-3 LCPUFA is associated with higher n-3 LCPUFA status in the circulation, 
which has in turn been associated with a number of health benefits in humans. Several 
studies have investigated the n-3 LCPUFA (EPA + DHA) ‘status’ of psychiatric patients. 
These studies have found that patients with bipolar disorder (Mcnamara et al., 2010; Chiu et 
al., 2003; Ranjekar et al., 2003), schizophrenia (Ranjekar et al., 2003; Evans et al., 2003; 
Khan et al., 2002; Reddy et al., 2004; Parletta et al., 2016), ADHD (Chen et al., 2004; Colter 
et al., 2008; Stevens et al., 1995; Young et al., 2004) and major depressive disorder (MDD) 
(Assies et al., 2010; Edwards et al., 1998; Maes et al., 1996; Peet et al., 1998; Riemer et al., 
2010; Mcnamara et al., 2010) and depression (Parletta et al., 2016) exhibit significant deficits 
in EPA+DHA levels compared with demographically similar healthy subjects. In order to 
move the field of oemga-3 research in mental health forward, large clinical trials are 
warranted that also measure the levels of omeag-3 at baseline and post-intervention. In 
order to be able to conduct such large trials, a high throughput method of assessing n-3, as 
well as other fatty acids and phospholipid species is warranted. 
The developed and validated high throughput method using an automated methyl tert-butyl 
ether extraction followed by electrospray ionization mass spectrometry ESI-MS method used 
in Chapter 2  allows for the determination of human erythrocyte fatty acid concentration 
and the n-3 index from low sample volumes as well as for the identification of molecular 
phospholipids. The new method is simple, convenient, low in cost, allow us to extract large 
number of samples (96 samples/run) in a short time and provides additional information on 
molecular phospholipid concentrations. The Lepage & Roy method has a number of 
disadvantages such as it uses manual sample preparation and is time consuming (6 hours to 
prepare only 24 samples/day), requires a relatively large amount of sample (400ul of 
erythrocytes) and cannot generate molecular phospholipid data. Analysis of fatty acids by 
GC also requires sample derivatization to improve fatty acid volatility. This creates further 




required by the new method such issues are avoided. The limitation of this new high 
throughput method is that the MS cannot differentiate between n-3 DPA and n-6 DPA due to 
their same molecular mass. A resolution for this limitation is warranted. 
 
The methods developed in Chapter 2 enabled us to apply this high throughput method to a 
large clinical trial in the following Chapters 3, 4 & 5.  A comparison between the UHR 
individuals and healthy controls in Chapter 3 found that lower proportions of PUFA were 
observed in the UHR group. Specifically, EPA was 29.3% lower, DHA was 27.2% lower and 
AA was 15.8% lower compared to the healthy group. Conversely, the proportion of nervonic 
acid was 64.4% higher in the UHR group compared to healthy controls. The n-3 index was 
also 26.9% lower in the UHR group. At a lipid class level, the UHR group had higher levels 
of SM and lower levels PE compared to healthy group which have both already been 
observed previously in schizophrenic patients (Ponizovsky et al., 2001; Keshavan et al., 
1994; Hitzemann and Garver, 1982). Low n-3 index have repeatedly been observed in UHR 
patients compared to healthy population (McNamara, 2011; Rice et al., 2015) this might give 
possibility in transition of n-3 index from cardiac health to psychotic health. Previous studies 
have reported metabolism disturbances and deficiencies of PUFA erythrocyte membranes 
which are commonly seen in patients with schizophrenia (Reddy et al., 2004; Peet et al., 
1998; Khan et al., 2002) and which might have happened with the UHR population before 
their transition to psychosis. Interestingly, it has been recently reported healthy controls have 
significantly higher consumption of n-3 PUFA than UHR participants who converted and did 
not convert to psychosis (Pawelczyk et al., 2015; 2016), this suggests that PUFA 
consumption may play a role in the conversion to psychosis in UHR individuals and can 
improve mental health (e.g. depression) (Parletta et al., 2017).  
 
The randomized controlled trial of n-3 fatty acids supplementation in people at UHR of 
developing psychosis over 6 months (Chapter 4) resulted in increased concentration of PC, 




11.8%-50.0% and reduce n-6 species e.g., 18:2, 20:3, 20:4, 22:4 ranging from 7.4%-42.9%. 
Interestingly, SM species did not change in the n-3 LCPUFA supplementation group 
however, three out of five SM species significantly increased after 6 months of 
supplementation with placebo. The response of n-3 index to n-3 supplementation (from 3.0% 
to 4.10%) was much lower than previous studies that administered EPA+DHA for up to 12 
months (Katan et al., 1997; Cao et al., 2006; Browning et al., 2012; Flock et al., 2013). This 
is likely a consequence of low compliance (< 44%) in both groups and a high level of 
antidepressant treatment received by both groups (McGorry et al., 2017).   
 
Even though numerous differences were seen between UHR and healthy groups (Chapter 
3), there were no difference seen between people at high risk who developed psychosis and 
did not develop psychosis (Chapter 5). Therefore, the n-3 index, fatty acids and molecular 
phospholipid species do not predict transition to psychosis in people at UHR. This suggests 
that the alterations in erythrocyte (and possibly the brain) lipids occurs prior to UHR and the 
erythrocyte samples could help to determine UHR of developing psychosis but not used to 
determine psychosis.   
In conclusion, this thesis has presented an optimized method that allows the identification 
and quantification of the n-3 index, fatty acids and molecular phospholipid species 
in erythrocytes; using an automated extraction and ESI-MS analysis. A significant outcome 
of this thesis was identifying that people at UHR of developing psychosis have different 
levels of the n-3 index, fatty acids and molecular phospholipid species compared to healthy 
subjects, also, none of the assessed n-3 index, fatty acids and molecular phospholipid 
species predict transition to psychosis in those at ultra-high risk. To the best of my 
knowledge, the work presented in this thesis is the most comprehensive examination to date 
of erythrocyte membrane lipid composition of people at UHR of psychosis.  
 
The data from this thesis supports a number of directions and recommendations for 




phospholipid species in UHR group compared to healthy group. Future research that aims to 
study UHR populations should consider the following points: 
1) Investigations of erythrocytes morphology should be undertaken to see if there are 
any differences in the cell shapes between the healthy and UHR groups. 
2) Very low compliance of supplementation intake was found in current randomized 
controlled trial so the future studies investigating n-3 fatty acids supplementation for 
UHR of developing psychosis should improve the participants’ compliance with taking 
their supplementation.  
3) In addition to having a UHR of developing psychosis population screened for this 
study, future studies might consider low and mid risk of developing psychosis 
populations to try and elucidate when the lipid changes actually occur between being 
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(B) Inclusion and exclusion criteria for UHR of developing psychosis subjects. 
Individuals who were referred to the treatment service meeting standardized ‘at-risk’ 
criteria were approached about participating in this clinical trial. The symptomatic 
inclusion criteria were based on the guidelines developed by the Melbourne group, 
consisting of a subset of three groups considered ‘at-risk’ that were assessed using the 
Comprehensive Assessment of At-Risk Metal State (CAARMS). The Inclusion criteria 
used focused on (i) the ability to give informed consent; (ii) subjects who were between 
the ages of 13 and 40 years (depending on site) at presentation; and (iii) subjects who 
met the criteria of one of the ‘at-risk’ groups (Table 1). 
 
Randomized (n= 304) 
Received placebo as randomized 
(n= 151) 
Received n-3 as randomized 
(n= 153) 
 
Lost to follow-up (n= 39) 
 
Completed (n= 114) 
 
Transitioned (n= 17) 
 
Lost to follow-up (n= 40) 
 
Completed (n= 111) 
 





Table 1:- Inclusion criteria for ultra-high-risk of developing psychosis subjects (Markulev et 
al., 2015). 
Group Criteria 
1: Vulnerability group 
(trait and state risk 
factors) 
Family history of psychosis in first-degree relative OR 
schizotypal personality disorder (as defined by DSM-IV) in 
identified patient. 
Impact: A 30% drop in the social and occupational functioning 
assessment scale (SOFAS) score as compared to previous 
functional level, sustained for one month within the past year; 
OR a SOFAS score of 50 or less for at least the past 12 
months. 
2: Group with attenuated 
positive psychotic 
symptoms 
(2a) Subthreshold intensity: 
Intensity: Global Rating Scale Score of 3–5 on Unusual 
Thought Content subscale, 3–5 on Non-Bizarre Ideas subscale, 
3–4 on Perceptual Abnormalities subscale and/or 4–5 on 
Disorganized Speech subscales of the CAARMS. 
Frequency: Frequency Scale Score of 3–6 on Unusual Thought 
Content, Non-Bizarre Ideas, Perceptual Abnormalities and/or 
Disorganized Speech subscales of the CAARMS. 
Duration: symptoms have been present for at least a week. 
Recency: symptoms that presented themselves within the past 
year. 
Impact: A drop of 30% in SOFAS score from the prior level of 
functioning, sustained for one month within the past year OR a 
SOFAS score of 50 or less for at least the past 12 months.  
(2b) Subthreshold frequency:  
Intensity: A Global Rating Scale Score of 6 on the Unusual 
Thought Content subscale, 6 on the Non-Bizarre Ideas 





6 on the Disorganized Speech subscales of the CAARMS. 
Frequency: A Frequency Scale Score of 3 exhibited on the 
Unusual Thought Content, Non-Bizarre Ideas, Perceptual 
Abnormalities and/or on the Disorganized Speech subscales of 
the CAARMS. 
Recency: symptoms have been present within the past year. 
Impact: A 30% drop in the SOFAS score compared to the prior 
level of functioning, sustained for a month within the past year; 
OR a SOFAS score of 50 or less for at least the past 12 
months. 
3: Those with Brief limited 
intermittent psychotic 
symptoms 
Intensity: A Global Rating Scale Score of 6 on the Unusual 
Thought Content subscale,  6 on the Non-Bizarre Ideas 
subscale, 5 or 6 on the Perceptual Abnormalities subscale 
and/or  6 on Disorganized Speech subscales of the CAARMS. 
Frequency: Frequency Scale Score of 4–6 regarding Unusual 
Thought Content, Non-Bizarre Ideas, Perceptual Abnormalities 
and/or Disorganized Speech subscales. 
Duration: symptoms have been present for less than a week 
and they remit spontaneously on every occasion. 
Recency: symptoms have been present within the past year. 
Impact: A 30% drop in the SOFAS score from the prior level of 
functioning, sustained for one month within the past year OR a 
SOFAS score of 50 or less for a minimum of the past 12 
months or longer. 
The criteria used to determine exclusion are if an individual has/is: (i) a past history of a 
treated or untreated psychotic episode of one week or longer; (ii) an organic brain disease 
such as epilepsy or an inflammatory brain disease; (iii) thyroid function test results which are 




any physical illness with psychotropic effect, if not stabilized; (v) currently treated with any 
mood stabilizer, or uses ketamine for recreational use; (vi)  past neuroleptic exposure that is 
equivalent to a total lifetime haloperidol dose of >50 mg ; (vii) been diagnosed with a serious 
developmental disorder such as Asperger's syndrome; (viii) a premorbid IQ that is measured 
at  < 70 and a documented history of developmental delay or an intellectual disability; (ix) 
current signs of acute suicidality/self-harm or  experiencing episodes of 
aggression/dangerous behaviour (indicated by a CAARMS severity score of 6 on items 7.3 
and/or 5.4); (x) currently pregnant; (xi)  experiencing current  attenuated symptoms that can 
be explained entirely by acute intoxication (e.g. current attenuated symptoms which can be 
fully explained by lysergic acid diethylamide [LSD] use); and (xii)  more than 4 weeks of 
regular n-3 supplementation (>2 capsules of standard strength  that provide >600 mg 
combined EPA/ DHA) within the last 6 months. 
Exit/discontinuation criteria were also used to describe patients in the study who: (i) 
voluntarily discontinued their participation, without prejudice to further treatment; (ii) concern 
for safety issues as judged by the investigator; (iii) were severely non-compliant to protocol 
as judged by the investigator; (iv) incorrectly enrolled (e.g., the enrolled patient does not 
meet the required inclusion /exclusion criteria); (v) is lost to follow up; (vi) meet the exit 
criteria because of a ‘transition to psychosis’ or they develop mania (first-episode mania 








































(D) Questionnaire for healthy subjects. 
AIM 
The aim of this survey is to determine if you are eligible for this research project. 
Thank you for your cooperation. 
1              What is your age? 
 
2             What is your gender? 
____________________________________________________________________________ 
3              What is your weight? 
_____________________________________________________________________________ 
4               What is your height?  

































 9 Do you have any other medical conditions?  
 
 








Please answer the questions below by ticking either True or False. If you have ticked True, please tick 
“No”, “Mild”, “Moderate” or “Severe” to ‘How much distress did you experience?’ 
If TRUE: how much distress did you experience? 
                                                                                                                          No                 Mild          Moderate     Severe 
1 I feel uninterested in the things 
I used to enjoy 
o True  o False     
2 I often seem to live through 
events exactly as they 
happened before 
o True  o False     
3 I sometimes smell or taste 
things that other people can’t 
smell or taste. 
o True  o False     
4 I often hear unusual sounds like 
banging, clicking, hissing, 
clapping or ringing in my ears. 
o True  o False     
5 I have been confused at times 
whether something I 




experienced was real or 
imaginary. 
6 When I look at a person, or 
look at myself in a mirror, I 
have seen the face change right 
before my eyes. 
o True  o False     
7 I get extremely anxious when 
meeting people for the first 
time. 
o True  o False     
8 I have seen things that other 
people apparently can’t see. 
o True  o False     
9 My thoughts are sometimes so 
strong that I can almost hear 
them. 
o True  o False     
10 I sometimes see special 
meanings in advertisements, 
shop windows, or in the way 
things are arranged around me. 
o True  o False     
11 Sometimes I have felt that I’m 
not in control of my own ideas 
or thoughts. 
o True  o False     
12 Sometimes I feel suddenly 
distracted by distant sounds 
that I am not normally aware of  
o True  o False     
13 I have heard things other 
people can’t hear like voices of 
people whispering or talking. 
o True  o False     
14 I often feel that others have it 
in for me. 
o True  o False     
15 I have had the sense that some 
person or force is around me, 
even though I could not see 
anyone. 
o True  o False     
16 I feel that parts of my body 
have changed in some way, or 
that parts of my body are 
working differently than 
before. 
o True  o False     
Please return this questionnaire 
If you have any questions concerning this survey, please feel free to contact the researcher: 
Ayedh Alqarni 
School of Medicine 
University of Wollongong                             Email: asa043@uowmail.edu.au   
Wollongong, NSW                                            Tel:       
Australia                                      
 
 
 
 
